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Abstract 
Influenza is a severe disease in humans and animals, causing upwards of 40,000 deaths 
every year in America alone.  Influenza A virus (IAV) also causes periodic pandemics every 10 
to 50 years, killing millions of people.  Despite this, very few effective therapies are available.  
All strains of IAV are prone to developing resistance to antibodies due to the high mutation rate 
in the viral genome.  Because of this mutation rate, a yearly vaccine must be generated before 
every flu season, and efficacy varies year to year.  IAV has also mutated to escape several of the 
clinically-approved small molecule inhibitors.  A therapeutic agent that targets a highly 
conserved region of the virus could bypass resistance and also be effective against multiple 
strains of IAV.  IAV attachment is mediated by many individually weak hemagglutinin–sialic 
acid interactions that all together make a strong attachment to a host cell.  Polymerized sialic 
acid analogs can recreate these interactions and block infection.  However, they are not ideal 
therapeutics due to solubility issues and in vivo toxicity.  We used liposomes as a novel means 
for delivery of the sialic acid-containing glycan, sialylneolacto-N-tetraose c (LSTc). LSTc-
bearing decoy liposomes form multivalent, polymer-like interactions with IAV. Decoy liposomes 
competitively bind IAV in hemagglutination inhibition assays and inhibit infection of target cells 
in a dose-dependent manner.  LSTc decoy liposomes co-localize with IAV, while control 
liposomes do not.  Inhibition is specific, as inhibition of Sendai virus and respiratory syncytial 
virus is not observed.  In contrast, monovalent LSTc does not bind IAV or inhibit infectivity.  
LSTc decoy liposomes prevent the spread of IAV during multiple rounds of replication in vitro 
and extend survival of mice challenged with a lethal dose of virus. Considering the conservation 
of the hemagglutinin binding pocket and the ability of decoy liposomes to form high-avidity 
vii 
interactions with IAV hemagglutinin, our decoy liposomes have potential as a new therapeutic 
agent against emerging strains.   
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Chapter I 
Introduction 
Influenza A virus (IAV), a member of the orthomyxovirus family, causes upper and 
lower respiratory tract infections ranging from mild, non-life threatening illness to lethality 
(Sullivan 1996).  IAV also causes periodic pandemic outbreaks, which are an ever-present 
danger in a modern, interconnected world.  Historically, IAV pandemics have occurred with 
alarming speed and extremely high mortality rates.  Unfortunately the vaccine and therapeutics 
currently available for influenza are not sufficient to block the spread of a newly emerged strain 
to which the general population has no pre-existing immunity.  In order to generate more 
effective therapeutics, it is vital to fully understand influenza biology and to pursue therapeutics 
against all conserved regions of IAV proteins. 
A. Influenza the pathogen 
 Influenza causes up to 40,000 deaths per year in the United States alone (Sullivan 1996), 
and many more worldwide.  Most human infections consist of a sudden and acute fever, usually 
lasting three days, along with muscle pain and fatigue.  The majority of IAV infections are self-
limiting and do not require hospitalization, but potentially life-threatening complications such as 
pneumonia, bronchitis and secondary bacterial infections can occur.  Those who are at increased 
risk of mortality from IAV include patients with cardiopulmonary and other chronic diseases, 
young children and the elderly (Cox and Subbarao 2000)  Although seasonal influenza is not 
usually lethal in the general population, newly emerged pandemic strains have caused upwards 
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of 20-fold increased IAV-related mortality in the otherwise healthy, general population 
(Simonsen, Clarke et al. 1998). 
IAV pandemics have occurred in the past at intervals of 10 to 50 years, and they present a 
public health risk.  The most recent pandemic was a triple reassortment H1N1 virus from human, 
swine and avian IAV species.  It began in Mexico in 2009 and quickly spread around the globe, 
ultimately claiming over 18,500 lives in the first 12 months alone (Dawood, Iuliano et al. 2012).  
Three IAV pandemics have occurred during the previous century: the 1918 H1N1, the 1957 
H2N2, and the 1968 H3N2 pandemics, each differing in severity and mortality rates.  The 1918 
pandemic caused the highest mortality as compared to mortality from seasonal IAV (Cox and 
Subbarao 2000; Potter 2001).  All three recent pandemics were antigenically novel, and they 
were all shown to bind to the canonical α2-6 and α2-3 linked SA (Glaser, Stevens et al. 2005; 
Pappas, Viswanathan et al. 2010; Lin, Xiong et al. 2012). 
 The speed of IAV spread allows it to become pandemic when there are too few 
individuals with cross-reactive antibodies present in the general population.  IAV strains evolve 
to avoid existing antibody responses in the population by two general mechanisms, antigenic 
drift and antigenic shift.  Antigenic drift occurs when point mutations accumulate in circulating 
strains, allowing the strain to avoid pre-established immunity (Potter 2001), and antigenic shift 
occurs when an entire gene segment is swapped between two strains, often the immunodominant 
proteins HA or NA (La Gruta, Kedzierska et al. 2007).  Pandemic strains are thought to typically 
result from antigenic shift.  Both mechanisms of antigenic change result in escape of antibody 
neutralization, allowing new strains to re-infect the general population.  IAV can spread from an 
infected individual two days post-infection, while a new antibody response requires five to seven 
days for maturation and viral clearance (Fields, Knipe et al. 2013).  The quick spread of IAV 
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makes it a very dangerous virus that has killed millions in the past, and will kill millions in the 
future.   
 
B. Influenza the virus  
 IAV is a member of the orthomyxaviride family of negative-sense, segmented, single-
stranded RNA viruses and it contains eight gene segments, encoding at least twelve proteins 
(Figure 1.1A).  The major surface protein of IAV is the adhesion and fusion protein, 
hemagglutinin (HA).  HA binds as a homotrimer to cell surface sialic acid (SA) on glycoproteins 
and glycolipids.  After endocytosis, HA also undergoes a pH-dependent conformational change 
and fuses the viral membrane with the endosomal membrane.  HA is the immunodominant 
antigen and the majority of neutralizing antibodies made by B-cells are against one of the five 
major antigenic sites on the globular head of HA.  IAV has two minor surface proteins: 
neuraminidase (NA) and matrix protein 2 (M2).  NA releases progeny virus from infected cells 
by cleaving surface SA bound to HA on the budding virion.  The M2 protein is a proton channel, 
responsible for viral uncoating (Jing, Ma et al. 2008).  IAV is divided into subtypes based on 
antibody binding to HA and NA.  Currently seventeen HA and nine NA subtypes have been 
described.  Individual strains of IAV are described as the combination of HA and NA subtypes 
that they possess, for example, the two major subtypes that circulate in the human population is 
H1N1 and H3N2 IAV.  H2N2 IAV have circulated through the human population this century, 
and were responsible for the 1957 pandemic, but currently no longer infects humans (Krause, 
Tsibane et al. 2012).  The reason for the disappearance of this strain from the human population 
is currently not understood, but raises concern of its reemergence and pandemic potential due to  
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Figure 1.1 Influenza A Virus structure and genome. 
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Figure 1.1 Influenza A Virus structure and genome. 
 
The schematic representation illustrates the overall structure of a virion (A) and the location of 
its gene segments and proteins encoded (B).  The ribonuclear protein (RNP) complex contains 
the NP and polymerase proteins and surrounds all eight gene segments, which are located in the 
virion core.  The matrix protein gives structural support to the lipid bilayer.  The surface 
glycoproteins are hemagglutinin, neuraminidase and M2.  HA is important for attachment and 
subsequent fusion to host cells and is also the immunodominant protein, targeted by the majority 
of neutralizing antibody.  B, Illustrates of the 8 gene segments and the 12 protein products 
produced from each segment, including their amino acid length of each protein 
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a lack of preexisting immunity.  IAV evolves through two mechanisms, antigenic drift and 
antigenic shift 
 IAV has ten internal proteins.  The matrix protein (M1) and nucleoprotein (NP) give 
rigidity to the virion and organize the viral RNA, respectively.  The viral polymerase consists of 
PB1, PB2 and PA proteins. An alternate reading frame on the PB1gene segment encodes for 
PB1-F2, which can trigger apoptosis in some cell types.  A recently discovered open reading 
frame resulting from ribosomal frameshifting produces an alternative PA protein, PA-X, which 
contains the endonuclease domain of PA and a novel C terminal region that suppresses host gene 
expression (Jagger, Wise et al. 2012).  IAV encodes two non-structural proteins (NS), NS1 and 
NS2 (also known as nuclear export protein, NEP).  NS2 is responsible for export of the viral 
transcripts from the cell nucleus (Robb, Smith et al. 2009).  NS1 has several known functions, 
including blocking host mRNA production, suppression of the interferon response and binding of 
double-stranded RNA, preventing RNA sensing by cytoplasmic RNA sensors (Lu, Wambach et 
al. 1995; Fields, Knipe et al. 2013). 
Viral binding 
 Through HA, IAV binds to specific glycosylation motifs with terminal SA linked to the 
penultimate galactose (Gal) sugar residue.  Each host species has different SA-Gal linkages 
present in their upper airways, and therefore the linkage chemistry determines IAV species 
specificity.  In the human upper airways, glycans that terminate in SA are predominately linked 
with an α2-6 linkage to the penultimate sugar, and IAV strains adapted to infect humans bind to 
this linkage (Ibricevic, Pekosz et al. 2006).  Bird upper airway and gut lining have terminally 
sialylated glycans with α2-3 linkages, where IAV replicates in birds.  Avian-adapted strains of 
IAV bind to α2-3 linked SA.  Pigs, however, have mixed α2-3 and α2-6 linked SA displayed 
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throughout their airways and are infected by IAV adapted to either host (Fields, Knipe et al. 
2013).  For this reason the swine population is an especially important reservoir of reassortment 
and adaptation between birds and humans.  Some recent crossover strains are thought to bind to 
both α2-3 and α2-6 linked SA, and further nucleic acid mutations fix the preference for α2-6 SA 
in the strain as an outbreak or adaptation continues (Glaser, Stevens et al. 2005).  Many cell lines 
and chicken eggs used to passage IAV in the laboratory contain both SA linkages (Ito, Suzuki et 
al. 1997) and therefore almost all commonly studied IAV strains, included those used here, are 
promiscuous binders that can bind and infect cells displaying either α2-3 or α2-6 linked SA.   
Influenza A virus internalization 
 Once IAV has bound to surface SA, the virus is internalized through receptor-mediated 
endocytosis.  Entering virus is cycled through the endocytic pathway to the acidic, late endosome 
phase (Figure 1.2).  The low pH of the late endosome enables a conformational change in HA 
and allows the viral envelope to fuse to the endosomal membrane.  The M2 protein is a proton 
ATPase ion channel, located on the surface of the virion.  After the late endosome acidifies, M2  
pumps protons across the viral membrane and acidifies the endosome interior, causing the 
disassociation of M1 from the viral genome (Lakadamyali, Rust et al. 2004).  IAV replicates in 
the cell nucleus, and NP imports the genome via its nuclear localization sequences.  Viral 
proteins are then translated in the cytoplasm, with the major surface proteins shuttling from the 
endoplasmic reticulum to the plasma membrane, where progeny virion assembly and budding 
occur.  After successful packaging and budding, NA on the progeny virions is required for the 
final release from an infected cell.  IAV NA is an exo-α-sialidase that cleaves terminal α2-3, α2-
6 and α2-8 linked SA from host and viral glycoproteins and glycolipids, releasing the mature   
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Figure 1.2 Infection and replication cycle of IAV and the current drug targets. 
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Figure 1.2 Infection and replication cycle of IAV and the current drug targets. 
 
IAV HA binds to sialylated glycolipids and glycoproteins on the cell surface and is internalized 
by receptor-mediated endocytosis.  Binding can be inhibited by neutralizing antibody or receptor 
decoys.  Upon endosome acidification, HA undergoes a conformational change to fuse with the 
membrane.  The M2 ion channel (inhibited by amantadine) acidifies the virion interior and 
releases M1 from the RNP complex, allowing for genome release into the cell.  IAV replication 
occurs in the nucleus and complementary RNA (cRNA) is translated in the cytoplasm.  Surface 
membrane proteins are inserted into the endoplasmic reticulum (ER) and shuttled to the cell 
surface via the golgi.  IAV’s polymerase makes progeny viral RNA (vRNA) and together with de 
novo protein synthesis, assembly occurs at the apical cell surface.  Budding is dependent on NA 
cleavage of SA on the cell surface as well as on viral proteins (inhibited by Oseltamivir and 
Zanamivir) 
  
 10 
 
virions and prevents self-aggregation or reattachment to the infected cell surface (Nayak, Hui et 
al. 2004).  
 
C. The immune response to Influenza A virus 
Innate response to IAV
 When IAV undergoes a combination of antigenic drift and antigenic shift between human 
and avian circulating strains, the new IAV strains may not be susceptible to existing antibodies. 
IAV infection clearance is dependent on an adaptive, sterilizing B-cell mucosal antibody 
response that typically takes five to seven days to appear in these re-infected patients (Fields, 
Knipe et al. 2013; Seibert, Rahmat et al. 2013).  Conventional human circulating strains and 
avian circulating strains undergo constant antigenic shift and antigenic drift, creating new virus 
that is not neutralized by antibodies made during previous infections, and are now susceptible to 
a new round of infection, although these patients are not completely naïve .  The innate immune 
response is therefore critical to delay viral replication before the adaptive immune response can 
mature and clear the infection.  IAV first infects respiratory epithelial cells in the human upper 
respiratory tract that express α2-6 linked SA and from these cells produce large amounts of 
progeny virus.  Infected epithelial cells are also the first cells to mount an innate immune 
response that is crucial for limiting viral spread.  IAV is recognized by a number of innate 
pattern recognition receptors (PRRs).  Toll-like receptors (TLR) 3 recognizes endosomal dsRNA 
and activates type I interferon (IFN) by the interferon regulatory factors (IRFs) .  TLR7 
recognizes endosomal ssRNA, and activates pro-inflammatory cytokines via NF-κB.  The 
cytosolic retinoic acid inducible gene-I (RIG-I) recognizes 3’ triphosphate RNA generated 
during viral replication and also signals through the IRFs to produce type I IFN (Fields, Knipe et 
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al. 2013).  Protein kinase R (PKR), another cytosolic viral sensor, is activated by the presence of 
dsRNA, and is also an IFN-stimulated gene.  PKR recognizes IAV dsRNA and phosphorylates 
eukaryotic translation initiation factor 2a (eIF2a), which in turn halts protein translation.  PKR 
activation also initiates the apoptosis cascade and both mechanisms limit virus replication 
(Fields, Knipe et al. 2013).  IAV, like many other viruses, inhibits PKR activation.  IAV NS1 
inhibits PKR by blocking IFN production, and therefore limiting the amount of PKR protein 
produced, by binding to dsRNA, preventing PKR-dsRNA interaction, and by binding directly to 
the N-terminal region of PKR to prevent activation (Li, Min et al. 2006).  Viral RNA and the M2 
protein have also been shown to indirectly activate the cytosolic inflammasome receptor, NLRP3 
(Allen, Scull et al. 2009; Ichinohe, Pang et al. 2010).  TLR activation produces proIL-1α/β and 
pro-IL-18, and subsequent NLRP3-dependent caspase activation induces cleavage of these key 
cytokines into their mature form.   
 IAV’s surface proteins, HA and NA are processed through the Golgi (Figure 1.2) and like 
other cellular membrane proteins are glycosylated.  The lectin receptor family is a group of 
innate immune sensors that bind to specific glycosylation motifs.  Mannose binding protein 
(MBP) and surfactant protein D (SP-D) both have been shown to recognize IAV. MBP 
recognizes high-mannose glycosylation and binds to mannose residues on IAV HA, preventing 
attachment in a similar mechanism as antibody neutralization (Anders, Hartley et al. 1990).  IAV 
can escape from MBP binding by selecting for mutants that lose mannose glycosylation 
(Hartshorn, Sastry et al. 1993), but removal of a glycosylation site may make these mutants 
susceptible to circulating antibodies, as addition of a glycosylation site is a common antibody 
escape mechanism (O'Donnell, Vogel et al. 2012).  SP-D also binds to IAV, and research has 
demonstrated that SP-D agglutinates IAV (Hartshorn, Chang et al. 1996), stimulates neutrophil 
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binding and respiratory burst (Hartshorn, Crouch et al. 1994), and is important for survival in the 
mouse after IAV infection (LeVine, Whitsett et al. 2001) 
 Natural killer (NK) cells have also implicated in killing IAV-infected cells. NK cells are 
innate cytotoxic cells that do not require previous antigen stimulation to kill infected target cells.  
Recognition of non-self is, in part, due to the lack of major histocompatibility complex (MHC) 
class I on an infected cell.  MHC class I is down regulated during many infections, including 
IAV.  In addition to the recognition of a lack of MHC class I, the NK cell receptors NKp46 
(Mandelboim, Lieberman et al. 2001) and NKp44 (Arnon, Lev et al. 2001) have been shown to 
bind to IAV HA.  However, this recognition is dependent on NK receptor sialylation, and may be 
an artifact of the experimental setup and not true in vivo. NK cells are also susceptible to IAV 
infection, are permissive for replication and undergo apoptosis after infection (Mao, Tu et al. 
2009).  Therefore the benefits of NK recruitment during infection remain controversial. Taken 
together, these initial recognition events are key to establishing an antiviral state with the Type I 
IFNs, to limit the spread of virus and to recruit additional leukocytes to the infected lung with the 
proinflammatory cytokines and chemokines.  Key cytokines that are induced during IAV 
infection include IL-1α/β, IL-6, IL-8 (KC in mice), MCP1, MIP-1α/β, IP-10 and TNF in both 
mouse (Wareing, Lyon et al. 2004) and human (Fritz, Hayden et al. 1999) infection.   
Innate receptors trigger chemokine production in the IAV infected lung.  Patrolling blood 
neutrophils, mononuclear, and NK cells then infiltrate into the lungs along the chemokine 
gradients.  Infiltrating leukocytes recognize IAV through the same PRRs described above, 
secrete additional cytokines, phagocytose virus and kill infected cells.  They also aid in the 
maturation of resident dendritic cells (DCs) that, along with leukocyte differentiation cytokines, 
are the link to the adaptive immune response.  DCs express many PRRs, and after encountering 
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IAV antigens and inflammatory signals, undergo maturation, migrate to the draining lymph 
nodes and are critical for both proper T- and B-cell maturation (Summerfield and McCullough 
2009).  As professional antigen presenting cells, DCs can process IAV antigens via both MHC 
pathways.  Phagocytosed IAV antigens are processed in the endosome and loaded onto MHC 
class II for presentation to CD4 helper T cells, which are crucial for the priming of antigen 
specific B-cells and for efficient production of neutralizing antibodies (Gerhard, Mozdzanowska 
et al. 1997).  Through the MHC class I pathway, DCs present antigen to CD8 T-cells by transfer 
of endocytosed antigen to the cytoplasm for cross-presentation on MHC class I molecules.  DCs 
also process antigen when infected by IAV.  De novo IAV protein synthesis in the cytoplasm is 
processed and loaded in class I MHC molecules for presentation to CD8 T-cells.  In addition, 
DCs also aid in the expansion and differentiation of B-cells directly (Douagi, Gujer et al. 2009).  
With the aid of CD4 helper T-cells, B-cells undergo class-switching, somatic hypermutation and 
produce neutralizing antibody that clears IAV from the infected lung (Fields, Knipe et al. 2013; 
Seibert, Rahmat et al. 2013). 
Adaptive immune response to IAV
 Adaptive immunity consists of two arms, the B-cell humoral response and the cytotoxic 
T-cell cellular response and is responsible for final clearance of almost all infections.  Clearance 
of IAV is largely dependent on the B-cell neutralizing antibody response.  The antibody response 
appears five days post infection and plateaus two to three weeks post infection (Murphy, 
Chalhub et al. 1973).  The timing of the antibody response is similar during human exposure to 
avian IAV; neutralizing antibodies appear five days after the onset of symptoms of confirmed 
H5N1 IAV cases and level off twenty to twenty-five days post first symptoms (Katz, Lim et al. 
1999).  During IAV infection, B-cells make antibodies to the HA, NA, NP, M1 and M2 proteins.  
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Antibodies against the surface glycoproteins HA and NA are protective, whereas antibodies 
against the internal proteins NP and M1 are not (Fields, Knipe et al. 2013).  HA and NA are the 
immunodominant antigens, the majority of all antibodies made target these two proteins, and 
their presence correlates with resistance to illness and inhibition of IAV replication in humans 
(Clements, Betts et al. 1986).  Anti-HA antibodies act by preventing HA binding to SA on host 
cells, preventing infection.  Anti-NA antibodies act after infection, and prevent progeny IAV 
release from infected cells, reducing circulating viral titer.  Passively transferred antibodies 
against HA alone can protect against infection, even in SCID mice lacking B- and T-cells 
(Scherle, Palladino et al. 1992).  Anti-HA antibodies are strain-specific, and are therefore 
susceptible to escape by mutation of the highly variable globular head of HA (van de Sandt, 
Kreijtz et al. 2012).  However, if the HA protein has not changed antigenically, the antibody 
response is robust and can protect against similar strains many years later. Older patients had 
partial protection from the 2009 IAV pandemic from cross-reactive antibodies generated from 
IAV infections in the 1950s (Hancock, Veguilla et al. 2009; Ikonen, Strengell et al. 2010). 
 Non-neutralizing antibodies generated during IAV infection also play an important role 
in viral control and protection.  Anti-NA antibodies are not neutralizing, but still reduce 
infectious titer by trapping budding virus onto infected cell surfaces.  Non-neutralizing anti-NP 
antibodies also reduce viral titers (Carragher, Kaminski et al. 2008).  The exact mechanism is not 
fully elucidated, but it may result from antibody-dependent cell cytotoxicity, where antibodies 
bind to exposed antigens, and the FcγRIII on infiltrated NK cells bind to the Fc region of the 
antibody, resulting in NK-mediated cell lysis.   
 Cellular immunity is also important during IAV infection.  Due to the pervasiveness of 
influenza and the availability of the vaccine, there are virtually no naïve people in the general 
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population.  When reinfected, a patient will have cross-reactive T-cell responses to conserved 
internal epitopes to the new IAV strain.  In an experimental naïve mouse model, the T-cell 
response takes typically six to fourteen days to appear, and resolves twenty-one days post 
infection (Ennis, Rook et al. 1981).  There are two major groups of T-cells, CD8+, cytotoxic 
lymphocytes (CTLs) and CD4+ helper T-cells.  CTLs kill IAV-infected cells displaying a 
specific antigen on surface MHC class I.  CTL epitopes produced during human infection have 
been map to the HA, M, NP, and PB2 proteins.  HA epitopes are generally subtype-specific, 
while epitopes on the internal proteins are cross-reactive to multiple subtypes (Fleischer, Becht et 
al. 1985).  Unlike antibody, pre-existing memory CD8 T-cell levels do not correlate with 
protection, but they do correlate with the speed of clearance. 
 The second major T-cell subsets, CD4+ helper T-cells, are important for proper 
development of antigen specific B-cells during IAV infection.  The contribution of helper T-cells 
to the IAV response have been demonstrated by in vivo depletion, resulting in slower IAV 
clearance (Eichelberger, Wang et al. 1991).  CD4+ helper T-cells are more important during 
secondary infection with the same, or similar, IAV strain and quickly produce proinflammatory 
cytokines and chemokines after infection, resulting in early control of virus (Strutt, McKinstry et 
al. 2010; Teijaro, Turner et al. 2011). 
Pulmonary recovery after IAV infection
 The immune system is vital not only in the control and clearance of IAV, but also for the 
repair of the lung after infection.  During infection, there is significant cell death in the lungs, 
either from lytic viral replication, infected cell death from apoptosis and necrosis, or specific 
killing by the adaptive immune system.  IAV also significantly alters the lung environment after 
clearance.  IAV has been shown to affect pulmonary arterial morphology, PRRs expression, and 
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T-cell function.  These changes leave patients susceptible to secondary bacterial superinfection 
and other pulmonary disorders (Fields, Knipe et al. 2013; Pociask, Scheller et al. 2013).  The 
repair process after IAV infection is poorly understood, but two cytokines, I:-4 and IL-22, have 
been demonstrated to be key to rebuilding the lung architecture and shutting off the immune 
response.  The anti-inflammatory cytokine IL-4 accumulates late in infection, in mice IL-4 levels 
increase at 8 days post infection (Gowdy, Krantz et al. 2010). IL-4 has been shown to blunt CTL 
primary (Aung, Tang et al. 1999) and memory (Bot, Holz et al. 2000) responses to RSV and 
IAV, respectively.  Along with TGFβ, IL-4 has been shown to help CD8+ T-cells develop into 
IL-10 producing, inefficient cytotoxic effectors (Visekruna, Ritter et al. 2013).  IL-4 also drives 
differentiation of macrophages into alternatively activated (M2) macrophages (Gowdy, Krantz et 
al. 2010).  M2 macrophages reduce inflammation by producing the potent anti-inflammatory 
cytokine IL-10, and low levels of IL-12, a key proinflammatory cytokine important in T-cell 
survival and function.  
 IL-22 is another important repair cytokine that has recently been shown to be important 
in the recovery to IAV infection (Pociask, Scheller et al. 2013) and in other models (Sugimoto, 
Ogawa et al. 2008; Schnyder, Lima et al. 2010).  Mice lacking IL-22 had significantly slower 
and less overall repair of the lung epithelium than wild-type mice after IAV infection.  IL-22-/- 
mice also had more lung stiffness and less lung function following IAV infection.  And IL-22-/- 
mice had dysregulated epithelial repair and development genes in the lung, such as secretoglobin 
family 1A, which is important for Clara cell development, and caveolin 1, which is important for 
alveolar type I and endothelial cells (Pociask, Scheller et al. 2013).  The immune system is vital 
for control, elimination and recovery from influenza with the two arms of the immune system, 
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the innate and adaptive immune responses, resulting in a non-lethal, limited infection in the 
majority of exposed patients. 
D. Combating influenza – chasing a moving target 
 While IAV is a major public health concern, the current therapeutic options are limited, 
with vaccination being the most effective tool against the disease.  The IAV vaccine is a yearly, 
trivalent inactivated vaccine, formulated at least six months before the next annual IAV season.  
The current vaccine consists of H3N2, H1N1 and influenza B virus isolates that are predicted to 
dominate the upcoming season.  Vaccine production starts in January with the FDA’s strain 
selection, commercial production beginning in January and February, shipping in September and 
product release around October (Gerdil 2003).  Thus the lead-time from beginning to end for the 
IAV vaccine is about nine months, and if the circulating strain drifts or the chosen strains do not 
dominate the flu season, the vaccine offers little protection (Potter 2001).  Osterholm et al. 
(2012) reviewed 31 IAV vaccine studies and found that the typical trivalent inactivated vaccine 
was only 59% protective in adults (Osterholm, Kelley et al. 2012).  Furthermore, in pandemic 
outbreaks, vaccines cannot be generated and delivered at the required speed or dosage level, due 
to the long lead-time of vaccine production (Moscona 2005).  
Small molecule inhibitors  
Therapeutic treatments for IAV include small-molecule inhibitors such as M2 ion 
channel blockers, amantadine and rimantadine, and neuraminidase inhibitors, including 
oseltamivir and zanamivir.  Amantadine works by binding to the pore opening of the M2 ion 
channel (Figure 1.2), blocking acidification of the endosome-virion interior, the M1-genome 
interaction is not weakened, and prevents genome release into the host cell cytoplasm (Jing, Ma 
et al. 2008).  Oseltamivir and zanamivir target NA by binding the deep, conserved enzymatic 
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pocket responsible for cleaving SA from HA on budding virus, thus preventing mature virion 
release from infected cells.  These and other potent NA inhibitors were designed to fit into this 
pocket as observed in the crystal structure of NA (von Itzstein, Wu et al. 1993). 
In the past decade, resistance to the amantadines has increased dramatically, restricting 
their utility (Potter 2001). Historically, clinical isolates have had resistance rates of 1-3%, but 
during the 2003 flu season, resistant H3N2 isolates from China and Hong Kong emerged and 
quickly spread worldwide.  During the 2005-2006 flu season H3N2 resistance rates for China 
were near 100%, greater than 90% in America, 50% in Europe and averaged 90% worldwide 
(Deyde, Xu et al. 2007; Hayden 2009). Resistance has also arisen in H1N1 isolates, which make 
up a smaller percentage of clinical cases, ranging from 71% resistance in China to about 5% in 
America, and 15% worldwide during the 2006-2007 season (Deyde, Xu et al. 2007).  H1N1 
amantadine resistance has also become fixed, albeit slower than H3N2 resistance, climbing to 
100% resistance in a survey of clinical cases in Hong Kong in 2008 and 2009 (Cheng, To et al. 
2010). The 2009 triple reassortment pandemic strain is also amantadine resistant; Gubareva et al. 
(2010) found that greater than 99% (3,359 out of 3,362) of isolates tested were resistant to 
amantadine (Gubareva, Trujillo et al. 2010). 
Resistance to the NA inhibitor oseltamivir has also rapidly increased: only 12.3% of 
H1N1 viruses tested were oseltamivir-resistant in the 2007-2008 season, but this number 
escalated to 98.5% in the 2008-2009 season (Dharan, Gubareva et al. 2009).  Resistant viruses 
have a mutation in the hydrophobic active site of NA that prevents oseltamivir binding, but does 
not affect zanamivir binding.  Therefore, the frequency of zanamivir resistant isolates is 
markedly lower, but the same escape mechanism is also a danger for acquiring zanamivir 
resistance (Collins, Haire et al. 2008).  Another drawback of NA inhibitors is that they must be 
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used early in the course of an infection to be fully effective (Govorkova, Baranovich et al. 2013).  
If resistance to either of these drugs becomes fixed in the IAV population, then a significant 
amount of available IAV therapeutics would be rendered ineffective.  Clearly, alternative 
treatment options are needed, as resistance becomes an increasing threat. 
Antibody therapeutics 
Antibody treatment as a therapeutic has a long history, beginning before the 1900s with 
Emil von Behring’s Nobel winning anti-diptheria serum, a crude horse sera used to treat multiple 
diseases before the advent of modern antibiotics (Lachmann 2009).  In the intervening years, the 
use of therapeutic antibodies have evolved to be safe, with pure monoclonal antibodies that are 
very effective at treating severe clinical cases, with little side effects.  The majority of 
neutralizing antibodies generated during an IAV infection are against the globular head of HA.  
Neutralizing monoclonal antibodies (mAbs) have been shown to block HA by binding around 
the edge of the receptor-binding domain to create steric hindrance and prevent SA from entering 
the HA binding groove (Krause, Tsibane et al. 2012; Ohkura, Kikuchi et al. 2012).  Broadly 
neutralizing mAbs have been found that bind to multiple HA subtypes.  These mAbs, including 
the F16 antibody, which binds to all 16 HA subtypes (Corti, Voss et al. 2011), have been hyped 
as the next generation of therapeutics; however mAbs have major drawbacks that limit their use 
as therapeutic agents.  Most anti-HA mAbs bind around the receptor-binding site T) to one of the 
five HA antigenic sites.  Escape mutants can rapidly appear in and around these highly variable 
regions, preventing antibody binding and producing an escape variant (Krause, Tsibane et al. 
2012; Rudneva, Ignatieva et al. 2012).  Escape mutants can be generated in vitro or in vivo in the 
presence of neutralizing mAbs.  Mutations on HA include the addition or removal of a charged 
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amino acid residue, additional N-glycosylation sites, or simple steric changes (Hensley, Das et 
al. 2009; O'Donnell, Vogel et al. 2012). 
Neutralizing mAbs as therapeutics also suffer other, more practical issues.  mAbs are 
large, complex molecules that require sophisticated culturing and purification systems.  mAbs’ 
size also reduces the rate of tissue penetration.  In addition, studies have demonstrated that in 
order to achieve clinical efficacy, large doses of antibody are required, driving up production 
costs (Chames, Van Regenmortel et al. 2009).  All of these properties and requirements as well 
as high production costs and significant lead-time make mAbs unsuited for use as a common 
therapeutic.   
Decoy receptors 
An alternative therapeutic strategy is to target the attachment and fusion of IAV particles 
to host cells, specifically the RBS on HA.  A drug targeting the RBS mimics the pathogen’s 
natural ligand on a host cell and therefore is referred to as a receptor decoy.  The principle of 
receptor decoys as therapeutics is wide-ranging; Dennehy et al. (2007) dramatically inhibited 
bacterial phage growth when decoy cells – bacteria susceptible to infection but not permissive to 
phage replication – were mixed into a population of phage permissive bacteria.  Human 
pathogens are also susceptible to decoy therapeutics.  Asher et al. (2005) created transgenic mice 
with coxsackievirus B receptor expressed on erythrocytes, creating a decoy cell that bound virus 
but did not allow for replication.  The recombinant decoy mice had reduced viral load and less 
mortality after coxsackievirus infection. Ziebert et al. (1992) blocked poliovirus infectivity using 
a soluble form of the receptor’s ligand as a decoy.  For IAV, and other viruses that bind to SA, it 
is possible that sialylated glycans in breast milk may act as natural receptor decoys for newborns 
(Martin-Sosa, Martin et al. 2003).  
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Influenza virus decoy receptors 
The receptor decoy approach has also been used to combat IAV.  Like all RNA viruses, 
the IAV polymerase is error prone and the antigenic sites on the immunodominant proteins 
rapidly change. However, regions critical for IAV function, such as the RBS of HA, are well 
conserved (Suwannakarn, Chieochansin et al. 2010) and therefore make ideal drug targets.  
While SA is the key monosaccharide on the host-glycan that interacts with HA, the monovalent 
HA-SA interaction is weak.  Several groups have tested different monovalent SA-containing 
molecules and found that they bind and inactive IAV, but the 50% inhibitory concentration 
(IC50) of these SA analogs for IAV attachment varies from the millimolar (Sauter, Bednarski et 
al. 1989; Glick, Toogood et al. 1991; Matrosovich, Gambaryan et al. 1993) to the micromolar 
range (Weinhold and Knowles 1992).  IAV attachment involves many individually weak HA-SA 
binding events.  Combining many weak HS-SA interactions creates a strong, multivalent link, a 
process utilized by many viruses (Kiessling and Pohl 1996).  Synthetic multimers of SA can 
recreate a multivalent bond between virus and receptor decoy. Building on the findings from 
monovalent SA analogs, Glick et al. (1991) created SA-containing dimers, doubling the number 
of SA residues available on each molecule for binding HA, and presumably increasing binding 
affinity.  SA dimers do have stronger affinities than monovalent SA, but they are still in the same 
log IC50 range (Glick, Toogood et al. 1991).  In order to increase the SA decoy attachment IC50 
by any significant amount, SA oligomerization is required.   
Oligomerization of sialosides greatly increases the apparent affinity for HA, making them 
strong inhibitors.  Several groups have made multivalent SA molecules either by linking SA into 
a dendrimer structure (Reuter, Myc et al. 1999), or by linking SA to one of several polymer 
backbones (Spaltenstein and Whitesides 1991; Lees, Spaltenstein et al. 1994; Mochalova, 
Tuzikov et al. 1994; Mammen, Dahmann et al. 1995; Gambaryan, Tuzikov et al. 2002).  When 
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complexed into a polymer backbone, SA forms multivalent interactions with many HA trimers 
on a single IAV virion, and possibly on multiple virus particles, creating larger complexes ideal 
for immune surveillance.  Polymerized receptor decoys also suffer from several critical defects.  
One major drawback to these polymers is that some backbones are cytotoxic.  Most SA polymers 
above are built with backbones of polyacrylamide derivatives, and the breakdown monomer of 
polyacrylamide is a potent human neurotoxin and carcinogen.  Polymerized SA decoys have 
rigid backbones, with fixed spacing of SA.  This fixed spacing could prevent maximal binding of 
SA to HA, limiting the binding strength.  Polymers are also often partially insoluble and 
antigenic, making them less than ideal for in vivo use.   
Sialylated decoy liposomes 
An alternative method for generating multivalent, polymer-like molecules is to create 
sialylated liposomes.  Liposomes, first described in the 1950s, are synthetic vesicles produced 
from purified phospholipids, which consist of a hydrophilic lipid bilayer that surrounds an 
aqueous interior.  Liposomes are especially suited for creating polymer-like functional groups 
because the lipid bilayer is fluid, allowing for lipid-conjugated functional groups to diffuse 
across the surface (Baumgart, Hess et al. 2003).  Using naturally occurring lipids and other 
components, such as cholesterol, liposomes are not immunogenic and have long in vivo half-
lives (Immordino, Dosio et al. 2006).  Additionally, many changes can be made to the basic 
formulation, such as inclusion of charged lipids, lipids with different acyl chemistries, and drug 
loading into the liposome interior.   
The data presented in this dissertation demonstrates that SA-containing liposomes are 
effective inhibitors of IAV infection.  Previously, several groups have created SA-containing 
decoy liposomes that were capable of inhibiting IAV hemagglutination better than the 
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monovalent building blocks and on par with other SA-polymer decoys.  These studies show that 
liposomes can be used to create polymer-like multivalency of SA, but they were limited in scope.  
The majority only tested binding by the HAI assay (Kingerywood, Williams et al. 1992; Sun, 
Kanie et al. 2000).  The two studies that tested infectivity inhibition also had major flaws; 
Spevak et al., (Spevak, Nagy et al.) had a disconnect between their HAI and infectivity results 
when they used liposomes with different mole percentages of SA.  Decoy liposomes created by 
Guo et al., (Guo, Sun et al.) inhibited H3N2 IAV but were ineffective against H1N1 IAV.  These 
previous decoy liposome studies have a few notable differences from the data presented in this 
dissertation.  First, each study used a single SA residue attached directly to the phospholipid or 
steric linker.  IAV will bind to a single SA residue linked in either a α2-3 or α2-6 bond directly 
to the lipid backbone, but longer glycan chains allow for optimal presentation of the terminal SA 
for different subtypes of IAV.  LSTc is a long glycan, and it adopts an umbrella-shaped 
conformation when bound to human-adapted HA while LSTa forms a conical conformation 
when bound to avian-adapted HA (Xu, Newhouse et al. 2009) and LSTc and LSTa have been 
shown to bind to several HA subtypes (Chandrasekaran, Srinivasan et al. 2008).  The liposomes 
presented in this study contain a two acyl, unsaturated phospholipid with a low melting 
temperature, meaning that the decoy liposomes will be fluid at body temperature, whereas the 
lipids used in previous studies have had higher melting temperatures, possibly reducing the 
bioavailability of liposomal SA and reducing efficacy.  The changes our group have made in the 
decoy liposome formulations represent a new generation of state-of-the-art decoy liposomes 
capable of inhibiting multiple IAV subtypes’ infectivity as well as other pathogens when decoy 
liposomes are created with the corresponding decoy glycolipid 
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E. Model systems for studying Influenza 
 Our receptor decoy liposomes target IAV via its receptor protein HA, by providing the 
virus with higher affinity α2-6 linked SA analogs.  There are many methods that can be used to 
measure the effectiveness of these decoy liposomes to bind and inactivate IAV. One proven 
method for rapid screening for competitive binding is the hemagglutination inhibition assay, or 
HAI. IAV binds to SA on the surface of red blood cells (RBCs), which contain both α2-6 and α2-
3 linked SA, causing hemagglutination.  A constant amount of virus that will agglutinate RBCs 
is tested against candidate drugs, diluted serially two-fold.  Here SA-containing decoy liposomes 
are challenged with a constant amount of IAV.  If the drug is present in sufficient quantities, then 
hemagglutination will be inhibited.  Once diluted past the inhibitory concentration of drug, IAV 
will agglutinate, and a inhibitory concentration of the drug can be calculated.  In our studies, 
decoy liposomes or control liposomes are serially diluted and mixed with four HA units of one of 
several IAV strains.  The reciprocal of the last dilution of decoy liposome that inhibits 
agglutination is the HAI titer, and the inhibitory concentration (IC90) molarity of SA can be 
calculated for that dilution.  Because the assay can be completed in about two hours, many IAV 
strains and decoy liposome formulations can be screened for competitive binding in a rapid 
manner, and this assay serves as an initial test of decoy effectiveness.   
 Decoy-virus binding can also be directly visualized with microscopy.  Binding, in the 
form of colocalization, can be detected with adhered virus and decoys in solution.  By using 
fluorescent tags added onto IAV and distinct tags incorporated into liposomes, specific 
colocalization can be measured by confocal microscopy after washing away unbound decoy or 
control liposomes. This model allows us to directly visualize binding and with powerful 
colocalization analysis calculations, (Bolte and Cordelieres 2006) determine if the data is 
biologically significant.  Flow cytometry can also be used to measure binding.  IAV will adhere 
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to cells displaying surface SA and decoy inhibition of decoy binding can be measured by 
fluorometric analysis of labeled virus.  IAV can be labeled either by covalent Alexa Fluor 
labeling or by anti-IAV antibody staining.  Binding of labeled virus is measured in the presence 
or absence of an anti-viral drug.  Flow cytometry has the advantage of using relevant target cells, 
e.g., the human lung epithelial cell line A549, to demonstrate decoy liposome-dependent binding 
inhibition.   
 Whereas competitive binding indicates that a drug would neutralize the virus and prevent 
infection, direct measurement of infectivity is required for verification.  The Madin-Darby 
Canine Kidney (MDCK) cell is the standard cell line used to test IAV replication.  Used widely 
as a model epithelial cell line, MDCK cells have both α2-6 and α2-3 linked SA and are 
permissive to IAV.  To measure infectivity inhibition, decoy or control liposomes are mixed with 
a fixed amount of virus before addition to MDCK cells.  In this experimental setup, viral 
particles are expected to bind to native SA on MDCK cells only when not competitively bound 
to decoy liposomes.  Viral particles bound to decoy liposomes are unable to attach to the MDCK 
cells and thus would be inhibited.  In this assay, unbound virus and decoys are washed out after a 
one-hour infection, and agar is added on top of the cell monolayer.  Internalized virus is allowed 
to grow in the MDCK monolayers, viral spread is prevented by the agar, and distinct plaques 
form where one infectious particle originally infected the MDCK monolayer.  
 The plaque inhibition model assays the decoy liposome’s ability to block initial binding 
and infectivity, and with serial dilutions of liposomes, can quickly generate dose response data 
from which a 50% inhibitory concentration (IC50) of each liposome formulation can be 
calculated.  An advantage of this system is that MDCK cells present both α2-6 and α2-3 SA 
linkages, allowing IAV isolates that bind to either or both to be tested against our decoy 
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liposomes.  When tested with only α2-6 linked SA containing liposomes, these cells present a 
higher bar to inhibition if the IAV isolate can bind to both α2-6 and α2-3 linked SA. 
 The MDCK infectivity model can be expanded to assay viral growth over several 
replication cycles.  The IAV growth model is a similar assay, but after the initial one-hour 
infection, IAV growth media is added with decoy or control liposomes and replication is allowed 
to continue.  In this model, the amount of virus that is challenged with decoy liposomes is 
several logs higher than in the MDCK infectivity assay above.   This model is well suited to fully 
test the log scale of inhibition from decoy liposomes.  However, this system is more cumbersome 
and time-consuming and is therefore not useful for screening small formulation changes to the 
liposome platform.   
 Of the several in vivo model systems for IAV infection, the pulmonary mouse infection is 
the most applicable for testing our decoy liposomes.  The mouse system benefits from a plethora 
of species-specific molecular and genetic tools.  IAV infection in mice is dose-dependently 
lethal, with predictable weight loss kinetics that can be used as a proxy for successful inoculation 
of virus, with higher doses resulting in faster and greater weight loss (Powell, Dwyer et al. 2006).  
IAV infection in mice results in cytokine and type I IFN production in the lungs, followed by 
leukocyte infiltration.  Viral titers peak 4 to 7 days post infection and clearance is dependent on 
B-cells (Graham and Braciale 1997), as is also true in humans.  The major difference between 
the mouse model and humans is that the human upper airways mainly contain α2-6 linked SA, 
and lower airways have both α2-6 and α2-3 linked SA, while mice have an even distribution of 
α2-6 and α2-3 linked SA throughout their airways (Fields, Knipe et al. 2013).  Due to this 
disparity, some mouse-adapted IAV strains bind α2-3 linked SA more than when first isolated 
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from humans, but a decoy that uses α2-6 SA to inhibit mouse pathogenesis is predicted to also 
work on α2-6-adapted virus when α2-3 linked SA is not present.   
 
F. Thesis objectives 
IAV is an important public health threat.  It evolves rapidly by a combination of antigenic 
shift and antigenic drift, limiting the effectiveness of the current therapeutics.  The current 
vaccine must be reformatted yearly and, due to lead-time, may not fully protect the recipients.  In 
addition, IAV has rapidly developed resistance to several small molecule inhibitors, and 
resistance remains a threat for the few remaining clinical inhibitors available.  To be successful, 
an inhibitor of IAV must target a highly conserved region of the virus.  The SA receptor binding 
site, or RBS, is highly conserved between IAV subtypes.   A receptor decoy that binds strongly 
to the RBS would bind and inactivate multiple strains of IAV and resist escape mutations.   
In this dissertation, I will examine the use of decoy receptor liposomes as a method of 
creating strong, neutralizing interactions with IAV as a potential therapeutic.  The specific aims 
of this dissertation are as follows: 
1. Characterize novel LSTc-containing decoy receptor liposomes as an IAV therapeutic 
⁃ Investigate the mechanism by which decoy liposomes neutralize IAV  
⁃ Establish the degree of inhibition of a number of IAV H1 and H3 subtypes 
⁃ Characterize an in vivo mouse model of protection with decoy liposomes 
2. Optimize the decoy liposome platform  
⁃ Test additions and modifications of the liposome formulation in order to improve 
IAV inhibition  
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⁃ Exchange the decoy receptor glycolipid with LSTa and characterize the inhibitory 
properties against IAV and  
3. Create decoy liposomes that target the heparan sulfate binding viruses 
⁃ Generate heparin octasaccharide glycolipid-containing decoy liposomes and 
characterize the inhibitory properties against herpes simplex virus, respiratory 
syncytial virus and human parainfluenza virus 3. 
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Chapter II 
Materials and Methods 
Purification of LSTc and LSTa − LSTc and LSTa were either obtained from a commercial source 
(Dextra, Reading, UK) or purified from milk. Frozen bovine milk was thawed and centrifuged at 
4,000 x g for 10 min at 4°C. The upper fatty layer was discarded and the lower aqueous layer 
was mixed with 2 volumes of ethanol and kept at 4°C overnight. Precipitate was removed by 
centrifugation at 12,000 x g for 10 min at 4°C; the supernatant, consisting primarily of 
oligosaccharides and lactose, was dried under nitrogen at room temperature and then 
reconstituted with 0.2 volumes of fresh 20% methanol and stored at -20°C until use. To separate 
LSTc or LSTa from other oligosaccharides, the reconstituted solution was subjected to dual stage 
purification, using size exclusion as the first step to remove high molecular weight material and 
to exchange the sample into a suitable buffer. As the second step, weak anion exchange 
purification was performed using ammonium formate as the eluting agent. Fractions were 
monitored by mass spectrometry, pooled and lyophilized. Purity of sample was assessed using 
capillary electrophoresis. 
 
Purification of HS-octa − Full length heparin was purchased from a commercial source, and 
cleaved into oligosaccharides with heparinase. To separate octasaccharide from other 
oligosaccharides, the reconstituted solution was subjected to dual stage purification, using size 
exclusion as the first step to remove high molecular weight material and to exchange the sample 
into a suitable buffer. As the second step, weak anion exchange purification. Fractions were 
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monitored by mass spectrometry, pooled and lyophilized. Purity of sample was assessed using 
capillary electrophoresis. 
 
Glycolipid synthesis – 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) (Avanti Polar 
Lipids, Alabaster, AL) and N-(FMoc-13-amino-4,7,10-trioxa-tridecyl)succinamic acid (FMOC) 
(Polypeptide Laboratories, San Diego, CA) were purchased from commercial sources and used 
without further purification. Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride 
(EDC) was purchased from Sigma-Aldrich (St. Louis, MO). Thin layer chromatography (TLC) 
was performed on silica-coated glass plates. Column chromatography was performed using silica 
gel 60 Å. Mass spectrometry was performed using 4800 MALDI-MS and MALDI-TOF 
instruments (Voyager DE-STR, Applied Biosystems, Carlsbad, CA). Solvent evaporation was 
performed on a rotary evaporator under reduced pressure at 30-35°C. All other synthetic lipids 
were purchased as solutions in chloroform (Avanti Polar Lipids, Alabaster, AL) including: 
DOPC (1, 2-dioleoyl-sn-glycero-3-phosphocholine), DOPG (1, 2-dioleoyl-sn-glycero-3-
[phospho-rac-(1-glycerol)] (sodium salt)), and DOPE-NBD (1, 2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt)).  Cholesterol 
(purity ≤99%, MW 386.65) was purchased dry (Sigma-Aldrich, St. Louis, MO) and dissolved in 
chloroform.  Chloroform was >99.8% pure, stabilized with ethanol (Acros Organics, Morris 
Plains, NJ), ethanol was 200 proof (Goldshield Chemical Co., Hayward, CA), hydrochloric acid 
was certified ACS plus (Fisher Scientific, Pittsburgh, PA), and all water used was ultra-purified 
(MilliQ A10, Millipore, Billerica, MA).   
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DMB-HPLC quantification – LSTc incorporation into glycolipid was quantified by HPLC as 
described by Klein et al. (Klein, Veenstra et al. 1997); briefly, glycolipid or standard was treated 
with 2N glacial acetic acid at 80˚C for 5 h and then dried by centrifugal evaporation.  Samples 
were treated with 30 µL 1,2-diamino-4,5-methylene dioxybenzene (DMB) labeling mixture (1.6 
mg 1,2-diamino-4,5-methylenedioxybenzene dihydrochloride, 3.1 mg sodium hydrosulfite, 58 
µl  β-mercaptoethanol, 82 µL glacial acetic acid per mL) at 50˚C for 2.5 h in the dark.  Samples 
were diluted with 20 µL ddH20, and analyzed by reverse phase HPLC using a TSKgel ODS-
120T column (Tosoh Corp., South San Francisco, CA) running 7% methanol in 
water.  Fluorescence of the DMB-SA complex is detected at ex373/em448. 
 
Liposome Preparation – Gas-tight syringes (Hamilton Co., Reno, NV) and 4 mL borosilicate 
glass vials with Teflon-lined caps (National Scientific, Rockwood, TN) were thoroughly cleaned 
before use.  Syringes were rinsed 10x with 100% ethanol and then 10x with chloroform.  Vials 
were soaked in 300 mM HCl for 1.5 h, and then rinsed thoroughly with water, 3x with ethanol 
and 3x with chloroform.  Residual solvent was evaporated under a filtered stream of dry nitrogen 
gas.   
 Lipids were mixed and deposited in clean vials using clean syringes.  Solvent was 
evaporated under a filtered stream of dry nitrogen gas while manually rotating the vial until only 
a thin layer of lipid remained on the inner walls.  Residual solvent was removed by placing 
uncapped vials in a desiccator (Dry Seal; Wheaton, Millville, NJ) followed by application of 
reduced pressure for 24 h using an oil-free diaphragm vacuum pump (Gast, Benton Harbor, MI).   
 Aqueous lipid solutions were made by hydrating lipid films in 150 mM phosphate 
buffered saline (PBS) (140 mM NaCl, 8.5 mM NaH2PO4, 1.5 mM Na2HPO4, pH 7.4) and 
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vortexing for 2 min in 30 s intervals.  Lipid solutions were then subjected to 10 rapid cycles of 
freeze-thawing by submersion in liquid nitrogen and 70°C water, respectively, to break apart 
multi-lamellar structures, and then extruded through 200 nm pores.  Extrusion consisted of either 
10 passes through an aluminum oxide membrane using a Lipex Thermobarrel Extruder (Northern 
Lipids, Burnaby, BC, Canada) or 21 passes through a polycarbonate membrane using a 
LiposoFast-Basic Extruder (Avestin; Ottowa, ON, Canada).  Extruders were thoroughly cleaned 
and primed with buffer before use.  After the final pass, samples were collected in a clean vial, 
sealed with a Teflon-lined cap and stored at 4°C until use.  
 Lipid concentration post-extrusion relative to pre-extrusion was determined by 
fluorimetry.  Typical recoveries were ~50% with the Lipex Thermobarrel Extruder and ~80% 
with the LiposoFast-Basic Extruder.  The concentration of lipid in a final solution made from a 
stock mixture of 3 mol% DOPE-NBD and 97 mol% DOPC was determined colorimetrically, as 
described (Weirich, Israelachvili et al. 2010) and served as a reference for fluorimetric 
measurements on solutions made from the same lipid stock.  Results were consistent with 
concentrations estimated based on mass lipid deposited and volume hydrated. Samples 
containing DOPE-NBD or DOPE-Rh were hydrated to an estimated concentration of 7.7 mM 
total lipid.  
 
Liposome modifications – The decoy liposome formulation described above was modified to 
include the following additions.  The construction process for each modification was the same as 
above, except where noted, all changes were made to both control and LSTc-containing decoy 
liposomes. Size changes: liposomes were extruded through either a 20 or 200 nm pore during the 
passes through the extruder membrane.  Liposomes with cholesterol: 30 mol% of cholesterol was 
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added to the lipid mix, and the amount of DOPC used was decreased by 30 mol%.  Osmotic 
crushed liposomes: control and decoy liposomes were extruded into a buffer containing 15 mM 
PBS.  The liposomes remained in this buffer till immediately before testing, when they were 
diluted to the desired concentration of SA in 150 mM PBS, causing water outflux from the 
liposome interior.  PEGylated liposomes were created by adding 10 mol% PEG-1000–DOPE 
(Avanti Polar Lipids) to the lipid mix and decreasing the DOPC amount used by the same 
amount.  Liposomes with 15 mol% negative charge were created by either (i) increasing DOPG 
lipid by 7.5 mol%, or (ii) increasing LSTc-DOPE glycolipid by 7.5 mol% and decreasing DOPC 
lipid by the same extent in both methods.   
 
Liposome Characterization – Diameter and polydispersity of liposomes were determined by 
dynamic light scattering (Zetasizer Nano; Malvern Instruments, Worcestershire, UK) specifying 
a lipid refractive index of 1.480 and a dispersant (150 mM PBS) refractive index of 1.332.  
Measurements were taken using 40 µL disposable cuvettes at room temperature (20°C) and a 
backscattering angle of 173 degrees. Data are reported as the average of five measurements 
separated by 15 s.  Decoy liposomes were stored at 4°C for 12 months and were stable over this 
period, retaining their anti-IAV properties.   
 
Viral strains – Influenza A/Puerto Rico/8/34 virus (PR/8, H1N1) was generously provided by 
Susan Swain (University of Massachusetts, Worcester, MA).  Influenza A/Philippines X-79 
(H3N2) was provided by Richard Dutton (University of Massachusetts, Worcester, MA).  
Influenza A/Aichi/68 (X-31, H3N2) and Sendai virus (Cantell Strain) were purchased from 
Charles River Laboratories (North Franklin, CT). Influenza A/Beijing/262/95 (H1N1) was 
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purchased from Meridian Life Science (Saco, ME). HSV-1 kos was generated in the laboratory 
of Dr. David Knipe (Harvard Medicical School.  Influenza viruses and Sendai virus were 
originally grown in the allantoic cavity of embryonated chicken eggs.  Influenza viruses were 
stored at -80°C prior to use and titrated on Madin-Darby canine kidney (MDCK) cells. 
Respiratory syncytial virus (RSV) strain A2 was grown in Vero cells in 5% fetal bovine serum 
(FBS), cell debris was frozen at -80°C and subsequently titrated on Vero cells. Recombinant 
influenza A/WSN/33 with AlexaFluor 647 covalently attached to the HA protein via sortase 
(WSN HA-647) was prepared as described (Popp, Karssemeijer et al. 2012) and stored at 4°C 
prior to use. 
 
Cell lines – MDCK cells were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA) and were cultured in Eagle’s minimal essential medium (MEM) with 10% fetal 
bovine serum (FBS), 2 mM L-glutamine, 2 mM Penicillin/Streptomycin (Pen/Strep), 0.1 mM 
non-essential amino acids and 1 mM sodium pyruvate. A549 cells were obtained from ATCC 
and cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS and 2 mM 
Pen/Strep.  Vero cells were obtained from ATCC and cultured in DMEM with 10% FBS and 2 
mM Pen/Strep.   
 
Mouse infection studies – Female C57BL/6 wild-type mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME).  Mice were 8 to 10 weeks of age at the time of infection. IAV 
(1,000 plaque forming units or PFU) was combined with LSTc decoy liposomes (170 µM SA) or 
the equivalent amount of control liposomes in a final volume of 30 µL and incubated at 37°C for 
30 min. Samples were stored on ice until use.  Mice were infected intratracheally with 30 µL of 
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sample and monitored daily. Mice were scored as deceased when found dead or were clearly 
imminently moribund, in which case they were euthanized. The University of Massachusetts 
Medical School Institutional Animal Care and Use Committee approved all experimental 
protocols. 
 Mice infected for lungs harvests were infected as described above, except as noted.  Mice 
infected with 350 PFU of IAV were given an overdose of anesthesia, lungs were removed, and 
stored in 300 µL ice-cold PBS.  Lungs were stored at −80°C prior to use.  Lung samples were 
thawed on ice, homogenized and clarified.  IAV viral titer were tested by serial dilution of 
samples in PBS-1% BSA and plaqued on MDCK cells as described below.  Lung IL-1β levels 
were measured from lung samples by EILSA (BD Biosciences, San Jose, CA).   
 Mice infected before decoy liposome treatment were given 350 PFU of IAV diluted into 
sterile saline in a final volume of 30 µL and incubated at 37°C for 30 min and stored on ice prior 
to use.  Mice were anesthetized, infected intratracheally with 30 µL of virus, and rested for 30 
min before being anesthetized again and treated intratracheally with LSTc decoy liposomes (170 
µM SA) or the equivalent amount of control liposomes diluted in sterile saline in a final volume 
of 30 µL (stored on ice).  Mock treatment mice were anesthetized and given 30 µL of ice-cold 
saline. Mice infected after decoy liposome treatments were treated in a similar fashion but with 
the regimen reversed, and they received 1,000 PFU of PR/8.    All mice were followed as 
described above.   
 
Hemagglutination inhibition assay – Red blood cells (RBCs) were isolated from normal human 
peripheral blood, blood type O.  Whole blood was washed in sterile PBS three times to remove 
serum.  Packed RBCs were diluted 1:30 in sterile PBS and stored at 4°C prior to use. All 
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procedures involving human subjects were approved by the University of Massachusetts Medical 
School Committee for the Protection of Human Subjects in Research and in accordance with the 
Declaration of Helsinki. 
 HA titers for each virus were determined on RBCs prior to inhibition studies per 
standard protocol (Choi, Mammen et al. 1996). For hemagglutination inhibition (HAI) assays, 
liposome samples were diluted two-fold in PBS. Four HA units of virus in 25 L of PBS were 
added to all dilutions.  Samples were incubated for 30 min at room temperature.  50 L of diluted 
RBCs were added to the wells and incubated for an additional hour at room temperature to allow 
agglutination.  The HAI titer is the reciprocal of the last dilution of liposomes that results in non-
agglutinated RBCs. 
 
Plaque assay with immunostaining – MDCK cells were seeded into 12-well plates and incubated 
at 37°C for 24 hours to form monolayers.  Liposome samples were diluted to the desired 
concentration in sterile PBS-1% bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO) in 
a final volume of 225 l.  IAV was diluted to 300 PFU/mL and mixed 1:1 (v/v) with liposome 
samples and incubated at 37°C for 30 min.  MDCK cells were washed twice with PBS-1% BSA 
and samples were added to wells in duplicate (200 µL per well). Samples were incubated at 37°C 
for 1 hour on MDCK cells. Cells were washed with PBS-1% BSA and overlaid with freshly 
prepared 0.5% agar in DMEM-F12 and incubated at 37°C for 48 hours.  Cells were fixed and 
stained with anti-hemagglutinin antibody MAB8261 (Millipore, Billerica, MA).  Plaques were 
visualized with anti-mouse horseradish peroxidase–conjugated secondary antibody (BD 
Biosciences, San Jose, CA) and developed with peroxidase substrate kit (Vector Laboratories, 
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Burlingame, CA).  Viral plaques in the MDCK monolayer were counted and the PFU/mL was 
determined. 
  For some experiments, RSV was used in a similar fashion, except as noted.  Vero cells 
were grown to confluency in 24-well plates.  Liposome samples, heparin or HS-octa in solution, 
were diluted to the desired concentration in serum-free DMEM in a final volume of 130 µL.  
RSV was diluted to 1,000 PFU/mL and mixed 1:1 (v/v) with treatment samples and incubated at 
37°C for 30 minutes.  Vero cells were prewashed in serum-free DMEM before addition of 100 
µL of sample, in duplicate.  After one hour of infection, cells were washed with DMEM-10% 
FBS and incubated in DMEM-10% FBS and 2 mM Pen/Strep for three days at 37°C.  Cells were 
fixed with 80/20 (v/v) acetone/PBS and stained with anti-F and anti-G glycoprotein antibodies 
(MAB8599 and MAB858, respectively; 1:1000 dilution, Millipore, Billerica, MA).  RSV plaques 
were visualized and quantified as for IAV. 
 
HSV Plaque assay – HSV-1 plaque assays were done in a similar fashion to RSV plaque assays, 
except as noted.  After the one hour infection, cells were washed with PBS and incubated in 
DMEM with 1% FBS and 0.165 mg/ml of Human IgG (Innovative Research, Novi, MI) for two 
days at 37°C.  Cells were fixed and stained with 20% ethanol, 0.5% crystal violet.  
 
Lactate dehydrogenase release  – MDCK cells were plated into a 96 well plate at 2.5 × 104 cells 
per well and allowed to become adherent.  Cells were washed with PBS-1% BSA and treated 
with decoy liposomes ranging in concentration from 164 to 2,625 nM LSTc (2 fold increments) 
or control liposomes at lipid concentrations equivalent to the 2,625 nM LSTc decoy liposome 
treatment, for 1 hour at 37°C.  Cells treated with Triton X-100 were used at 100% lysis controls 
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and cells treated with PBS-1% BSA were used as no lysis controls, both in done duplicate.   
Cells were spun at 250 G for 10 min at 4°C and 100 µl of supernatants were tested with a 
colorimetric LDH release kit (Roche, Mannheim, Germany).   
 
Inhibition of IAV growth – MDCK cells were seeded into 24-well plates and allowed to grow to 
confluency overnight at 37°C. MDCK monolayers were washed with PBS-1% BSA, and treated 
with decoy liposomes ranging in concentration from 1 to 1,000 nM SA LSTc or control 
liposomes, at lipid concentrations equivalent to the 1,000 nM SA LSTc decoy liposome 
treatment, for 30 min at 37°C.  Treated MDCK cells were then infected at a multiplicity of 
infection (MOI) of 0.01 or 0.001 of PR/8 diluted in PBS-1% BSA without removal of liposome 
solution.  After an infection period of one hour at 37°C, the inocula were removed and MDCK 
cells were washed with PBS-1% BSA. Viral growth medium (0.5 mL) with identical liposome 
treatment as during the infection step was added.  After 24 hours, supernatants were taken and 
virus growth was measured by plaque assay 
 
Inhibition of RSV growth – Vero cells were seeded into 24-well plates and allowed to grow to 
confluency overnight at 37°C.  Vero cells were washed with serum free DMEM.  RSV was 
either (i) co-incubated with liposome treatments for 30 minutes at 37°C before infection or where 
indicated (ii) added to Vero cell monolayers 15 minutes at 37°C before liposome treatment.  
Decoy liposomes were use at concentrations ranging from 0.01 to 10µM HS-octa decoy 
liposomes containing either 10 or 30 mol% HS-octa or control liposomes, at lipid concentrations 
equivalent to the highest concentration decoy liposomes.  After an infection period of one hour at 
37°C, the inocula were removed and Vero cells were washed with serum free media. Viral 
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growth medium (0.5 mL) with identical liposome treatment as during the infection step was 
added.  After 24 hours, supernatants were taken and virus growth was measured by plaque assay. 
 
Inhibition of HSV growth – Vero cells were seeded into 24-well plates and allowed to grow to 
confluency overnight at 37°C.  Vero cells were washed with serum free DMEM.  HSV was co-
incubated with liposome treatments ranging from 10-4 to 10 µM HS-octa decoy liposomes or 
control liposomes, at lipid concentrations equivalent to the highest concentration decoy 
liposomes, for 30 minutes at 37°C before infection.  After an infection period of one hour at 
37°C, the inocula were removed and Vero cells were washed with serum free media. Viral 
growth medium (0.5 mL) with identical liposome treatment as during the infection step was 
added.  After 48 hours, cells were fixed and stained with 20% ethanol, 0.5% crystal violet and 
evaluated for monolayer loss. 
 
Flow cytometry – Adherent A549 cells were detached with 0.25% Trypsin/2.21 mM EDTA.  
Cells were washed twice with PBS, enumerated using a hemocytometer, and transferred to 96-
well round-bottom plate (Costar, Washington DC) at 50,000 cells per well.  Alexa Fluor labeled 
IAV (WSN HA-647) and decoy liposomes were co-incubated for 30 min.  WSN HA-647 was 
tested at 1.3, 6.5 and 13 HA units with 1000 nM, 7.5 mol% LSTc decoy liposomes, diluted in 
PBS-1% BSA in a final volume of 50 l.  Control liposomes without LSTc were diluted to the 
same lipid concentration as decoy liposomes. Cells were treated with virus/decoy mixtures for 15 
min at 37°C before being fixed with formalin (final concentration 1%). Cells were analyzed 
using a BD LSR II flow cytometer and FlowJo version 9.4.11 (TreeStar software). 
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Confocal microscopy – 30 HA units of WSN HA-647 were absorbed onto glass coverslips 
overnight, then treated with either 7.5 mol% LSTc decoy liposomes or control liposomes, both 
containing NBD-labeled lipids.  Decoy liposomes were diluted to 1,000 nM LSTc in a final 
volume of 50 µL; control liposomes were diluted to the same lipid concentration as the decoy 
liposomes. Decoy or control liposomes were incubated on the WSN HA-647 coverslips for 30 
min at 4°C and washed three times with PBS-1% BSA before imaging.  For experiments 
involved decoy liposomes binding to cell surfaces, A549 cells were grown overnight on glass 
coverslips and infected the next day with PR/8 IAV at a MOI of 1, diluted in PBS-1% BSA.  
After an infection period of one hour at 37°C, the inoculate was removed and A549 cells were 
washed with PBS-1% BSA.  A549 cells were incubated overnight in viral growth medium at 
37°C. Cells were then washed with PBS-1% BSA and mixed with decoy or control liposomes, 
diluted as described above for 30 minutes, at 37°C.  Cells were fixed and stained for anti-
neuraminidase (ab21305; 1:50 dilution, Abcam, Cambridge, MA) and visualized with anti-rabbit 
IgG Alexa-594 conjugated secondary antibody (A11012, Invitrogen) and Hoechst 34580 (diluted 
to 5 µg/ml; Invitrogen).  For all experiments, images were taken on a Leica SP2 AOBS confocal 
laser-scanning microscope with a 63X objective using the Leica Confocal Software (version 
2.6.1).  Multichannel images were obtained by sequential scanning with only one laser active for 
each scan to avoid cross-excitation.  Overall brightness and contrast of images were optimized 
using Image J (Schneider, Rasband et al. 2012).  
 
Statistics – Statistical analysis was performed using the unpaired, two-tailed Student’s t-test. 
Values of p ≤ 0.05 were considered significant.  Error bars are ± standard deviation or ± standard 
error of the mean (SEM), as listed in each figure legend.  For survival analysis, the Mantel-Cox 
 41 
Log-rank test was performed.  Statistics were calculated using Prism Version 6.0 (GraphPad 
Software). 
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Chapter III 
Use of sialic acid containing decoy liposomes to prevent influenza A virus 
infection 
Preface 
This chapter contains information dealing with the construction, characterization and 
quantification of LSTc-containing and control liposomes and their use as a therapeutic against 
IAV infection.  The entire process would not have been possible without the collaboration of the 
following labs, Dr. Zachary Shriver’s laboratory at the Massachusetts Institute of Technology 
purified LSTc glycans and constructed glycolipids to form the building blocks of the LSTc-
containing liposomes; Dr. Deborah Fygenson’s laboratory, especially Dr. Kim Weirich and 
Lourdes Velazquez, at the University of California at Santa Barbra constructed and characterized 
all liposomes, including the many modified liposomes that were perfected over the span of this 
dissertation; Dr. Hidde Plough and Dr. Joe Ashour at the Whitehead Institute provided the Alexa 
Fluor-labeled recombinant sortase IAV and assisted with manuscript preparation. I tested the 
liposomes in all experiments described below, including HAI assays, confocal and flow 
cytometry to test Alexa Fluor-labeled IAV binding, infectivity assays and growth inhibition 
studies, mouse infections and analysis, statistical analysis and manuscript preparation for 
publication. 
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Introduction 
Influenza poses a significant and on-going public health risk, even with the licensed 
vaccine.  The yearly reformatted vaccine has the potential to be made against a strain that does 
not become one of the dominate circulating strains in the following the flu season, and therefore 
can fail to provide adequate protection.  Likewise the vaccine will not protect against newly 
emerged, potentially pandemic IAV strains.  For these situations, anti-IAV therapeutics must be 
used in life-threatening cases.  Several small molecule inhibitors and commercial neutralizing 
mAbs are available for patients; however, circulating strains of IAV have shown an alarming 
ability to develop resistance to these drugs, so much so that use of some for example, 
amantadine, are no longer used clinically.  In this chapter I will describe a novel approach to 
create a potential therapeutic for IAV that combines the use of receptor decoy and liposomal 
delivery technologies.  By taking advantage of the virus’ own receptor and need to bind sialic 
acid in order to infect a target cells, our collaborators constructed lipid bi-layer liposomes 
functionalized with a sialic acid containing molecule to bind to IAV HA.  The use of liposomes 
as a scaffold for SA allows for optimal presentation to HA, and formation of multivalent 
interactions between decoy and virus.  The data described in this chapter demonstrate that sialic 
acid functionalized liposomes can bind to and inhibit IAV both in vitro and in vivo, and they may 
be a promising human therapeutic. 
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Use of sialic acid containing decoy liposomes to prevent influenza A virus 
infection 
Results 
Generation of decoy liposomes containing the sialic acid moiety LSTc or LSTa 
  We chose a lipid backbone for our decoys to promote LSTc flexibility and permit 
multivalent binding to IAV HA trimers. Our collaborators formulated decoy liposomes from 
a mixture of phospholipids with two 18:1 fatty acyl chains such as DOPC, a principal 
component of mammalian membranes (Figure 3.1A).  DOPC has a low gel transition 
temperature, which allows it to form relatively disordered membranes that remain fluid.  Into 
this background they incorporated LSTc-DOPE. DOPE carries a primary amine that is easily 
linked to LSTc, and that allows controlled addition of SA moieties with distinct linker 
chemistries and of defined stoichiometry.  This allows optimal presentation of the decoys to 
IAV HA. The DOPE primary amine also enables ready modification with the fluorescent dye 
NBD or rhodamine, a marker to assist with tracking and quantification. They added DOPG in 
some formulations to compensate for the net negative charge imparted by LSTc-DOPE. 
 Previous studies using glycan-specific lectins in histological analysis of tissue 
sections of the human respiratory tract demonstrated that the upper respiratory tract 
predominately contains glycans with α2-6 linked SA, while alveolar cells of the deep lung 
are dominated by glycans bearing α2-3 linked SA.  Further, solid phase glycan array analysis 
of human-adapted IAV from H1N1, H2N2 and H3N2 subtypes has revealed a high affinity  
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Figure 3.1 Summary of decoy liposome construction. 
 
 
Figure 3.1 Summary of decoy liposome construction. 
 
A, The different components of decoy liposomes are described. B, The chemical synthesis of 
LSTc-DOPE is outlined in the diagram. Additional details are described in the accompanying 
text. Rh, rhodamine; EDC, ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride; 
NaCNBH3, sodium cyanoborohydride; DMSO, dimethyl sulfoxide. 
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binding to long (tetrasaccharide or longer) α2-6 linked sialylated glycans as a key common 
feature (Chandrasekaran, Srinivasan et al. 2008; Xu, Newhouse et al. 2009). Therefore, a 
readily available ‘long’ α2-6 sialylated glycan LSTc (Neu5Aca2-6Galb1-4GlcNAcb1-
3Galb1-4Glc) was selected for use in decoy liposomes for human-adapted IAV.  In order to 
study promiscuous binding and mouse-adapted IAV strains, the related sialylated glycan with 
the α2-3 SA linkage, LSTa (Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4Glc), was also selected 
for incorporation into decoy liposomes.  LSTc and LSTa are also ideal sialylated glycans due 
to their ability to bind to multiple HA subtypes, a feature not true for all sialylated glycans 
(Ha, Stevens et al. 2001; Russell, Stevens et al. 2006; Xu, Newhouse et al. 2009); the 
chemistry for LSTa was the same as LSTc incorporation. 
  Glycolipid synthesis is schematically represented in Figure 3.1B.  Our collaborators 
attached DOPE, a commercially available amine-linked unsaturated phospholipid (Figure 
3.1B, compound 1) to an Fmoc-protected linker acid (compound 2) using carbodiimide 
coupling.  They obtained compound 3 by purification of the crude product by silica gel 
column chromatography and used piperidine to deprotect the FMOC-modified lipid-linker 
conjugate (compound 3) and monitored the reaction by TLC. The crude amine (compound 4) 
was purified by column chromatography and eluted in organic solvent.  The free amine of 
compound 4 is available for coupling to the sugar aldehyde (reducing end).  Conjugation 
with the free non-reducing sugar aldehyde of LSTc was achieved via reductive-elimination.  
LSTc (compound 5) and compound 4 were conjugated at 60°C in minimal acid to minimize 
hydrolysis (desialylation) of LSTc.  The final product (compound 6) was partially purified 
using flash chromatography and further purified by HPLC to obtain LSTc-containing 
 47 
glycolipids.  The final LSTc-DOPE product was assessed by DMB-HPLC to confirm the 
presence of SA in the glycolipid and was characterized the purified product by MALDI-MS 
and found the final glycolipid had m/z = 2029-2031 Da, expected m/z = 2032 Da (data not 
shown). 
 Our collaborators generated decoy liposomes with variable amounts of LSTc to 
determine the optimal amount of SA required for efficacy.  The LSTc glycan is negatively 
charged and all decoys containing less than 7.5 mol% LSTc were made with DOPG as 
needed to generate decoy liposomes with the same net negative charge (Figure 3.1A). SA 
concentrations for each preparation were estimated based on the percent of input LSTc-
DOPE and by the nanomolar concentration of total lipid. Liposomes with 0 mol% LSTc (and 
7.5 mol% DOPG) were used as control liposomes. Our collaborators used extrusion through 
200 nm pores to create the liposomes and measured their average size and polydispersity 
index using dynamic light scattering. 
 
Decoy liposomes containing LSTc bind to different strains of IAV 
 I used a standard hemagglutination inhibition (HAI) assay to assess binding of decoy 
liposomes to influenza A/Puerto Rico/8/34 (PR/8, H1N1).  The indicated percentage of 
sialoside at the liposome surface represents the mole percentage of lipid monomers used in 
the liposome synthesis reaction.  IAV binds to SA on the surface of RBCs, causing 
hemagglutination.  LSTc decoy liposomes provide an alternative SA binding option for IAV 
and will inhibit hemagglutination when present in sufficient quantity.  The ability of 
liposomes to inhibit hemagglutination can be expressed either as the HAI titer (i.e., the 
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reciprocal of the last dilution of liposomes required to inhibit hemagglutination) or as the 
concentration (molarity of SA) that results in 90% inhibition (IC90).  For PR/8, decoy 
liposomes with 7.5 mol% LSTc had HAI titers of 256 and an IC90 of 0.041 µM SA, and 
decoy liposomes with 5 mol% LSTc had HAI titers of 128 and an IC90 of 0.04 µM SA (Table 
3.1).  Decoy liposomes containing 1 mol% LSTc did not inhibit hemagglutination at the 
highest concentration tested, 0.52 µM SA.  Control liposomes, used at similar lipid 
concentrations as the LSTc decoy liposomes, did not inhibit hemagglutination.  Monovalent 
LSTc used at 5×105 M did not inhibit hemagglutination (Table 3.1).  I also tested the activity 
of decoy liposomes containing either 10, 20 or 30 mol% LSTc by HAI against various strains 
of IAV, but did not see any significant increase in HAI titers compared to liposomes 
containing 7.5 mol% LSTc (data not shown). 
 To test the specificity of our decoy liposomes, I performed the HAI assay with 
several additional strains of IAV as well as another RNA virus, Sendai virus (SeV).  SeV is a 
paramyxoviridae family virus that binds specifically to α2-3 linked SA (Markwell and 
Paulson 1980), which is not present in our LSTc decoy liposomes. Decoy liposomes 
containing 7.5 mol% LSTc inhibited all strains of IAV tested: A/Philippines/2/82/X-79 
(Philippines, H3N2) with an HAI titer of 16 (IC90 = 0.98 SA), X-31 (A/Aichi/68, H3N2) with 
an HAI titer of 32 (IC90 = 0.26 µM SA), and A/Beijing/262/68 (Beijing, H1N1) with an HAI 
titer of 64 (IC90 = 0.11 µM SA) (Table 3.2).  However, 7.5 mol% LSTc decoy liposomes did 
not inhibit SeV agglutination (Table 3.2), demonstrating that the observed binding is specific 
for α2-6 linked SA binding rather than a non-specific binding event. 
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Table 3.1 Assessment of different decoy liposome formulations by hemagglutination 
inhibition assay. 
 
 
 
Table 3.1 Assessment of different decoy liposome formulations by hemagglutination 
inhibition assay. 
 
LSTc-containing decoy liposomes competitively bind to A/PR/8 (H1N1). Several different 
liposome formulations were assessed. Decoy liposomes containing 0, 1, 5, or 7.5 mol% LSTc 
were effectively inhibited hemagglutination of PR/8 IAV. Monovalent LSTc did not inhibit 
PR/8. “No inhibition” indicates that no inhibition was observed at the highest concentration 
tested. IC90 values are shown as molarity of sialic acid. 
  
 
Mol% LSTc on 
liposomes HAI Titer  IC90 (µM SA) 
0  No inhibition N /A 
1 No inhibition > 0.52 
5 128 0.04 
7.5 256 0.041 
Monovalent LSTc No inhibition > 500,000 
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Table 3.2 Assessment of 7.5 mol% LSTc decoy liposomes by hemagglutination inhibition 
assay of multiple strains of influenza A virus and sendai virus. 
 
Table 3.2 Assessment of 7.5 mol% LSTc decoy liposomes by hemagglutination inhibition 
assay of multiple strains of influenza A virus and sendai virus. 
Decoy liposomes competitively bind to several strains of IAV. Decoy liposomes containing 
7.5 mol% LSTc are effective at inhibiting hemagglutination of Philippines, X-31, Beijing, 
and PR/8 IAV strains. IC90 values are shown as molarity of sialic acid. Hemagglutination of 
Sendai virus is not inhibited by 7.5 mol% decoy liposomes at the highest concentration 
tested. 
 
  
  
 
   
       
      
     
   
   
      
 
 
 
TAB E 2 
 
Virus HAI Titer  IC90 (µM SA) 
Philippines H3N2 16 0.98  
X-31 H3N2 32 0.26  
Beijing H3N2 64 0.11  
PR/8 H1N1 256 0.041 
Sendai No inhibition > 84 
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Decoy liposomes containing LSTc co-localize with IAV and inhibit binding of 
IAV at the surface of A549 human lung epithelial cells 
 I surmised that inhibition of hemagglutination results from the direct binding of SA on 
LSTc decoy liposomes to hemagglutinin.  To directly observe contact between decoy and 
IAV, I took advantage of a method for enzymatically attaching a fluorophore onto viral 
particles for single virion tracking (Popp, Karssemeijer et al. 2012).  WSN HA-647, 
generated by the Plough laboratory, was absorbed onto glass coverslips, then treated with 
either decoy or control liposomes containing NBD-labeled lipids.  WSN HA-647, decoy and 
control liposomes were each readily visible by confocal microscopy when fixed to glass 
coverslips (data not shown).  I observed significant co-localization when WSN HA-647 was 
treated with 1,000 nM SA decoy liposomes with 7.5 mol% LSTc (Figure 3.2 A, C, Pearson’s 
correlation coefficient: r = 0.423, p ≤ 0.01).  Control liposomes did not co-localize with 
adhered virus (Figure 3.2 B, D, Pearson’s correlation coefficient r = 0.023, p = 0.87).  I used 
cross-correlation analysis to validate the association of virus and decoy liposomes.  The 
cross-correlation function (CCF) establishes whether there is a relationship between two 
channels of a complex 3-D stacked image (van Steensel, van Binnendijk et al. 1996).  Figure 
3.2 E shows the CCF of WSN HA-647 treated with decoy or control liposomes.  The 
maximum CCF for LSTc decoy liposomes is at 0 x-voxel displacement and follows the 
standard decay curve for x shift in both positive and negative directions.  The distribution of 
LSTc decoy liposomes and virus have significantly more overlap than control liposomes and 
virus, where the CCF does not peak at 0 x-voxel displacement, but peaks at 20 x-voxel shift 
with an r = 0.023 and has a flat distribution of CCF throughout the x-voxel shift.   
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Figure 3.2 LSTc decoy liposomes bind directly to influenza A virus. 
 
 
 
Figure 3.2 LSTc decoy liposomes bind directly to influenza A virus. 
 
Immunofluorescent z-stack images were obtained of WSN HA-647 and fluorescent 
liposomes, viewed from above (A and B) or rotated 37 degrees (C and D). A and C, LSTc 
decoy liposomes, which contain NBD (green) bound specifically to WSN HA-647 (red) can 
be seen binding to the apical portion of virus foci when the field of view is rotated 37 
degrees. B and D, control liposomes do not show significant co-localization with WSN HA-
647. Scale bar, 1 µm. E, Van Steensel’s CCF coefficient analysis of images A and B. The 
CCF is the Pearson coefficient of WSN HA-647 and liposomes at each pixel shift in the x 
dimension; this calculation is based on a representative field of 45 by 45 µm. Decoy 
liposomes (open circles) significantly correlate to WSN HA-647 (p < 0.001), whereas 
control liposomes (black squares) do not (p = 0.21). 
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 To further test the competitiveness of LSTc decoy liposomes for IAV, I challenged 
human alveolar basal epithelial cells (A549 cells) with three different doses of WSN HA-647 
combined with either LSTc-bearing decoy liposomes or control liposomes.  Mixtures of virus 
and liposome were added to A549 cells where free virus would bind to cells.  Binding of 
virus at the single cell level was assessed by detection of WSN HA-647 by flow cytometry.  
WSN HA-647 in combination with control liposomes allowed a high degree of binding to 
A549 cells (Figure 3.3A, gray lines).  No significant shifts were noted for A549 cells 
challenged with control liposomes mixed with 1.3, 6.5, or 13 HA units of WSN-HA-647 
(Figure 3.3A, left, middle, and right panels).  However, decoy liposomes at 7.5 mol% LSTc 
reduced viral binding when challenged with WSN HA-647 (Figure 3.3A, black lines).  Decoy 
liposomes decreased 75%, 79% and 54% of binding when challenged with 1.3, 6.5, or 13 HA 
units of WSN HA-647 (Figure 3.4A, left, middle, and right panels, respectively).  At the 1.3 
HA unit dose of WSN HA-647, the mean fluorescence intensities (MFI) ± S.E.M. for control 
liposomes and decoy liposomes were 369 (± 158) and 89 (± 88) (p = 0.11) (Figure 3.3B).  
The MFIs for 6.5 HA unit dose of WSN HA-647 were 1071 (± 145) and 223 (± 86) (p ≤ 
0.001) and for 13 HA unit dose of WSN HA-647, 1142 (± 113) and 522 (± 89) (p ≤ 0.001) 
(Figure 3.3B).  Together these data demonstrate that the LSTc-containing decoy liposomes 
competitively bind to IAV and block its adhesion to SA on uninfected cells, suggesting a 
block of infection. 
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Figure 3.3 LSTc-containing decoy liposomes inhibit binding of influenza A virus to A549 
cells. 
 
 
 
Figure 3.3 LSTc-containing decoy liposomes inhibit binding of influenza A virus to A549 
cells. 
 
A, Representative flow cytometry plots of A549 cells treated with control liposomes (gray 
lines) combined with WSN HA-647 (1.3 HA units (left panel), 6.5 HA units (middle panel), 
and 13 HA units (right panel)), LSTc-containing decoy liposomes combined WSN HA-647 
(black lines), or A549 cells without virus (gray-shaded). LSTc-decoy liposomes contained 
7.5 mol% LSTc. B, shown is mean fluorescence intensity (MFI) quantification of data in A; 
data are presented as the mean ± S.E. ***, p ≤ 0.001 decoy liposomes versus control 
liposomes. 
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LSTc decoy liposomes co-localize specifically to IAV infected A549 cells  
  The data above demonstrate that the decoy liposomes bind to mature virions and can 
prevent binding to cell surfaces.  To further examine the utility of our LSTc decoy liposomes, 
I measured their ability to bind to budding virus on infected cell surfaces.  I observed decoy 
liposome binding with fluorescent co-localization microscopy.  I infected adhered A549 cells 
on glass coverslips, treated with either control or decoy liposomes containing NBD-labeled 
lipids, and washed to remove unbound liposomes before immunostaining for IAV NA.  
There was significant co-localization when PR/8 infected A549 cells were treated with LSTc-
containing decoy liposomes (Figure 3.4A, Pearson’s correlation coefficient r = 0.629, p ≤ 
0.001). Control liposomes did not bind to PR/8 infected cells (Figure 3.4B Pearson’s 
correlation coefficient r = 0.046, p = 0.78).  Co-localization was dependent on infection; 
LSTc-containing decoy liposomes did not bind to uninfected A549 cells (Figure 3.4C 
Pearson’s correlation coefficient r = 0.027, p = 0.87).  Cross-correlation analysis reveals a 
CCF peak at 0 x-voxel shift for LSTc decoy liposomes and standard decay curve in both the 
positive and negative x-voxel shifts (Figure 3.4D) indicating that decoy liposomes and NA 
staining have significant co-localization.  The CCF for infected A549 cells treated with 
control liposomes and uninfected cells treated with decoy liposomes peaked significantly 
lower, had flatter decay curves, and overall lower pixel intensity staining for liposomes 
(Figure 3.4D).  Taken together, these binding data demonstrate that the decoy liposomes bind 
to IAV in many environments, bind directly in a cell system, block IAV adhesion to 
sialylated cells and bind to virus budding from infected cells. 
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Figure 3.4 LSTc-containing decoy liposomes bind to PR/8 infected A549 cells. 
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Figure 3.4 LSTc-containing decoy liposomes bind to PR/8 infected A549 cells. 
  
Immunofluorescent images were obtained of IAV neuraminidase expression on A549 cells 
infected with PR/8 IAV (A and B) or mock infected (C) and fluorescent liposomes. A, LSTc 
decoy liposomes, which contain NBD (green), bound specifically to infected A549 cells 
expressing NA (red) B, control liposomes do not show significant co-localization with NA 
on infected A549 cells.  C, LSTc decoy liposomes do not bind to mock infected A549 cells.  
Scale bar, 10 µm.  D, Van Steensel’s CCF coefficient analysis of merged images in A, B and 
C. The CCF is the Pearson coefficient of IAV neuraminidase and liposomes at each pixel 
shift in the x dimension; this calculation is based on a representative field of 45 by 45 µm. 
Decoy liposomes significantly correlate to infected A549 cells (open circles), whereas 
neither control liposomes with infected A549 cells (black squares) or decoy liposomes with 
uninfected A549 cells (black triangles) correlated.  Data are representative of a single 
independent experiment repeated twice, both having similar results. 
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Decoy liposomes containing LSTc prevent IAV infection of MDCK cells 
 To investigate the impact of decoy liposomes on IAV infectivity, I co-incubated PR/8 
with either LSTc-containing decoy liposomes or control liposomes prior to infection of 
MDCK cell monolayers.  In this experiment, viral particles are expected to bind to native SA 
on MDCK cells only when not competitively bound to decoy liposomes. Increasing 
concentrations of LSTc decoy liposomes inhibited infectivity of PR/8 (Figure 3.5A) in these 
cells, while control liposomes did not inhibit infection.  The molarity of SA in the solution 
was calculated by multiplying the mole percent input of LSTc-DOPE glycolipids by the total 
lipid concentration.  At 1 nM SA, all decoy liposomes displayed weak inhibition.  As the 
total concentration of SA increased, each series with different mole percentages of LSTc on 
the liposome surface inhibited more PR/8.  Decoy liposomes with 1 mol% LSTc inhibited 
weakly, blocking only 22 ± 5.6% of PR/8 at 515 nM SA.  LSTc decoy liposomes at 5 mol% 
inhibited weakly at low concentrations of LSTc, but increasing the concentration of these 
decoys had a more pronounced inhibitory effect, inhibiting 73 ± 10% of PR/8 at 1,000 nM 
SA.  LSTc decoy liposomes at 7.5 mol% blocked PR/8 infection to the largest extent, 
inhibiting PR/8 almost completely at 1,000 nM SA, 93.8 ± 1.3% compared to control 
liposomes (Figure 3.5A).   
 These data show not only a dose-dependent response of LSTc in the medium on IAV 
inhibition, but also that the density of LSTc displayed on the surface of each liposome at a 
given concentration of LSTc affects the extent of viral inhibition.  For example, when each 
series of LSTc decoy liposomes was diluted to 100 nM of total SA and challenged with PR/8, 
7.5 mol% LSTc decoy liposomes inhibit to a greater degree than decoy liposomes with either 
5 or 1 mol% LSTc (Figure 3.5A).  This inhibition occurs despite the fact that decoy  
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Figure 3.5 LSTc decoy liposomes selectively inhibit influenza A virus infection of MDCK 
cells. 
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Figure 3.5 LSTc decoy liposomes selectively inhibit influenza A virus infection of MDCK 
cells. 
 
A, PR/8 (50 PFU/well) was incubated with control liposomes, LSTc-containing decoy 
liposomes, or monovalent LSTc before addition to MDCK cells. Plaques per well of virus 
treated with control liposomes (0 mol% LSTc) are defined as 100% infectivity (open 
square), and virus treated with different liposome formulations are expressed as the percent 
reduction from its respective control. Decoy liposomes with 7.5 mol% LSTc (circles) 
inhibited PR/8 to the greatest extent. Decoy liposomes with 5mol%LSTc (triangles) also 
significantly inhibited infection; however, decoy liposomes with 1 mol% LSTc (open 
diamonds) poorly inhibited infection. B, decoy liposomes containing 7.5 mol% LSTc inhibit 
multiple strains of IAV. Decoy liposomes inhibited Philippines (open triangles, 50 
PFU/well), X-31 (crosses, 50 PFU/well), Beijing (open circles, 15 PFU/well), and PR/8 
(filled circles, 50 PFU/well) strains of IAV.  LSTc decoy liposomes did not inhibit RSV 
(filled squares, 50 PFU/well).  The data represent the average ± S.E. of three experiments 
for PR/8 and two experiments for Philippines, X-31, Beijing, and RSV. 
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preparations with a higher density of LSTc per liposome have fewer liposomes in solution at 
equimolar concentrations of LSTc.  Decoy liposomes with denser LSTc are therefore more 
efficient at inhibiting IAV.  I also tested the infectivity inhibition of decoy liposomes 
containing more than 7.5 mol% LSTc and saw no significant increase of inhibition from 
liposomes with up to 30 mol% LSTc (data not shown).  These results were similar to the 
finding that decoy liposomes with more than 7.5 mol% did not increase HAI titers of IAV. 
 Next, I tested our decoy liposomes at 7.5 mol% LSTc on several additional IAV 
strains.  Decoy liposomes at 7.5 mol% inhibited all IAV strains in a dose-dependent manner.  
Decoy liposomes inhibited Philippines up to 58.3 ± 3.4% at 1,000 nM SA.  At 5,250 nM SA, 
decoy liposomes at 7.5 mol% inhibited infectivity of X31 by 47.3 ± 13.5% and infectivity of 
Beijing by 82.3 ± 5.9%.  Control liposomes lacking LSTc did not inhibit any of these strains.  
Decoy liposomes displayed high avidity for IAV in both the HAI and infectivity assays.  I 
also compared LSTc-containing decoy liposomes with monovalent LSTc at SA 
concentrations well in excess of the estimated SA concentrations for LSTc-containing 
liposomes.  However, 74,000 nM monovalent LSTc did not inhibit the infectivity of either 
PR/8 (Figure 3.5) or Philippines (data not shown).  At this high concentration, monovalent 
LSTc would be expected to bind to both PR/8 and Philippines HA during the pre-incubation 
period.  Given that infection was not inhibited, monovalent LSTc did not make multivalent, 
high avidity interactions with IAV, while LSTc complexed in liposomes can make 
multivalent, high avidity interactions with IAV. 
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Decoy liposomes containing LSTc do not prevent infection of respiratory 
syncytial virus in Vero cells 
 To test the specificity of LSTc-containing decoy liposomes, I assessed whether decoy 
liposomes would affect RSV infection of Vero cells.  RSV interacts with cellular heparan 
sulfate for attachment and infectivity (Feldman, Audet et al. 2000) and has not been reported 
to interact with SA receptors.  I co-incubated 7.5 mol% LSTc decoy liposomes or control 
liposomes with RSV prior to infection of Vero cells.  LSTc-containing liposomes did not 
affect RSV infectivity (Figure 3.5B), even at a SA concentration of 10,000 nM SA, an 
amount that inhibits nearly 100% of PR/8.  This lack of inhibition, along with the lack of 
hemagglutination inhibition of SeV, demonstrates that our LSTc-decoy liposomes 
specifically inhibit via α2-6 linked SA. 
 
Functionalized decoy liposomes are not toxic in vitro or in vivo  
 Liposome components are non-toxic, and they were chosen in part for their similarity 
to biological molecules.  The backbone lipid, DOPC, which comprises over 90% of each 
liposome, is a non-toxic synthetic derivative of phosphatidylcholine (PC), which makes up a 
large percentage of mammalian cell membranes (Kaneko, Baba et al. 1996).  Likewise, the 
LSTc glycolipid, a four-residue sugar purified from cow’s milk, is regularly consumed by the 
general public and is therefore thought to be non-toxic.  In addition, similar FDA-approved 
liposome drug carriers, which undergo extensive toxicity evaluation, are non-toxic (Hiemenz 
and Walsh 1996).  
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To measure toxicity, I tested cells for lactate dehydrogenase (LDH) release, a marker 
of cell death, after incubation with our liposomes.  I incubated control and LSTc-containing 
decoy liposomes with MDCK cells in the infection buffer for one hour and compared LDH 
release to cells treated with assay media alone or Triton X-100.  Addition of Triton X-100 
resulted in 100% cell death and an LDH release of 1.820 ± 0.078 OD, while no cell death 
(assay media alone) had background levels of 0.309 ± 0.01 OD (Figure 3.6A).  Neither 
LSTc-containing decoy liposomes nor control liposomes resulted in significant LDH release.  
When diluted in two-fold serial dilutions, decoy liposomes with 7.5 mol% LSTc resulted in 
an average of 0.309 ± 0.02 OD LDH release from MDCK cells, even at the highest 
concentration tested, 5,250 nM SA, a concentration higher than necessary for complete 
inhibition.  Control liposomes, which are similar except they containing DOPG lipid in place 
of LSTc glycolipid, resulted in an average of 0.358 ± 0.03 OD LDH release from MDCK 
cells (Figure 3.6A). 
 Decoy liposomes were also not toxic in vivo.  Overt toxicity in mice was measured by 
weight loss and behavior changes, as compared to mice that received mocek, saline 
treatment.  Mice treated with LSTc-containing decoy liposomes and saline showed no signs 
of toxicity or weight loss after treatment (Figure 3.6B).  In addition, lungs were harvested 
from mice four days post-treatment and IL-1β levels were examined. 
 
Decoy liposomes containing LSTc remain active for long periods 
 In order to be a useful therapeutic, LSTc decoy liposomes must be both chemically 
and biologically stable over long periods of time.  Liposomes can be lyophilized and stored  
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Figure 3.6 Decoy liposomes are not toxic in vitro or in vivo.  
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Figure 3.6 Decoy liposomes are not toxic in vitro or in vivo.  
 
A, Control or LSTc-containing decoy liposomes were serially diluted 2-fold and incubated 
with MDCK cells for one hour before testing for LDH release. Triton X-100 treated cells (x 
mark) resulted in 100% cell death and media (PBS-1%BSA) treated cells (filled square) 
was used as the background control.  Decoy liposomes with 7.5 mol% LSTc (filled circles) 
did not cause cytotoxicity at any dilution, including the highest concentration tested, 5250 
nM SA.  Control liposomes (open squares), at equivalent concentrations of lipid, also did 
not cause cytotoxicity.  B and C, C57BL/6 mice were given intranasal saline (open 
squares), or 170 µM SA of 7.5 mol% LSTc decoy liposomes diluted in saline (filled circles) 
and monitored for gross pathology and weight loss (B).  Mice that received decoy liposomes 
did not show any signs of sickness, had normal weight retention, and were not any different 
from mice that received saline alone. C, lung IL-1β levels were tested four days post-
infection from mice that received saline, or 170 µM SA of 7.5 mol% LSTc decoy liposomes 
diluted in saline or PR/8 alone.  Mice that received LSTc decoy liposomes did not have any 
elevation of IL-1β after liposome treatment, as compared to saline treated mice. 
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for long periods without losing their chemical and physical properties.  However, once 
resuspended into a liquid buffer, it is possible that they could degrade over time.  It is critical 
that the decoy liposomes maintain the inhibitory properties described above.  To measure 
stability, I tested an individual preparation of 7.5 mol% LSTc decoy liposomes against PR/8 
IAV infectivity, stored the liposomes at 4°C in PBS for over a year before challenging PR/8 
IAV infectivity (Figure 3.7).  After up to 15 months of storage, at 100 nM SA, the LSTc 
decoy liposomes inhibited 86.8 ± 1.5% PR/8 infectivity (Figure 3.7 black squares).  This 
inhibition was similar to the 84.3% PR/8 inhibition observed when the liposomes were first 
tested a year earlier (Figure 3.7 grey triangles) and similar to liposome preps used in 
experiments above (see Figure 3.5A, black circles).  These data indicate that LSTc-
containing decoy liposomes are biologically stable and remain active against IAV after long 
periods of liquid storage at 4°C. 
 
Decoy liposomes containing LSTc block viral growth of Influenza A virus in 
MDCK cells 
 To investigate the decoys’ ability to inhibit IAV during multiple rounds of infection, I 
infected MDCK cells with IAV in the presence of increasing concentrations of decoy or 
control liposomes, and allowed continued viral replication and spread in the presence of 
either decoy or control liposomes.  Control liposomes or decoy liposomes with 7.5 mol% 
LSTc at concentrations of 1 nM to 1,000 nM LSTc (10-fold increments) were added to 
MDCK cells 30 minutes before addition of PR/8.  After one hour, all inoculating virus was 
removed, and LSTc decoy or control liposomes were replenished to the same concentrations  
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Figure 3.7 LSTc-containing decoy liposomes are stable. 
 
 
Figure 3.7 LSTc-containing decoy liposomes are stable. 
 
PR/8 (50 PFU/well) was incubated with control liposomes or LSTc-containing decoy 
liposomes before the addition to MDCK cells. Plaques per well of virus treated with control 
liposomes (0 mol% LSTc) are defined as 100% infectivity (open square), and virus treated 
with decoy liposome with 7.5 mol% LSTc are expressed as the percent reduction from its 
respective control. Decoy liposomes first tested in August 2011 (grey triangles) inhibited 
PR/8 IAV to statistically similar levels as decoy liposomes tested in September 2011 
(circles) and November 2012 (filled squares, dotted line).  The data represent the average ± 
S.E. of biological repeats, done in duplicate. 
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as during the infection, in serum-free media to allow virus replication in host cells.  Twenty-
four hours after infection, supernatants were sampled and tested for PR/8 plaque-forming 
units.  The amount of virus recovered from wells treated with highly concentrated LSTc 
decoy liposomes was significantly reduced compared to wells with control liposomes, or 
with PR/8 and assay medium alone (Figure 3.8).  Infected MDCK cells treated with 100 or 
1,000 nM LSTc decoy liposomes had viral titers below the limit of detection, over 100-fold 
less than control liposome-treated cells (decoy liposomes 2.7 ± 0 vs. control liposomes 4.8 ± 
0.07; p ≤ 0.001, based on log10-transformed PFU/mL data) (Figure  
3.8).  10 nM LSTc decoy liposomes also significantly inhibited PR/8 replication (2.8 ± 0.2 
vs. control liposomes 4.8 ± 0.07; p ≤ 0.01) (Figure 3.8).  Decoy liposomes diluted to 1 nM 
LSTc or less did not prevent PR/8 replication (4.6 ± 0.04 vs. control liposomes 4.8 ± 0.07; p 
= 0.069).  These results suggest that adhesion of viral particles to LSTc decoy liposomes 
depletes the amount of free virus capable of infecting in successive rounds of replication, and 
that this interaction is long-lasting because the bound virus is not cleared in this in vitro 
system. 
 
Decoy liposomes containing LSTc extend survival of Influenza A virus-infected 
mice 
 To investigate the decoys’ ability to inhibit IAV in a physiological setting, I evaluated 
the effects of LSTc-containing decoy liposomes on mice infected with a lethal dose of IAV. 
LSTc decoy liposomes or control liposomes were co-incubated with 1,000 PFU of PR/8 at 
37°C for 30 minutes.  This dose of PR/8 typically causes 90% lethality (LD90) in C57BL/6  
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Figure 3.8 Inhibition of influenza A virus replication by LSTc decoy liposomes. 
 
 
 
 
 
Figure 3.8 Inhibition of influenza A virus replication by LSTc decoy liposomes. 
 
Control or LSTc-containing decoy liposomes were added onto confluent monolayers of 
MDCK cells 30 min before infection with PR/8 (multiplicity of infection 0.01). After 
infection, cells were incubated in the presence of liposomes for 48 h. Viral growth was 
measured by a plaque forming unit assay and plotted as PFU/ml versus total LSTc 
concentration present in the solution.  Control liposomes did not inhibit IAV growth (open 
squares); however, increasing concentrations of 7.5 mol% LSTc decoy liposomes inhibited 
PR/8 infectivity (filled circles). The dotted line denotes the limit of detection of the assay. 
Data are representative of a single independent experiment repeated once, each with similar 
results. 
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mice following intratracheal delivery.  The prediction was that any IAV not initially 
associating with LSTc decoy liposomes could subsequently infect susceptible cells within the 
lungs.  Thus, mice administered virus with LSTc decoy liposomes might be expected to 
succumb to IAV infection less quickly than mice administered virus in combination with 
control liposomes or mice receiving virus alone.   
 Mice that received control liposomes and 1,000 PFU of PR/8 died at the same rate as 
mice that received 1,000 PFU of PR/8 alone (Figure 3.9A, median survival of 8 days for both 
groups, Log Rank test, χ2 = 0.01, p = 0.9).  However, mice that received LSTc decoy 
liposomes and 1,000 PFU of PR/8 had significantly extended survival, with a median 
survival of 12 days compared to 8 days for mice that received control liposomes and 1,000 
PFU of PR/8 (Log Rank test, χ2 = 13.6, p ≤ 0.01), resulting in a 33.3% mean increase in 
lifespan post-infection (Figure 3.9A).  The median survival and survival curve slope was 
reproducible over multiple experiments (the data in Figure 3.9A and B represents the sum of 
three independent experiments with a combined n ≤ 19 mice for each group).  Weight loss 
after IAV infection is a standard proxy for severity of disease.  Mice that receive larger doses 
of IAV typically have more severe weight loss after infection as well as increased mortality 
(data not shown and Powell, Dwyer et al. 2006).   
 To test the effect of the mole percentage of LSTc contained on each liposome in vivo, 
I challenged mice with a lethal dose of PR/8 IAV, as described above, but with decoy 
liposomes containing 15 mol% LSTc.  15 mol% LSTc decoy liposomes did not have 
significantly higher potency against IAV in vitro (Figure 3.5 and data not shown), but this 
may not apply to an in vivo infection environment.  As seen previously, mice that received 
control liposomes and 1,000 PFU of PR/8 died with similar kinetics as mice that received  
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Figure 3.9 LSTc decoy liposomes extend survival after lethal influenza A virus challenge. 
 
 
 
Figure 3.9 LSTc decoy liposomes extend survival after lethal influenza A virus challenge. 
 
1,000 PFU of PR/8 was incubated with control liposomes or LSTc-containing decoy 
liposomes with (A) 7.5 mol% LSTc or  (B) 15 mol% LSTc at 37°C for 30 min, then used for 
intratracheal infection of C57BL/6 mice. Mice were monitored daily for survival. A. Mice 
that received LSTc decoy liposomes and PR/8 (dashed black line) had a 33% increase of 
mean survival time post-infection as compared with mice that received control liposomes and 
PR/8 (solid black line) or PR/8 alone (gray dotted line). The LSTc decoy liposome and 
PR/8-treated mice survival advantage was statistically significant (χ2 = 13.6, p ≤ 0.01; n ≤ 19 
for each strain). B. Mice that received decoy liposomes with 15 mol% LSTc had a significant 
38.5% time to death increase and was statistically significant (χ2 = 12.7, p ≤ 0.001; n ≥ 18) as 
compared to mice that received control liposomes. Data shown are combined from three 
independent experiments, each having similar results. 
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1,000 PFU of PR/8 alone (Figure 3.9C, median survival of 8 days for both groups, Log Rank 
test, χ2 = 2.3, p = 0.13).  Mice that received 15 mol% LSTc decoy liposomes and 1,000 PFU 
of PR/8 had significantly longer survival times, with median survival of 13 days, a 38.5% 
mean increase over control liposomes and PR/8 (Log Rank test, χ2 = 12.7, p ≤ 0.001), a day 
longer than 7.5 mol% LSTc decoy liposomes (not a significant increase, Log Rank test, χ2 = 
0.7, p = 0.4). The overall molarity of SA in the decoy liposome dose was 170 µM SA, the 
same as amount as 7.5 mol% LSTc liposomes above.  The survival trend and median survival 
time were reproducible over several experiments; the data presented here are the sum of 3 
experiments, with combined numbers listed.  These data are consistent with the co-incubation 
data showing 7.5 mol LSTc decoy liposomes increase survival and further support the 
hypothesis that decoy liposomes make long-lasting interactions that neutralize virus in the 
physiological setting of an infected lung.   
 IAV titers were not significantly different three days post-infection between mice that 
received co-incubated control liposomes and virus and mice that received co-incubated LSTc 
decoy liposomes and virus or mice that received virus alone (Figure 3.10A).  In addition, 
lung IL-1β levels were also not significantly different three days post-infection between all 
three treatment groups (Figure 3.10B).  These data sample only a small window of the 
overall infection, and therefore form an incomplete picture of the viral and cytokine profile 
throughout infection.  Additional time points would be required for a full understanding of 
the viral load and cytokine in control and decoy liposome treated mice, and additional 
cytokine screening would be required for a complete picture of the pulmonary cytokine 
milieu. 
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Figure 3.10 Mice that received LSTc decoy liposomes do not have altered viral titers or IL-
1β levels four days post influenza A virus infection. 
 
 
Figure 3.10 Mice that received LSTc decoy liposomes do not have altered viral titers or IL-
1β levels four days post influenza A virus infection. 
 
350 PFU of PR/8 was incubated with control or LSTc-containing decoy liposomes at 37 °C 
for 30 min, and used for intratracheal infection of C57BL/6 mice.  Mice from each treatment 
(n=3) were sacrificed 4 days post-infection; lungs were removed and tested for viral titers (A) 
and IL-1β cytokine levels (B).  Mice that received LSTc decoy liposomes and PR/8 did not 
have significantly different viral titers or IL-1β as compared to mice that received control 
liposomes and PR/8 or virus alone. 
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Decoy liposomes are not effective as therapeutics or prophylactics for Influenza 
A virus infection 
 To extend the co-incubated survival data above, I treated mice with decoy liposomes 
in a more clinically relevant setting, either before or after PR/8 IAV infection.  
Therapeutically treated mice were infected with 350 PFU of PR/8 IAV, rested for thirty 
minutes, and then treated with either 170 µM SA LSTc-containing decoy liposomes or an 
equivalent amount of control liposomes.  Mice were monitored daily for weight loss and 
survival.  The median survival for control liposomes-treated mice was 15 days, and 
undefined for decoy liposomes treated mice.  Decoy liposome-treated mice had 60% survival 
at the end of the experiment, thus median survival was undefined.  The time-to-death for the 
decoy liposome-treated mice was not statistically significant from control liposome-treated 
mice (Figure 3.11A, Log Rank test, χ2 = 0.84, p = 0.36), but because of the small number of 
mice used with this protocol, it is possible increased group sizes would give more statistical 
power.   
To test the liposomes’ efficacy as a prophylactic, I administered decoy liposomes 
containing 7.5 mol% LSTc to mice one hour before challenging them with 1,000 PFU of 
PR/8.  When co-incubated, this dose of SA is protective against this dose of PR/8, but it was 
no longer protective prophylactically  (Figure 3.11B).  Mice given either control liposomes 
or decoy liposomes before infection had mean survival times of nine or ten days (Log Rank 
test, χ2 = 2.3, p = 0.13).  These data demonstrate that the decoy liposomes can make and 
maintain long-lasting interactions with its target virus when co-incubated in a relatively small 
volume, but when introduced into an organ with large surface area as the lung, an effective 
dose for prophylactic or therapeutic treatment must be higher than tested here. 
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Figure 3.11 Therapeutic or prophylactic treatment of infected mice with LSTc decoy 
liposomes is not protective. 
 
 
 
Figure 3.11 Therapeutic or prophylactic treatment of infected mice with LSTc decoy 
liposomes is not protective. 
 
C57BL/6 mice were treated with control of LSTc-containing decoy liposomes after (A) or 
before (B) intratracheal PR/8 infection and were monitored daily for survival.  A, 
Therapeutic treatment: mice were infected with 350 PFU of PR/8 by intratracheal the route, 
rested for 30 minutes and then treated with 170 µM SA LSTc-containing decoy liposomes 
(dashed black lines), an equivalent amount of control liposomes (solid black line) or a 
mock saline treatment (virus alone, grey dotted line).  Mice that received LSTc decoy 
liposomes infection had a slight, but not statistically significant increase of mean survival 
time as compared with mice that received control liposomes and PR/8 or PR/8 alone.  B, 
Prophylactic treatment: mice were treated with 170 µM SA LSTc-containing decoy 
liposomes, an equivalent amount of control liposomes or a mock saline treatment, rested for 
1 h and then infected with 1,000 PFU of PR/8 by intratracheal the route.  Mice that received 
decoy liposomes before infection had no change in survival times as compared to mice that 
received control liposomes or mock infection (B).  Data shown are from one experiment. 
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Use of sialic acid containing decoy liposomes to prevent influenza A virus infection 
Discussion 
 Decoy receptors have the potential to attenuate infections by diverting the pathogen away 
from susceptible tissues (Asher, Cerny et al. 2005).  Pathogen receptor mimics are especially 
suited for use as decoys, because the target virus is unlikely to develop resistance through 
mutation.  Viruses require binding specificity and avidity to replicate efficiently and transmit 
between hosts. My approach uses liposomes to create a modifiable platform of synthetic decoy 
receptors that can form multivalent bonds with multiple strains of IAV that results in viral 
neutralization (Figure 3.12).  In order for a treatment to neutralize it must either block a required 
enzymatic function, such as IAV’s neuraminidase or M2 ion channel, or stimulate the immune 
system to block viral replication, such as the yearly vaccine.  The LSTc decoy liposomes 
described here fall into the former category, and act by binding the flu’s HA receptor on the 
receptor-binding site blocking its normal function of binding to cell surface-associated SA.  
Furthermore, the decoy liposomes are multivalent and can theoretically create immuno-
complexes of many bound virions and liposomes.  Viruses bound in large complexes would be 
non-infectious and more likely to be phagocytosed by leukocytes. 
Previous research has shown that SA-bearing receptor molecules can bind and inhibit 
IAV strains (Pritchett, Brossmer et al. 1987).  Indeed, many different sialosides containing a 
single SA residue can inhibit IAV hemagglutination (Pritchett, Brossmer et al. 1987; Sauter, 
Bednarski et al. 1989; Toogood, Galliker et al. 1991; Weinhold and Knowles 1992; Sparks, 
Williams et al. 1993).  Because IAV HA forms polyvalent interactions with the host cell, these 
mono-sialosides have relatively weak inhibitory properties, the strongest having an IC50 of 3.7   
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Figure 3.12 Summary: LSTc-containing decoy liposomes inhibit influenza A virus binding and 
infection.  
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Figure 3.12 Summary: LSTc-containing decoy liposomes inhibit influenza A virus binding and 
infection.  
 
A, IAV infects host cells by first attaching to α2-6 terminally linked SA. Control liposomes that 
do not contain LSTc do not inhibit IAV adhesion or infection. B, decoy liposomes with limited 
amounts of LSTc on their surfaces do not form highly multivalent interactions with IAV and 
only partially inhibit binding to host cells. C, decoy liposomes with 5 mol% or more LSTc on the 
surface are capable of competitively binding multiple strains of IAV, thereby preventing binding 
and infection of host cells. 
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µM (Weinhold and Knowles 1992).  To take advantage of the multivalent nature of HA binding, 
several groups created polymer-based sialosides, which are more potent inhibitors of RBC 
hemagglutination (Glick, Toogood et al. 1991; Spaltenstein and Whitesides 1991; Lees, 
Spaltenstein et al. 1994; Mammen, Dahmann et al. 1995; Kiessling and Pohl 1996).  While the 
IC50 concentrations for HAI were significantly improved, the evidence that polymerized 
sialosides are capable of inhibiting infectivity is not particularly compelling (Spevak, Nagy et al. 
1993; Itoh, Hetterich et al. 1995; Reuter, Myc et al. 1999).  Gamian et al. (1991) were unable to 
block H3N2 IAV infection of embryonated chicken eggs with polyvalent SA glycoconjugates or 
their monovalent parental building blocks. Mochalova et al. (1994) and Tuzikov et al. (2000) 
were able to prevent some IAV strains from infecting MDCK cells, but the doses required to 
block infection were significantly higher than those required to block RBC hemagglutination. In 
contrast, our decoy liposomes inhibited infectivity at similar concentrations as they inhibited 
hemagglutination.  One important distinction between decoy liposomes and polymer-based 
sialosides is their potential toxicity when used in vivo.  The decoy liposomes are constructed with 
derivatives of lipids found in the human body, such as phosphatidylcholine, and the entire 
liposome structure is non-toxic, whereas some polymer-based sialosides can cause cell death at 
high doses. 
 Decoy liposomes are highly adaptable and can be modified with many components while 
retaining their anti-viral inhibitory properties. Therefore, our collaborators and I used DOPC 
along with LSTc-DOPE glycolipid, to create multivalent, polymer-like decoy liposomes. DOPC 
is an ideal liposome lipid backbone because of its neutral charge and low melting temperature 
that makes the lipid membrane fluid at body temperature.  The liposome platform is highly 
flexible (described in detail in the next chapter), and it accommodates various modification 
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including changes to the ratio of different lipid components used or addition of a lipid-
conjugated fluorophore for tracking.  The lipid acyl chain length and double bond give the lipids 
a low melting temperature so that at body temperature the lipid bilayer will be fluid, allowing for 
efficient movement of the LSTc glycan through the liposome surface as a means of increasing 
the multivalency of HA-LSTc interactions.  The lipids used to create our decoy liposomes should 
be versatile inhibitors and as I have described here, where other decoy liposome formulations 
have fallen short. 
  These LSTc-containing decoy liposomes competitively bound to both H1N1 and H3N2 
subtypes of IAV (Table 3.1 and Table 3.2), while control liposomes lacking LSTc did not.  
Increasing the percentage of LSTc displayed on the surface of our decoy liposomes increased the 
HAI titer against IAV.  I also tested monovalent LSTc, the building block used to create our 
decoy liposomes.  Monovalent LSTc did not inhibit hemagglutination, even when tested at 
concentrations well in excess of the estimated molarity of LSTc incorporated into decoy 
liposomes.  Monovalent SA analogs have dissociation constants for HA of approximately 2 mM 
SA (Pritchett, Brossmer et al. 1987; Sauter, Bednarski et al. 1989; Glick, Toogood et al. 1991). I 
tested monovalent LSTc at 5 mM and saw no inhibition of IAV. These data suggest that our 
decoy liposomes act as multivalent, polymer-like decoys; based on the IC90 concentrations need 
to inhibit hemagglutination.  Polymer sialosides IC90 values are in the micro to nanomolar range, 
and the 7.5 mol% LSTc decoy liposomes inhibited IAV in the same overall range, from 1 µM 
SA for Philippines IAV, down to less than 50 nM SA for PR/8 IAV (Table 3.2).   Based on these 
data alone, the decoy liposome platform appears to be a promising non-toxic alternative to the 
cytotoxic sialoside polymers.  Furthermore, the interaction was virus-specific, as high 
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concentrations of LSTc decoy liposomes did not competitively bind to SeV (Table 3.2), while 
clearly capable of inhibiting IAV.  
The HAI results suggest that the hypothesized method of action is correct, that the decoy 
liposomes bind directly to HA and prevent RBC agglutination.  This is supported by the 
literature showing that the SA-containing glycans LSTc and LSTa bind to multiple subtypes of 
HA (Ha, Stevens et al. 2001; Russell, Stevens et al. 2006; Lin, Xiong et al. 2012).  I confirmed 
that this HA-LSTc interaction is direct using fluorescently labeled decoy liposomes and IAV 
covalently modified with Alexa Fluor 647.  Only LSTc-containing decoy liposomes, but not 
control liposomes, bound to fluorescently labeled IAV (Figure 3.2).  The size of the fluorescent 
punctate staining suggests that many decoy liposomes have bound to a number of IAV virions, 
forming a larger complex.  Additionally, electron micrographs of PR/8 bound to LSTc decoy 
liposomes also support the possibility of complex formation (Dr. James Comolli, personal 
communications). 
Alexa Fluor labeled virus can also be used to track viral binding to target cells.  Here I 
present data with the human lung epithelial cell line, A549, an IAV permissive cell with 
predominantly α2-6 linked SA.  When WSN HA-647 was mixed with control liposomes, strong 
binding to A549 cells was observed, whereas less binding was observed when virus was mixed 
with LSTc-containing decoy liposomes (Figure 3.4).  These data demonstrate that the LSTc-
containing decoy liposomes bind directly to the IAV virion, and that this binding prevents 
adhesion to sialylated cells.   
Building on the binding data above, I used the permissive A549 cells to examine whether 
decoy liposomes can also bind to IAV budding from a human cell.  All of the IAV strains tested 
so far were passaged through either chicken eggs or canine MDCK cells, and therefore binding 
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virus coming from A549 cells demonstrates that there is no human-specific post translational 
modification that prevents decoy liposome action.  Indeed, LSTc-containing decoy liposomes 
bound to A549 cells infected with PR/8 for 18 hours, but they did not bind to uninfected cells.  
Control liposomes did not bind to either infected or uninfected cells (Figure 3.3 and data not 
shown).  These data establish that our decoy liposomes can bind to not only intact virions, but 
also to budding and cell-associated HA.  This experiment cannot determine the fate or infectivity 
of the surface-associated virus bound to decoy liposomes, but it is possible that decoy liposomes 
bound to an infected cell surface may trap newly released virus and form larger immunogenic 
complexes at a site of infection. 
  The ability of LSTc decoy liposomes to bind to IAV, as observed data above, also 
protected cells from infection with multiple strains of H1N1 and H3N2 IAV (Figure 3.5). The 
degree of binding and inhibition of infectivity was also dependent on the percentage of 
functionalized LSTc lipids incorporated into decoy liposomes.  Decoy liposomes with only 1 
mol% of their surfaces functionalized with LSTc did not block hemagglutination and blocked 
only a small fraction of infectious virus.  Increasing the mole percent of LSTc increased HAI and 
reduced infectivity.  Decoy liposomes with 7.5 mol% LSTc inhibited IAV most efficiently; they 
significantly decreased infectivity at the lowest tested concentrations of LSTc, inhibiting PR/8 at 
an effective concentration of 10 nM SA.  All other series of LSTc decoy liposomes did not 
significantly inhibit IAV at this concentration.  In contrast, the monovalent form of LSTc did not 
inhibit either PR/8 or Philippines when tested at equimolar (data not shown) or at far higher 
concentrations of LSTc incorporated into decoy liposomes (Figure 3.5).  The inability of 
monovalent LSTc to inhibit IAV agrees with published data that show other monovalent SA 
analogs, while able to block hemagglutination, they are incapable of inhibiting IAV infectivity 
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(Gamian, Chomik et al. 1991; Mochalova, Tuzikov et al. 1994; Tuzikov, Gambaryan et al. 
2000).  LSTc incorporated into our decoy liposomes can make polymer-like, multivalent 
interactions with influenza virus due to the increased efficacy of the liposomes compared to 
monovalent LSTc.    
  The LSTc-containing decoy liposomes are specific for IAV.  I tested decoy liposomes 
containing 7.5 mol% LSTc against multiple strains of IAV, and show that they are capable of 
binding and inhibiting not just the H1N1 PR/8, but also the Beijing, H3N2 Philippines, and X-31 
strains (Table 3.2 and Figure 3.5B).  They do not, however, inhibit either SeV hemagglutination 
(Table 3.2) or RSV infectivity (Figure 3.5B). Control liposomes with DOPG lipid in place of 
LSTc glycolipids did not inhibit any of the viruses tested.  Furthermore, lack of infectivity is not 
a result of toxicity; neither control nor LSTc-containing decoy liposomes caused any cytotoxicity 
in vitro (Figure 3.6A) or gross toxicity in vivo (Figure 3.6B), demonstrating that the reduction in 
infectivity is probably a result of viral neutralization.  Inhibition of IAV is thus specific for the 
binding of HA to α2-6 linked SA, and is not a non-specific adhesion mediated by some other 
interaction. 
 While each of the IAV strains tested was inhibited by LSTc decoy liposomes, the degree of 
inhibition for each IAV strain varied considerably.  Each of the four strains tested is a 
conventional research strain propagated in chicken eggs.  PR/8, which exhibited the greatest 
degree of inhibition (see Table 3.2), is a commonly used H1N1 strain that has been extensively 
passaged in MDCK cell culture, and is adapted to growth in mice.  The extensive MDCK cell 
culture suggests that may have a small live-to-dead virion ratio, where less virus particles are 
defective than other strains.  Preliminary particle counts suggest this hypothesis (Dr. James 
Comolli, personal communications).  X31 and Philippines are each mouse-adapted reassortant 
 84 
strains.  Beijing 262/95 is a relatively recent human clinical isolate that resembles modern H1N1 
variants that emerged after 1994 (McDonald, Smith et al. 2007) and has undergone relatively 
little selection in the laboratory. One might expect that the Beijing human isolate would be most 
greatly inhibited by LSTc decoy liposomes given its adaptation to the human airway, which has a 
high prevalence of α2-6 linked SA (Ibricevic, Pekosz et al. 2006).  However, the Beijing strain, 
like the other viruses used in this study, was expanded in chicken eggs, which may have allowed 
for the selection of virions that favor binding to α2-3 linked SA.  Human RBC and MDCK cells, 
which were used in binding and infectivity assays, respectively, display a combination of α2-6 
and α2-3 linked SAs. The affinity between virus and host, either in the presence or absence of 
decoy liposomes, is influenced by the virion’s preferential binding to host α2-3 linked SA. Of 
note, the antigenic subtype did not appear to predispose viruses to greater or lesser susceptibility 
to LSTc decoy liposomes. 
 While the decoy liposomes can inhibit IAV infectivity, the amount of virus tested above is 
much smaller than the amount of virus that would be present in an actual infection.  To test the 
decoy liposome’s ability to inhibit viral spread of larger amounts of virus, I used a serum-free 
system to allow continued replication in the presence or absence of LSTc-containing liposomes. 
Decoy liposomes, but not control liposomes, inhibited viral replication (Figure 3.8).  The ability 
of LSTc decoy liposomes to inhibit viral replication in this system shows that they can block not 
only the initial infection event, but will remain active for days at body temperature and block 
progeny virus from re-infecting new target cells. The amount of IAV in this experiment is also 
much higher than in the initial infection studies (Figure 3.5), and here the LSTc decoy liposomes 
reduced the infectious titers by more than two logs, demonstrating significant efficacy against 
large amounts of virus.  
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 MDCK cells are widely used in IAV studies because they are permissive to IAV infection 
and propagation, and allow for analysis of viral binding, infection, and viral growth kinetics.  
MDCK cells express both α2-6 and α2-3 linked SA, which presents a higher bar for inhibition 
with the LSTc decoy liposomes, which only prevent IAV from binding α2-6 linked SA.  Here, I 
have further demonstrated that the inhibition by LSTc decoy liposomes seen in MDCK cells is 
also true in a human respiratory epithelial cell line (A549 cells) as well as in vivo in mice. 
 In addition to binding IAV and protecting cells from infection, our decoy liposomes also 
extended survival of mice challenged with a lethal dose of IAV (Figure 3.9).  Mice had 
significantly longer survival times when infected with a LD90 of IAV pre-incubated with LSTc 
decoy liposomes than mice infected with the LD90 pre-incubated with control liposomes.  Mice 
that received decoy liposomes with 15 mol% LSTc and IAV also had significantly longer 
survival times than co-incubated virus and control liposomes (Figure 3.9B).   
 When used for more clinically relevant prophylactic or therapeutic treatment of IAV-infected 
mice, the decoy liposomes were not protective.  Therapeutically treated mice first infected with 
PR/8 thirty minutes before being given LSTc decoy liposomes had the same time-to-death as 
infected mice that received control liposomes (Figure 3.11A).  Likewise, dosing mice with LSTc 
decoy liposomes before a lethal PR/8 infection did not reduce mortality (Figure 3.11B). Taken 
together, these data suggest that the dose of decoy liposomes that extended survival when co-
incubated with IAV, 170 µM SA, was insufficient when given before or after infection.  It is 
possible that a higher dose of decoy liposomes would be protective, but this has not been 
possible due to technical limitations, resulting in a lack of sufficient quantities of decoy 
liposomes from our collaborators.  The average airway surface area of an adult mouse is 
approximately 600 cm2, an area considerably larger than the volume of co-incubated virus and 
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decoy liposomes (0.3 cm2).  When given alone, the decoy liposomes would be diluted throughout 
the lung, greatly reducing their local concentration.  The co-incubation data suggests that the 
initial dosage would need to be increased by at least 3 logs to be effective.  However, these data 
demonstrate that when co-incubated, LSTc decoy liposomes are capable of maintaining long-
lasting interactions with IAV while in the hostile environment of the respiratory tract. Both an 
overall negative charge and a surface glycan enable liposomes to persist in the lungs (Deol and 
Khuller 1997), and our decoy liposomes contain both.  While co-incubating decoy liposomes 
with virus does not reflect a typical therapeutic delivery system, these mouse experiments 
demonstrate a proof-of-concept that LSTc decoy liposomes remain active and inhibitory in vivo.  
The extended survival of these mice suggests that the IAV binding and neutralization observed in 
vitro also occurs in vivo. 
 In this chapter I have shown that decoy liposomes containing LSTc have higher avidity for 
IAV than monovalent LSTc alone. Decoy liposomes bind directly to IAV virions and bound IAV 
cannot attach to SA-bearing epithelial cells.  Furthermore, virus bound to decoy liposomes are 
not infectious.  This block is virus-specific, and decoy liposomes specifically block IAV, but not 
other respiratory viruses that do not bind to α2-6 linked SA. LSTc-containing decoy liposomes 
can also block subsequent rounds of viral infection in vitro.  When co-incubated with virus, 
decoy liposomes maintain long-lasting association with virus in vivo, significantly extending 
survival times of mice given decoys and a lethal dose of IAV.  These results show that the decoy 
receptor liposome platform is a valid method for combating IAV, and that the platform can be 
modified to combat other pathogens with defined host receptors. 
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Chapter IV 
Optimizing the anti-influenza A virus liposome platform 
 
Introduction 
 In the previous chapter, I described the use of novel, LSTc-bearing decoy liposomes as a 
potential IAV therapeutic.  In this chapter I will discuss how various modifications to the decoy 
liposomes provided a better understanding of the properties required for inhibition.  I also will 
describe changes I made to the decoy glycolipid and their inhibitory effect on IAV.  Our 
liposome modifications demonstrate that a highly fluid, low curvature liposome is required to 
achieve efficient inhibition.  This inhibition is most likely dependent on the movement of SA 
glycolipids along the liposome surface, so that they can form multivalent interactions with IAV 
virions that increase the overall binding strength, decrease the dissociation rate and prevent the 
virus from binding and infecting a target cell.   
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Optimizing the anti-influenza A virus liposome platform 
Results 
Large, low curvature decoy liposomes are more efficient at inhibiting IAV  
 The initial liposomes tested were formed by extrusion through a 20 nm pore (see 
Materials and Methods), resulting in liposomes with an average radius of 31.6 ± 1 nm.  Previous 
studies have shown that larger liposomes have less surface curvature and less line tension, which 
is the energy between two lipid domains.  Liposomes with less line tension have less structured 
lipid micro-domains and more lipid mobility (Baumgart, Hess et al. 2003).  Decoy liposomes 
with more lipid fluidity, and therefore more LSTc mobility, theoretically should be more 
effective.  To increase the decoy liposome fluidity our collaborators increased the liposome size 
by using a larger lipid extrusion pore.  Using a 200 nm pore extruder, our collaborators increased 
the average liposome radius to 56.8 ± 3.5 nm.  To limit generation of multilamellar bodies, lipid 
bilayers within a larger liposome, extruder pores larger than 200 nm were not tested.  
Multilamellar decoy liposomes would have internal LSTc-DOPE and would result in available 
LSTc presented at the surface.   
 To determine the effect of liposome size on IAV infectivity, I co-incubated PR/8 with 
control or 7.5 mol% LSTc-containing decoy liposomes extruded through either a 20 nm or 200 
nm extrusion pore before infecting MDCK cell monolayers.  Increasing liposome size increased 
the inhibition of LSTc decoy liposomes (Figure 4.1).  At the lowest concentration tested, 1 nM 
SA, 20 nm extruded LSTc liposomes did not inhibit PR/8 (120 ± 3.4% infectivity of controls), 
but 200 nm extruded LSTc liposomes significantly inhibited PR/8 53.1 ± 3.1% (p ≤ 0.01).  The 
difference between these decoy liposomes was greatest at low concentrations of SA; the  
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Figure 4.1 Larger decoy liposomes with less surface curvature are more efficient at inhibiting 
influenza A virus. 
 
 
 
Figure 4.1 Larger decoy liposomes with less surface curvature are more efficient at inhibiting 
influenza A virus. 
 
PR/8 (30 PFU/well) was incubated with control liposomes, 20 nm pore extruded or 200 nm pore 
extruded LSTc-containing decoy liposomes before the addition to MDCK cells. Plaques per well 
of virus treated with control liposomes (0 mol% LSTc) are defined as 100% infectivity (open 
squares).  Decoy liposomes with 7.5 mol% LSTc extruded through a 200 nm pore filter (dotted 
triangles) significantly inhibited PR/8 more than decoy liposomes extruded a 20 nm pore filter 
(circles).  The data represent the average ± S.E. of two experiments. 
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inhibitory advantage of 200 nm pore extruded liposomes diminished as the concentration of SA 
increased.  At high concentrations of SA, both 20 and 200 nm extruded LSTc liposomes 
inhibited PR/8 to the same extent, approximately 70% inhibition at 300 nM SA and greater than 
87% inhibition at 1,000 nM SA. These data suggest that larger decoy liposomes with less 
curvature can make more interactions with IAV per liposome and therefore block infectivity 
more efficiently. 
Osmotic crushing slightly improves the efficacy of LSTc decoy liposomes 
 In addition to changing the liposome curvature by increasing overall size, our 
collaborators altered their curvature by osmotic crushing.  Osmotic crushing results in truncated, 
"squashed" sphere liposomes (Figure 4.2A) that have a high curvature equator region and 
flattened, lower curvature polar regions (Foo, Chan et al. 2003).  As seen with the larger 
liposomes, lower curvature may increase their LSTc glycolipid mobility and therefore the 
decoy’s efficacy. LSTc decoy liposomes were created with the same protocol described 
previously, but extruded into 15 mM PBS, instead of 150 mM PBS.  Immediately before each 
infectivity experiment, I diluted liposomes to the desired SA concentration in 150 mM PBS, 
causing osmotic outflow from the liposome interior and crushing into truncated sphere 
liposomes.  I tested the effect of crushing on IAV infectivity as described above, with co-
incubation of control and LSTc decoy liposomes with PR/8 IAV.  Osmotically crushed LSTc 
decoy liposomes had a slight, but significant increased efficacy against PR/8 infectivity (Figure 
4.2B).  At the highest concentration tested, 100 nM SA, crushed liposomes inhibited 61.1 ± 1.7% 
of PR/8 as compared to 37 ± 9.5% (p ≤ 0.05).  The increase was modest, about 1.5 fold, 
suggesting that either the degree of crushing achieved was small or that areas of high curvature 
(the equator region) created micro-domains  
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Figure 4.2 Osmotic crushing does not significantly affect influenza A virus inhibition. 
 
 
Figure 4.2 Osmotic crushing does not significantly affect influenza A virus inhibition. 
 
(A) Schematic representation of undeformed, spherical liposomes (left) that have equal curvature 
throughout the sphere and osmotically crushed (right) liposomes that have a equator region 
(dotted line) with high curvature and two low curvature polar regions.  (B) PR/8 (30 PFU/well) 
was incubated with control liposomes, LSTc-containing decoy liposomes and osmotically 
crushed LSTc-containing decoy liposomes before the addition to MDCK cells. Plaques per well 
of virus treated with control liposomes (0 mol% LSTc) are defined as 100% infectivity (open 
square).  Osmotically crushed decoy liposomes (dotted triangles) inhibited PR/8 infectivity 
slightly better than spherical decoy liposomes (circles).  The data represent the average ± S.E. of 
two experiments. Figure 4.2 Increasing fluidity of the decoy liposome’s surface increases 
efficacy. 
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that limited LSTc mobility across the liposome.  I did not perform direct, electron microscopy 
measurement of liposome crushing. 
 
Increasing the fluidity of the liposome lipid bilayer increases efficacy of LSTc decoy 
liposomes 
 Inclusion of cholesterol into a lipid bilayer has a two-fold effect on lipid fluidity.  In 
rigid, gelled bilayers, cholesterol interferes with the packing of hydrophobic tails and increases 
the lipid diffusion coefficient.  In highly fluid bilayers, cholesterol increases the mechanical 
rigidity and decreases the diffusion coefficient by reducing the free space between the lipid tails 
(Rubenstein, Smith et al. 1979).  In order to test the impact of cholesterol on our decoy 
liposomes, our collaborators incorporated 30 mol% cholesterol during liposome construction and 
tested the impact on IAV infectivity, as described above. At 1 or 10 nM SA, decoy liposomes 
with 7.5 mol% LSTc and 30 mol% cholesterol inhibited PR/8 infectivity significantly better than 
decoy liposomes with no cholesterol (Figure 4.3); 62% vs no inhibition (120 ± 3.4% of control, p 
≤ 0.001) at 1 nM SA and 60.3 ± 1.7% vs 10.3 ± 6.9% (p ≤ 0.05) inhibition at 10 nM SA.  At 
these low SA concentrations of decoy liposomes, the addition of cholesterol increased inhibition 
by 68%.  At 100 nM SA, decoy liposomes with cholesterol inhibited PR/8 slightly better than 
decoy liposomes without cholesterol, but it was not significant (58.6 ± 10.3% vs 77.6 ± 1.7% 
infectivity p = 0.21). And at the highest concentration tested, 1,000 nM SA, decoy liposomes 
with and without cholesterol inhibited PR/8 infectivity to similar levels, both greater than 87%.  
Control liposomes with 30 mol% cholesterol did not affect PR/8 infectivity.  These data 
demonstrate that cholesterol affects the decoy liposome inhibitory properties, most likely by  
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Figure 4.3 Increasing fluidity of the decoy liposome’s surface increases efficacy. 
 
 
Figure 4.3 Increasing fluidity of the decoy liposome’s surface increases efficacy. 
 
PR/8 (30 PFU/well) was incubated with control liposomes, LSTc-containing decoy liposomes 
with and without 30 mol% cholesterol before addition to MDCK cells. Plaques per well of virus 
treated with control liposomes (0 mol% LSTc) are defined as 100% infectivity (open square).  
7.5 mol% LSTc decoy liposomes with 30 mol% cholesterol (dotted triangles) significantly 
inhibited PR/8 infectivity more efficiently than decoy liposomes with 7.5 mol% LSTc without 
cholesterol (circles). The data represent the average ± S.E. of two experiments. 
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improving the fluidity of the lipid bilayer, increasing the diffusion of the LSTc–DOPE glycolipid 
thereby increasing its bio-availability.  
 
PEGylation of decoy liposomes abrogates their inhibitory properties 
 Incorporation of polyethylene glycol (PEG)-conjugated lipids into liposomes has been 
shown to extend blood circulation times and to decrease phagocytosis, increasing the in vivo 
half-life of the liposomes (Blume and Cevc 1993).  Therefore, our collaborators constructed 
liposomes with 10 mol% PEG-1000–DOPE and 10 mol% less of the neutral lipid, DOPC. The 
addition of PEG did not have an effect on control liposome size or polydispersity index (PDI).  
LSTc-containing decoy liposomes with PEG were slightly smaller than control liposomes, but 
did not differ in their PDI measurements (data not shown).  Although PEGylated, 7.5 mol% 
LSTc decoy liposomes did inhibit PR/8 infectivity, they inhibited significantly less than decoy 
liposomes without PEG at all concentrations tested, 23.5 ± 1.4% vs. 52.9 ± 2.8% (PEGylated 
decoy liposomes vs decoy liposomes, p ≤ 0.05) of PR/8 infectivity at 1 nM SA and 60.8% vs. 98 
± 1.4% PR/8 (p ≤ 0.05) at 1,000 nM SA (Figure 4.4).  The addition of PEG-1000 into our decoy 
liposomes resulted in approximately a two-fold decrease of efficacy in vitro.  This is most likely 
from steric interference between the PEG molecule and the LSTc glycan, effectively masking the 
LSTc glycan from HA.  These data suggest that while PEGyled liposomes have longer in vivo 
half-life and therefore may be useful in a drug delivery context, but they are not suited for decoy 
receptor presentation on a liposome surface.   
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Figure 4.4 Addition of PEG reduces decoy liposome’s inhibitory properties. 
 
 
Figure 4.4 Addition of PEG reduces decoy liposome’s inhibitory properties.  
 
PR/8 (30 PFU/well) was incubated with control liposomes, LSTc decoy liposomes and LSTc 
decoy liposomes with PEG-1000 before the challenge on MDCK cells. Plaques per well of virus 
treated with control liposomes (0 mol% LSTc) are defined as 100% infectivity (open square).  
PEGylated decoy liposomes (dotted triangles) inhibited significantly less PR/8 infectivity than 
LSTc decoy liposomes with 7.5 mol% LSTc and no PEG (circles).  The data represent one 
representative experiment that was repeated twice and presented as biological repeats ± S.E.  
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Additional decoy liposome surface negative charge does not increase IAV inhibition  
 Surface charge, or zeta potential, is a major determinant of the interaction between two 
charged bodies in a microscopic environment, such as an invading virus and a susceptible 
epithelial cell.  Viruses, which have relatively neutral zeta potentials, are attracted to negatively 
charged (with a significant portion of the charge coming from SA) cell surfaces (Hagenaars, 
Mastrobattista et al. 2009).  To electrically attract IAV to the decoy liposomes, our collaborators 
increased the negative charge of the liposomes, either by incorporating additional negative lipid 
(DOPG) or negatively charged LSTc-DOPE and co-incubated them with PR/8 IAV before 
infecting MDCK cells (Figure 4.5).  Control liposomes with either 7.5 or 15 mol% negative 
charge from DOPG lipid did not inhibit PR/8 infectivity.  Increasing the negative charge to 15 
mol% per decoy liposomes by either increasing the percentage of LSTc to 15 mol% (Figure 4.5) 
or by additional DOPG lipid (data not shown) did not significantly affect PR/8 infectivity as 
compared to decoy liposomes with 7.5 mol% negative charge.  Inhibition of PR/8 infectivity was 
consistently better with 7.5 mol% negatively charge decoy liposomes, despite doubling the 
amount of LSTc glycolipids per liposome, at all concentrations tested, from 10 nM SA to 1,000 
nM SA.  These data demonstrate that increasing the negative charge of LSTc decoy liposomes 
does not increase PR/8 inhibition. The increase in negative charge may have been too small, or 
the additional negative charge may have created an unfavorable repulsion between the MDCK 
cells and the decoy liposomes.   
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Figure 4.5 Increasing negative charge of decoy liposomes does not affect influenza A virus 
inhibition. 
 
 
 
 
 
Figure 4.5 Increasing negative charge of decoy liposomes does not affect influenza A virus 
inhibition. 
 
PR/8 (30 PFU/well) was incubated with control liposomes or LSTc-containing decoy with one of 
two negative charges before the addition to MDCK cells. Plaques per well of virus treated with 
control liposomes (0 mol% LSTc) are defined as 100% infectivity (open square).  Decoy 
liposomes with 7.5 mol% negative charge and LSTc (circles) inhibited better than decoy 
liposomes with 15 mol% negative charge and LSTc (dotted triangles).  The data represent the 
average ± S.E. of three experiments. 
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Combining decoy liposomes and the NA inhibitor oseltamivir increases decoy 
liposome efficacy  
 One concern with decoy receptor therapy for IAV is that NA removes terminal SA, 
normally from infected cell surfaces, but potentially also in the form of decoy LSTc.  Bacterial 
NA cleaves human LSTc in a crude preparation of breast milk (Martin-Sosa, Martin et al. 2003), 
and viral NA removes SA from purified monovalent LSTc in vitro when assayed by proton 
NMR (Kristina Prachanronarong and Celia Schiffer, personal communication).  Therefore, to 
examine the effect of IAV NA on LSTc decoy liposomes binding and inhibition, I combined 
decoy liposomes with and without the neuraminidase inhibitor (NAi) oseltamivir and tested the 
effect on infectivity.  Inclusion of oseltamivir with LSTc decoy liposomes increased inhibition of 
PR/8 infectivity (Figure 4.6).  As expected, oseltamivir mixed with control decoys (Figure 4.6, 
clear bars) did not significantly affect infectivity.  Oseltamivir alone would only inhibit budding 
IAV, and all drug treatments are washed out before replication begins.  LSTc decoy liposomes 
alone also inhibit PR/8 (Figure 4.6, left grouping), as seen previously.  Adding oseltamivir to the 
co-incubation and one-hour infection resulted in further inhibition of PR/8 infectivity.  When 
combined with 386 nM SA of LSTc decoy liposomes, 1 µM oseltamivir (Figure 4.6B, cross-
hatched bars) significantly reduced PR/8 infectivity by an additional 30% (48 ± 4.9% decoy 
liposomes alone vs 25.5% PR/8 infectivity for LSTc decoy liposomes and 10 µM oseltamivir, p 
≤ 0.05).  
 Higher concentrations of LSTc decoy liposomes had additional synergistic affects with 
oseltamivir. Co-incubating 1,160 nM SA of LSTc decoy liposomes (Figure 4.6, grey bars) with 
oseltamivir and PR/8 resulted in an additional 60% decrease of infectivity when incubated with 
both decoy liposomes and 10 µM oseltamivir (Figure 4.6C), as compared to decoy liposomes  
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Figure 4.6 Combining LSTc decoy liposomes with the NA inhibitor oseltamivir improves decoy 
inhibition of influenza A virus. 
 
 
 
Figure 4.6 Combining LSTc decoy liposomes with the NA inhibitor oseltamivir improves decoy 
inhibition of influenza A virus. 
 
PR/8 (30 PFU/well) was incubated with control liposomes or LSTc-containing decoy liposomes 
with or without the NAi oseltamivir before the addition to MDCK cells.  Infection lasted for 1 
hour at 37°C before virus and drug treatments were washed away and plaques allowed to 
develop. Plaques per well of virus treated with control liposomes (0 mol% LSTc and 0 µM 
oseltamivir) are defined as 100% infectivity (A, clear bar), and PR/8 samples treated with LSTc 
decoy liposomes and oseltamivir are expressed as the percent reduction from their respective 
control.  A-C. Inhibition of PR/8 infectivity with control liposomes (clear bars) or increasing 
amounts of LSTc-containing decoy liposomes; 386 nM SA (horizontal hatching), 1,1600 nM 
SA (grey) or 3,860 nM SA (black) and 0 µM (A), 1 µM (B) or 10 µM oseltamivir. The data are 
biological repeats of one independent representative experiment, repeated three times, all with 
similar results.   
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alone, 13.7% vs. 34.3 ± 1% (p ≤ 0.01) PR/8 infectivity, respectively.  At the highest LSTc 
concentration tested, 3,860 nM SA of decoy liposomes (Figure 4.6, black bars), inclusion of 
oseltamivir resulted in 82% of additional inhibition, with the combination of 3,860 nM SA decoy 
liposomes and 10 µM oseltamivir (Figure 4.6C) inhibiting all but 4.9 ± 2.9% infectivity as 
compared to 28.4 ± 2.9% infectivity (p ≤ 0.05) with decoy liposomes and no oseltamivir.  
Addition of less oseltamivir, 1 µM, followed the above trend of increasing inhibition of LSTc 
decoy liposomes, but to a lesser degree, as expected (Figure 4.6B).  These data demonstrate that 
decoy liposomes act synergistically with oseltamivir to inhibit IAV.  
 
Decoy liposomes with the α2-3 linked SA-containing glycolipid inhibit IAV 
 IAV binds to terminal SA, linked in either an α2-6 or an α2-3 linkage to the penultimate 
sugar residue, depending on which host species they are adapted to infect.  The human upper 
respiratory tract has glycans with α2-6 linked SA, and therefore I have focused primarily on 
decoy liposomes decorated with that linkage. However, highly virulent H5N1 avian strains that 
infect humans (Chandrasekaran, Srinivasan et al. 2008) and recent avian or swine crossover 
strains bind to α2-3 linked SA (Pappas, Viswanathan et al. 2010).  Therefore, our collaborators 
created decoy liposomes functionalized with α2-3 linked SA, via the glycolipid LS-
Tetrasaccharide A (LSTa).  LSTa glycan underwent the same purification, chemical linking and 
quality controls as described for LSTc in Chapter 3. LSTa-containing liposomes had similar 
polydispersity indexes as LSTc-containing liposomes.   
To test IAV binding of LSTa-containing decoy liposomes, I utilized the standard HAI 
assay and found that LSTa decoy liposomes inhibited all IAV strains tested, except Beijing 
H1N1 (Table 4.1).  All the strains that were inhibited by LSTa-containing decoy liposomes have  
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Table 4.1 Assessment of LSTa decoy liposomes by hemagglutination inhibition assay of multiple 
strains of influenza A virus. 
 
Virus HAI Titer  IC90 (µM SA) 
Philippines H3N2 180 0.16 (± 0.8) 
X-31 H3N2 16 1.8 (± 2.9 ) 
HK 68 H3N2 90 0.32 (± 0.3 ) 
Victoria H3N2 16 1.8 (± 5.1) 
Beijing H1N1 No inhibition > 14.6 
 
 
Table 4.1 Assessment of LSTa decoy liposomes by hemagglutination inhibition assay of multiple 
strains of influenza A virus. 
 
LSTa decoy liposomes competitively bind to several strains of influenza virus. Decoy liposomes 
containing 30 mol% LSTa are effective at inhibiting hemagglutination of Philippines, X-31, and 
HK68 IAV strains. IC90 values are shown as molarity of sialic acid ± the 95% confidence 
interval. Hemagglutination of Beijing IAV is not inhibited by 30 mol% LSTa decoy liposomes at 
the highest concentration tested. 
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been described to bind to α2-3 linked SA.  The Beijing 95 is a more recent isolate, and is 
believed to have had less egg passage, and therefore less α2-3 adaptation.  Control liposomes 
lacking LSTa did not cause any HAI when tested at the same lipid concentrations as LSTa 
liposomes.  Like LSTc liposomes, liposomes with 30 mol% LSTa inhibited Philippines with HAI 
titers of 180 and an IC90 of 0.16 µM SA, X-31 with HAI titers of 16 and an IC90 of 1.8 µM SA, 
HK 8/68 with HAI titers of 90 and an IC90 of 0.32 µM SA, and Victoria 3/75 (H3N2) with HAI 
titers of 16 and an IC90 of 1.8 µM SA. I also tested Beijing 262/95 (H1N1) against the 30 mol% 
LSTa liposomes, but it did not inhibit hemagglutination at the highest concentration tested, 14.6 
mM SA, which is roughly three logs more LSTa decoys than what was inhibitory for the other 
IAV strains.  Interestingly, Beijing IAV is inhibited only by LSTc-containing decoy liposomes 
(see Table 3.2), which suggests that it binds exclusively to α2-6 linked SA, whereas all of the 
other strains tested appear to be promiscuous binders that bind both α2-6 and α2-3 linked SA.  
While LSTa decoy liposomes inhibited IAV, the degree of HAI was less than that of LSTc-
containing liposomes; this may be due to any of a number of factors, including the binding 
strength of HA to α2-3 linked SA, susceptibility of LSTa to viral NA, and proper incorporation 
and presentation of LSTa into decoy liposomes. 
 
Decoy liposomes with the α2-3 linked SA glycan inhibit influenza virus infectivity 
 To investigate the impact of LSTa-containing decoy liposomes on infectivity, I co-
incubated several strains of IAV with control or decoy liposomes with 30 mol% LSTa before 
infecting MDCK cell monolayers.  LSTa decoy liposomes significantly inhibited all IAV strains 
tested (Figure 4.7).  At the highest concentration tested, 14,585 nM SA, LSTa decoy liposomes 
inhibited PR/8 up to 40.6 ± 7.2%, Philippines up to 31%, X31 up to 56.7 ± 3.9%,  
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Figure 4.7 LSTa decoy liposomes inhibit influenza A virus infection of MDCK cells. 
 
 
Figure 4.7 LSTa decoy liposomes inhibit influenza A virus infection of MDCK cells. 
 
Decoy liposomes containing 30 mol% LSTa inhibit multiple strains of IAV. Decoy liposomes 
inhibited Philippines (open triangles, 50 PFU/well), X-31 (crosses, 50 PFU/well), Beijing (open 
circles, 15 PFU/well), PR/8 (filled circles, 30 PFU/well), and HK68 (half closed diamonds, 60 
PFU/well) strains of IAV.  The data are representative averages ± S.E. of one experiment for 
Philippines, X-31, Beijing and HK68 and two experiments for PR/8. 
 
  
 104 
HK68 up to 42 ± 0.8% and Beijing 26.1% ± 4.3% of infectivity as compared to control 
liposomes.  Unlike LSTc decoy liposomes, all of the strains tested, except Beijing, were inhibited 
to similar levels by both doses.  The overall degree of inhibition obtained here was less than 
comparative doses of LSTc-containing decoy liposomes, perhaps due to strain preference for α2-
6 linked SA over α2-3 SA. Supporting this is the relative lack of inhibition of Beijing IAV, a 
strain that is reported to have less cell culture adaptation than the other common research strains 
(McDonald, Smith et al. 2007).  In previous studies, an H3N2 strain had a 5-fold preference for 
LSTc over LSTa with the HAI assay (Pritchett, Brossmer et al. 1987).  Together with the HA 
data above, these data demonstrate that LSTa decoy liposomes can also inhibit IAV binding and 
infectivity. 
 
LSTc- and LSTa-containing decoy liposomes synergistically inhibit IAV infectivity 
 Many of the key emerging avian and swine IAV strains that successfully infect humans 
can bind to both α2-3 and α2-6 linked SA, and it is therefore reasonable to expect that a 
population of decoys that contained both SA linkages might inhibit IAV to a greater degree than 
either one alone.  To test this hypothesis, I performed a ‘checkerboard’ experiment by co-
incubating PR/8 with either LSTc liposomes or LSTa liposomes individually, or with a 
combination of both types at varying concentrations and assayed for infectivity on MDCK cell 
monolayers.  LSTc liposomes alone inhibited PR/8 by 84.7 ± 1.7 % at 11,600 nM SA (Figure 
4.8, left grouping), which is in line with the degree of inhibition seen in Chapter 3 (see Figure 
3.5). When used individually, LSTa liposomes also inhibited PR/8 to a similar extent as seen 
above, to 39 ± 3.4 % at 15,600 nM SA (Figure 4.8, white bars).  Again these results confirm that 
LSTc decoy liposomes are more effective at inhibiting IAV than LSTa decoy liposomes.  When  
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Figure 4.8 Combining LSTc- and LSTa-containing decoy liposomes increases inhibition of 
influenza A virus. 
 
 
 
Figure 4.8 Combining LSTc- and LSTa-containing decoy liposomes increases inhibition of 
influenza A virus. 
  
PR/8 (30 PFU/well) was incubated with control liposomes, LSTc-containing decoy liposomes, 
LSTa-containing decoy liposomes or a mixture of LSTc- and LSTa-containing decoy liposomes 
before the addition to MDCK cells. Plaques per well of virus treated with control liposomes (0 
mol% LSTc and 0 mol% LSTa) are defined as 100% infectivity (A, clear bar), and PR/8 
samples treated with different liposome formulations are expressed as the percent reduction from 
its respective control.  (A-C) Samples received the indicated amount of decoy liposomes with 15 
mol% LSTa and increasing amounts of LSTc-containing decoy liposomes, either control 
liposomes (clear), 1,160 nM SA (horizontal hatching), 3,900 nM SA (grey) or 11,600 nM SA 
(black), as indicated in the key.  The data represent biological repeat average ± S.E. of one 
representative of two experiments.  
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combined, LSTc and LSTa decoy liposomes had a synergistic effect.  At a constant 
concentration, 1,160 nM SA, of LSTc liposomes, 470 nM SA or 15,600 nM SA of LSTa-
containing liposomes inhibited PR/8 infectivity 69.5 ± 3.4% and 76.3 ± 3.4%, respectively, from 
a baseline inhibition of 57.6 ± 1.7% when challenged with LSTc decoy liposomes alone (Figure 
4.8).  When used together, this represents an additional 32% increase of inhibition above either 
LSTc or LSTa liposomes alone.  Higher doses of LSTa decoy liposomes also results in synergy. 
LSTc-containing decoy liposomes at 3,900 nM SA inhibited PR/8 infectivity to 74.5 ± 1.7% in 
the absence of LSTa liposomes, but inhibition increased to 88.1 ± 1.7% and 88.1 ± 5% when 
combined with either 470 nM SA or 15,600 nM SA LSTa-containing liposomes, an additional 
18% inhibition increase.  Finally, 11,600 nM SA of LSTc-containing liposomes alone inhibited 
84.7 ± 1.7% PR/8 infectivity.  Addition of LSTa at 470 and 15,600 nM SA increased the 
inhibition to 94.9 ± 1.7 and 98.3 ± 1.7% of all PR/8 inhibited, resulting in an additional 16% 
increase of inhibition as compared to either decoy liposomes alone.  Inhibition was most 
dramatic when low concentrations of both LSTc- and LSTa-containing decoy liposomes were 
combined, due in part to the almost complete inhibition of IAV at the tested viral dose (30 
PFU/well).  The synergistic effect can be seen when 470 nM SA of LSTa liposomes (3.4% 
inhibition alone) and 1,160 nM SA LSTc liposomes (57.6% inhibition alone) are combined, 
resulting in 69.5% inhibition.  These data suggest a mixture of decoy liposomes would 
effectively combat a strain of IAV that retains the ability to bind to both α2-3 and α2-6 linked 
SA. 
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Optimizing the anti-influenza A virus liposome platform 
Discussion 
The data presented here describe several diverse modifications made to the decoy 
liposome platform, including changing the decoy receptor to target IAV strains adapted to other 
host species.  Using liposomes to achieve polymer-like, multivalent decoys makes it easily 
adaptable, which is not true for polymer-based decoy receptors.  The results presented in this 
chapter demonstrate that changing liposome size, fluidity, and charge can improve efficacy of 
IAV inhibition.  In addition, the decoy receptor can be changed to LSTa, and along with LSTc-
containing decoy liposomes, can synergistically target IAV.  LSTa decoy liposomes may also 
target avian adapted IAV strains.  These data highlight the adaptability of the decoy liposome 
system, and with the creation of decoy liposomes containing LSTa, indicate that additional 
glycolipid decoy mimics can be utilize to target additional pathogens. 
 
Generation of liposome formulations for enhanced IAV inhibition 
The basic decoy liposome formulation showed promising inhibition against IAV with the 
SA-containing molecule, LSTc.  In an attempt to improve inhibition, our collaborators and I 
modified several aspects of the platform to determine the optimal formulation for IAV inhibition.  
Doubling the size of the decoy liposome increased inhibition by almost five fold at low 
concentrations of SA (Figure 4.1). These data indicate that low decoy curvature is very important 
for optimal interactions between LSTc and HA.  Baumgart et al. (2003) have shown that 
liposomes with minimal curvature have less line tension, and therefore less of a diffusion barrier 
between lipid components as compared to liposomes with higher curvature (Baumgart, Hess et 
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al. 2003). Further increase in liposome size is not technically feasible in this study due to the 
formation of multilammeler vesicles created with larger extruder pores, which would reduce the 
amount of LSTc available at the vesicle exterior for binding to virus and thus negate the positive 
effects of further curvature reduction.   
 Osmotic crushing is another method of changing liposome curvature.  Osmotically 
crushed liposomes are shaped like truncated spheres that have two polar regions with low 
curvature and an equator region with high curvature.  As shown previously, large decoy 
liposomes with low curvature were more inhibitory.  We hypothesized that crushed decoy 
liposomes would interact more efficiently with IAV via their two low curvature domains.  
Crushing our decoy liposomes resulted in a small but significant increase in IAV inhibition  
(Figure 4.3), but crushed liposomes were less effective than the larger, spherical liposomes tested 
above.  It is possible that the high curvature equator region prevented LSTc glycolipids from 
migrating from one polar domain to the other. 
 Liposome fluidity can be adjusted by changing the membrane components.  Adding 
cholesterol into a lipid bilayer affects lipid packing and makes the bilayer more fluid 
(Rubenstein, Smith et al. 1979).  Cholesterol also increases liposome fluidity, and it has been 
shown to increase lateral diffusion and reduce line tension (Coderch, Fonollosa et al. 2000).  The 
addition of 30 mol% cholesterol improved the PR/8 inhibition of LSTc decoy liposomes by three 
fold (Figure 4.2), suggesting that cholesterol enhanced the ability of LSTc decoy glycans to 
diffuse through the liposome membranes, increasing the bio-availability of the LSTc decoy.  
 Addition of PEG to liposome was previously shown to increase in vivo half-life (Blume 
and Cevc 1993).  Increased in vivo half-life would improve the efficacy of our decoy liposomes, 
allowing more time for a patient’s adaptive immune response to clear the virus, thus decreasing 
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mortality.  Decoy liposomes with long half-lives may act more like a molecular sink, and could 
be administered to patients less often.  Unfortunately, inclusion of PEG-1000 onto our decoy 
liposomes abrogated their ability to inhibit PR/8 IAV (Figure 4.4).  PEG increases the circulation 
times of drug delivery decoys, but in the context of decoy liposomes, PEG appears to mask the 
LSTc glycolipid.  The molecular weight of PEG-1000 and LSTc are comparable, suggesting that 
there may be steric interference between PEG and LSTc glycolipid.  In addition, PEGylated 
liposomes were previously shown to have reduced lipid fluidity (Blume and Cevc 1993), which 
would make the LSTc glycolipid less able to migrate through the membrane and bind to IAV.  
For these reasons, PEGylated decoy liposomes are not a viable option for extending in vivo half-
life. 
The outcome of an interaction between two lipid membranes is partially dependent on 
their electrostatic properties.  In the context of an enveloped viral infection, such as IAV, the net 
membrane charge, or zeta potential, of the virion and of the target host cell are critical for 
infection.  Using decoy liposomes as a therapy further complicates the equation, introducing a 
third lipid membrane that must have a favorable zeta potential for interaction with the 
appropriate partners – strong for the virus and weak for cell membranes.  IAV has a relatively 
neutral zeta potential of about -20 mV (Hagenaars, Mastrobattista et al. 2009).  Mammalian cells 
have a strong negative charge. Liposomes with 7.5 mol% of negatively charged lipids, similar to 
the decoys liposomes used here, also have a relatively neutral zeta potential, of about -25 mV 
(Woodle and Lasic 1992).  Therefore increasing the negative charge of the decoy liposomes may 
make them more attractive to the less negatively charged IAV and less attractive to the very 
negative host cells, which may impede decoy liposome function.  In addition, negatively charged 
liposomes were shown to have longer in vivo lifespans in the lung environment as compared to 
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neutral liposomes (Deol and Khuller 1997).  Therefore, our collaborators doubled the mole 
percent of negatively charged molecules, either by adding negative lipid in place of neutral lipid 
or by adding negatively charged LSTc.  Doubling the negative charge on decoy liposomes did 
not increase PR/8 inhibition; rather, inhibition was slightly reduced (Figure 4.5).  This 
contradicted our initial hypothesis and may result from electrostatic repulsion of decoy 
liposomes from the cell monolayer, where the competitive binding of decoy LSTc to virus would 
be most effective at blocking IAV attachment to SA on susceptible cells.   
One potential problem of using a decoy receptor drug is that some pathogens, IAV 
included, enzymatically remove their host receptor during the course of infection. IAV NA on 
budding virions removes terminal SA from glycolipids and glycoproteins on the infected cell and 
on IAV itself.  Desialylation allows IAV release from an infected cell by preventing nascent HA 
from binding the infected cell or other virions (See Figure 1.2).  The NA inhibitors Oseltamivir 
and Zanamivir prevent release of budding virus and effectively neutralize the virus (Collins, 
Haire et al. 2008). The SA on both LSTc and LSTa are theoretically vulnerable to NA and could 
be cleaved when the decoy liposome binds to IAV.  The literature suggests that unpurified 
human LSTc is cleavable by bacterial NA (Martin-Sosa, Martin et al. 2003).  Moreover, purified 
monovalent LSTc is cleavable by viral NA (Kristina Prachanronarong and Dr. Celia Schiffer, 
personal communication) and therefore NA may cleave decoy liposomes LSTc negatively 
affecting inhibition.   
To examine the effect of NA cleavage on LSTc decoy liposomes, I mixed decoy 
liposomes with or without the NA inhibitor, oseltamivir, and compared PR/8 inhibition.  At all 
concentrations of decoy liposomes tested, addition of oseltamivir increased inhibition of 
infectivity (Figure 4.6).  The effect was most dramatic at high concentrations of decoy liposomes 
 111 
and fairly high concentration of oseltamivir, which resulted in an additional 80% of infectivity 
inhibition.  These data demonstrate that the LSTc-containing decoy liposomes act synergistically 
with oseltamivir to further inhibit IAV infectivity.  In addition, NA may remove some SA from 
the decoy liposomes, and this may explain some of the inhibition differences between the IAV 
strains tested against LSTc-containing decoy liposomes (see Figure 3.4B and Table 3.2), because 
NA activity levels differ by strain.   
The linkage of SA to the penultimate sugar residue can be made NA resistant, and 
previous decoy studies have found this modification makes decoy receptors more efficient (Itoh, 
Hetterich et al. 1995; Sun, Kanie et al. 2000).  These data demonstrate that my decoy liposomes 
would benefit from an LSTc molecule with an NA-resistant linkage, which can be created in the 
laboratory.  Another potential solution would be to load the decoy liposome interior with a NAi.  
Loading would result in a local, high Oseltamivir concentration at the decoy liposome, as 
oseltamivir would escape slowly through the lipid bi-layer.  This approach would not only make 
the decoy liposomes more efficient, it would help deliver a proven anti-IAV drug to the site of 
infection.  This could be used as a method of targeting NA inhibitors to infected respiratory cells, 
preventing release of budding virus, with lower NAi doses and possibly reduced toxicity. 
Decoy liposomes with α2-3 linked SA inhibit IAV binding and infectivity 
 IAV that is adapted to infect humans predominantly binds to α2-6 SA, while avian and 
swine adapted strains bind to α2-3 SA.  There is evidence of strains emerging from the avian and 
swine population and infecting humans, bind to both α2-6 and α2-3 SA before the adaptation to 
α2-6 linked SA binding is fixed (Glaser, Stevens et al. 2005).  Furthermore, humans have α2-3 
linked SA in the lower respiratory tract, and when avian-adapted IAV reaches this area, life-
threatening pneumonia can develop.  Therefore, our collaborators created decoy liposomes with 
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LSTa, a glycan with α2-3 linked terminal SA.  LSTa decoy liposomes were able to bind and 
inactivate several IAV strains tested, but to a lesser degree than LSTc-containing decoy 
liposomes.  The reduced affinity was seen with both the HAI and infectivity assay and most 
likely represents a preference of each strain for α2-6 linked SA.  Notably, a more recent clinical 
isolate, Beijing IAV, was inhibited less by LSTa decoy liposomes than the strains adapted to 
mouse infection, such as PR/8 or X-31 (Figure 4.7 and Table 3.1).   Combining LSTc- and 
LSTa-containing decoy liposomes increased the degree of inhibition against PR/8 IAV (Figure 
4.8), demonstrating synergy between two decoy receptors against a promiscuous binder IAV.  
These data suggest that some virions in a virus population may favor one linkage over another, 
and a mix of decoy liposomes can effectively target such viruses.  Combined decoy treatment 
may also be useful when combating a strain with unknown binding preferences.  It would be 
interesting to test LSTa decoy liposomes against an avian-specific IAV strain, as it may 
demonstrate the true potential of LSTa decoy liposomes against other antigenic IAV subtypes.  
The data presented here have determined that optimal inhibition occurs when decoy 
liposomes have low curvature and highly fluid lipid membranes.  In addition, decoy liposomes 
with LSTa, a glycolipid with α2-3 linked SA, inhibited all but one IAV strains tested and acted 
synergistically with LSTc-containing decoy liposomes to further inhibit IAV.  These data 
demonstrate the adaptability of the decoy liposome platform and how they could be modified for 
use in different applications and potentially different diseases.  The decoy liposomes tested here 
have been especially made for use in the lung, but they could easily optimized for other uses, 
such as in vitro binding arrays.  
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Chapter V 
Heparin sulfate decoy liposomes inhibit respiratory syncytial virus and herpes 
simplex virus 
 
Preface 
This Chapter contains information relating to the creation of decoy liposomes containing 
the decoy glycolipid HS-octa, and their use as a therapeutic against RSV, HSV and PIV3.  Dr. 
Zachary Shriver’s laboratory created and purified HS-octa glycans and constructed LSTa-
glycolipids.  Dr. Deborah Fygenson and her laboratory were responsible for constructing the HS-
octa decoy liposomes.  I tested the liposomes in all experiments described below, including 
infectivity assays, growth inhibition studies, and statistical analysis.  Natasha Qaisar and Serna 
Pham performed the PIV3 HAI assays.   
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Introduction 
 In the previous two chapters I described the creation and optimization of sialic acid-
bearing decoy liposomes as a potential IAV therapeutic.  In this chapter I will discuss developing 
the decoy liposome platform to target a new set of viruses by utilizing a new decoy receptor 
glycolipid.  My findings demonstrate that decoy liposomes with heparin sulfate octasaccharides 
(HS-octa) inhibit HS-binding viruses better than the HS-octa building block in solution or the 
full-length heparin, and in addition, HS-octa decoy liposomes are not anticoagulants.   
Heparan sulfate (HS) is a broad group of related, linear chain glycosaminoglycans 
(GAGs) made up of 10 to 200 disaccharide repeats, containing N-acetyl-D-glucosamine and an 
uronic acid.  While all HS-GAGs have the same basic disaccharide repeat, each member is 
chemically distinct from further modifications to each repeat. HS-GAGs can be sulfonated with 
either an N- or O-linkage, and they have three sites per disaccharide repeat for O-sulfonate 
attachment.  Epimerization of the uronic acid can add further variety to each HS-GAG family 
member.  With so many possible modifications, HS-GAG family members differ widely in 
structure.  Heparin is one HS-GAG family member, it is highly sulfonated, giving it the highest 
negative charge density of all known biological molecules.  It is made mostly by mast cells and 
is used clinically as a potent anticoagulant.  Clinical heparin is a pleiotropic population of 
heparin chains that vary in length and molecular weight, which range from 5,000 to 40,000. It is 
a well-studied HS-GAG and many binding partners have been described (Iozzo 1998).  
Important here, the heparin domains required for its anticoagulant properties have been defined: 
heparin binds to antithrombin III and the factor IIa /Xa complex (Petitou, Herault et al. 1999). 
Antithrombin III binding requires a specific pentasaccharide repeat of heparin / HS and a second, 
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distal binding saccharide partner on the same chain.  Shorter oligosaccharides of heparin, also 
generalized as heparan sulfates by the literature, do not possess the longer binding sites of these 
clotting factors and therefore are not anticoagulants (Dr. Zachary Shriver, personal 
communication and Petitou, Herault et al. 1999).  
Many pathogens bind to HS-GAGs, which taken together, are expressed ubiquitously on 
cell surfaces throughout the body.  HS-binding viruses use HS either for initial attachment or as a 
sole host ligand (Zhu, Li et al. 2011).  Due to its many sulfonate and carboxylate groups, HS-
GAGs have highly negative charge densities and HS-binding viruses have evolved attachment 
proteins with clusters of positively charged amino acids, forming heparan-binding domains 
(HBD).  Because HS is a linear repeating molecule, it is thought to make multiple interactions 
with many HBDs on a single virion and to make multivalent interactions with virus.  Here our 
collaborators and I have created and tested HS-octa decoy liposomes that inhibit HS-binding 
viruses.  These data, along with LSTc and LSTc functionalized decoy liposomes may be used in 
the future as an adaptable platform to target many different important pathogens. 
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Heparin sulfate decoy liposomes inhibit respiratory syncytial virus and herpes 
simplex virus 
Results 
Heparin sulfate oligosaccharide liposomes 
 While all of the liposome formulations described above had a wide range of 
modifications; they all had sialic acid as the decoy receptor for IAV inhibition.  Replacing the 
decoy receptor glycan allows the decoy liposome platform to target other important pathogens.  
One such glycan receptor is heparin / heparan sulfate GAGs.  HS is a representative of a family 
of long, linear polysaccharides found abundantly throughout the body, both in the extracellular 
matrix and attached to cell membranes.  Many viruses have been discovered to bind to HS, as 
either an initial receptor before binding a protein receptor or as specific receptor (Zhu, Li et al. 
2011).  Specifically, HS has been demonstrated to play an important role in respiratory syncytial 
virus (RSV) (Krusat and Streckert 1997) and herpes simplex virus (HSV) (WuDunn and Spear 
1989).   
 Therefore our collaborators created decoy liposomes decorated with HS oligosaccharides, 
in order to inhibit HS-binding viruses.  The starting HS molecule used was clinical heparin, 
which consists of a population of heparin chains of varying lengths, with an average molecular 
weight of 15,000.  Heparin was cut into smaller fractions with heparinase and purified by anion 
exchange chromatography.  The negative charge on each disaccharide repeat allows for fairly 
pure populations of specific numbers of sugar residues (Zachary Shriver, personal 
communication).  An octasaccharide (referred here as HS-octa) was chosen for use in the decoy 
liposomes due to its lack of anticoagulation properties and because it has enough binding motifs 
while not being too large to cause liposome destabilization or incorporation issues.  HS-octa 
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decoy liposomes were created in the same manner as for the LSTc–DOPE liposomes described 
in Chapter 3.  Compounds 1 − 4, as described in Figure 3.1 were created with the same method, 
and purified HS-octa was covalently attached to the DOPE lipid-linker (compound 4).   
 HS-octa decoy liposomes were extruded with the same protocol as for LSTc decoy 
liposomes, they were also extruded through a 200 nm extruder pore, and had average radii of 
57.6 ± 2.1 nm and PDI of 0.136 ± 0.01, which are similar to the sizes and polydispersity of LSTc 
decoy liposomes.  Our collaborators generated a series of HS-octa decoy liposomes with 
increasing mole percentages of HS-octa incorporated in each liposome to test the optimal density 
of HS-octa required for inhibition.  The maximum mole percentage of HS-octa incorporation was 
30 mol%, decoy liposomes with less HS-octa had DOPG incorporated as needed to retain a 30 
mol% of negatively charged lipid.  Of note, DOPG has less of a negative charge per molecule 
than HS-octa–DOPE.  Liposomes with 0 mol% HS-octa and 30 mol% DOPG were used as 
control liposomes. 
 
Heparin and HS-octa inhibition is specific for HS-binding viruses 
 In order to test the heparin decoy glycan for species-specific inhibition, I co-incubated 
RSV A2, HSV kos and PR/8 IAV with full-length heparin sulfate, HS-octa in solution or media 
control before infecting Vero or MDCK cell monolayers.  Full-length heparin inhibited RSV and 
HSV (Figure 5.1 A, B), as established by the literature (WuDunn and Spear 1989; Feldman, 
Audet et al. 2000), but the same concentrations of heparin did not inhibit IAV (Figure 5.1C), 
which has also been previously shown (Martinez and Melero 2000).  In my hands, neither full-
length or the octasaccharide inhibited IAV, demonstrating that the process of creating the HS- 
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Figure 5.1 Heparin sulfate and HS-octa specifically inhibit RSV and HSV infection of Vero 
cells. 
 
Figure 5.1 Heparin sulfate and HS-octa specifically inhibit RSV and HSV infection of Vero 
cells. 
A, RSV (50 PFU/well), B HSV (50 PFU/well) and C, IAV (PR/8, 50 PFU/well) were incubated 
with full-length heparin, HS-octa saccharide or media control before addition to Vero (A and B) 
or MDCK cells (C).  Full-length heparin (circles) inhibited RSV and HSV to a greater extent 
than HS-octa saccharide (triangles).  Neither inhibited IAV.  Data are represented as percent 
reduction, with media control (open squares) defined as 100% infectivity. The data represent the 
average ± S.E. of two experiments for HSV and RSV and one experiment for PR/8 IAV. 
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octa does not introduce any non-specific inhibition properties or contamination.  Full-length 
heparin was very efficient at blocking RSV infectivity, inhibiting 60.1 ± 10.8% of RSV at as 
little as 0.006 µM HS.  Higher doses resulted in up to 96% inhibition (Figure 5.1A).  As 
expected, HS-octa was less efficient at inhibiting RSV than the full-length heparin. HS-octa 
blocked 44% of RSV infectivity when used at 0.04 µM HS-octa and blocked approximately 60% 
of RSV infectivity inhibition at the highest concentration tested, 40 µM HS-octa.   
 A similar trend resulted when HSV was challenged with full-length heparin and HS-octa.  
Full-length heparin blocked 52% HSV infectivity at the lowest concentration tested, 0.006 µM 
HS and up to 95% HSV infectivity at 6.6 µM HS (Figure 5.1B).  HS-octa in solution did not 
inhibit HSV strongly, blocking only 33% of HSV infectivity at the highest concentration tested, 
40 µM HS-octa.  The difference between the full length and octasaccharide is expected because 
the shorter HS-octa has fewer negatively charged side groups available for binding to the virus 
and reduced steric hindrance.  The full-length heparin however, cannot be used therapeutically 
either in solution or complexed into a decoy liposome due to its potent anticoagulant properties.  
These data confirm that the HS-octa building block remains inhibitory to HS-binding viruses, 
and does not have a binding gain-of-function to the unrelated virus, IAV.  These data also 
validate the use of HS-octa as a receptor in decoy liposomes, for species-specific inhibition of 
HS-binding viruses. 
 
Decoy liposomes with HS-octa inhibit Respiratory syncytial virus  
 Next I assessed decoy liposomes functionalized with HS-octa glycolipids linked to DOPE 
at different mole percentages on RSV infectivity.   Our collaborators created a series of 
liposomes containing increasing mole percentages of HS-octa glycolipid, and control liposomes 
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containing the negatively charged lipid, DOPG, in place of decoy.  The series ranges from 
control liposomes (0 mol% HS-octa and 30 mol% DOPG) to 30 mol% HS-octa (and no DOPG).  
To calculate the molarity of HS-octa in solution, I multiplied the mole percent input of HS-octa-
DOPE by the total lipid concentration, as described above for the LSTc liposomes.  Increasing 
concentrations of decoy liposomes with HS-octa inhibited RSV infectivity (Figure 5.2A) in these 
cells, while control liposomes did not.  At low concentrations (0.001 µM HS-octa), all decoy 
liposome formulations tested inhibited RSV weakly.  Increasing the mole percentage of HS-octa 
per decoy liposomes increased RSV inhibition, in a dose dependent manner.  Decoy liposomes 
with 3 mol% HS-octa (Figure 5.2A, open diamonds) weakly inhibited RSV, blocking only 30 ± 
18.2% RSV infectivity at 1 µM HS-octa, the highest concentration tested. 7.5 mol% HS-octa 
liposomes were more effective, inhibiting 26.6 ± 4.8% (p ≤ 0.005) and 48.3 ± 2.6% (p ≤ 0.0001) 
RSV infectivity at 0.1 and 1 µM HS-octa, respectively.  Unlike LSTc decoy liposomes, where 
efficacy plateaued at 7.5 mol% LSTc incorporation (see Figure 3.5), decoy liposomes with 10 
mol% HS-octa inhibited better than 7.5 mol% HS-octa decoy liposomes, blocking 39 ± 5.9% of 
RSV infectivity at 0.1 µM HS-octa.  Decoy liposomes with 30 mol% HS-octa inhibited RSV to 
the greatest extent, blocking 76.5 ± 3.9% of RSV infectivity (p ≤ 0.0001) at very low 
concentrations (0.01 µM HS-octa).  Increasing concentrations of 30 mol% HS-octa decoy 
liposomes had an even more pronounced inhibition effect, blocking 90.2 ± 2.2% (p ≤ 0.0001) 
and 98.1 ± 1.9% RSV infectivity (p ≤ 0.0001) at 0.1 µM and 1 µM HS-octa, respectively as 
compared to control liposomes.   
 The HS-octa decoy liposomes blocked RSV infectivity to a greater extent than the 
heparin controls.  As seen previously, full-length heparin in solution inhibited RSV with an IC50 
of approximately 10 µM HS-octa (Figure 5.2A and B grey diamonds) and the non-liposome  
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Figure 5.2 HS-octa decoy liposomes inhibit RSV infectivity. 
 
 
 
Figure 5.2 HS-octa decoy liposomes inhibit RSV infectivity. 
 
RSV (30 PFU/well) was incubated with control liposomes, LSTc-containing decoy liposomes, 
full-length heparin or HS-octa before the addition to Vero cells. Plaques per well of virus treated 
with control liposomes (0 mol% HS-octa) are defined as 100% infectivity (open square), and 
virus treated with different liposome formulations are expressed as the percent reduction from its 
respective control. Decoy liposomes with 30 mol% HS-octa (X-es) inhibited PR/8 to the greatest 
extent. Decoy liposomes with 10 mol% HS-octa (circles) also significantly inhibited infection; 
however, decoy liposomes with 3 mol% HS-octa (open diamonds) or 7.5 mol% HS-octa (open 
triangles) poorly inhibited infection.  HS-octa building block (grey squares) inhibited weakly, 
and the anticoagulant, full-length heparin (grey diamonds) inhibited both viruses, slightly less 
than 30 mol% HS-octa decoy liposomes.  The data represent the average ± S.E. of two 
experiments for RSV. 
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associated HS-octa building block inhibited weakly, blocking only 14.6 ± 5.7% of RSV 
infectivity at the highest concentration tested, 40 µM HS-octa.  The HS-octa decoy liposomes 
inhibited RSV approximately four logs lower concentrations of the octamer heparin saccharide 
used to create them.  These data demonstrate that incorporation of HS-octa into liposomes 
increases RSV inhibition, presumably by allowing glycolipid migration through the bilayer and 
increasing the bio-availability of HS-octa binding motifs despite the shorter chain length of HS-
octa, as compared to full-length heparin.  
 
Decoy liposomes containing HS-octa block Respiratory syncytial virus growth  
 To investigate whether the decoy liposomes inhibit more than one round of viral 
replication, I infected Vero cells with RSV either before liposome treatment or co-incubated in 
the presence of increasing concentrations (in 10-fold increments) of decoy or control liposomes.  
All inoculating virus was removed and viral replication and spread occurred in viral growth 
media in the presence of the same treatment of control or decoy liposomes as during infection.  
When liposomes were added 15 minutes after infection (Figure 5.3A), the highest doses decoy 
liposomes with 10 mol% or 30 mol% inhibited viral growth.  Decoy liposomes with 10 mol% 
HS-octa significantly inhibited RSV titers at the highest concentration tested, 1 µM HS-octa, 
resulting in only 3,000 ± 500 PFU/ml as compared to control liposome treated cells that had 
15,250 ± 1750 PFU/ml of RSV (p ≥ 0.05).  Decoy liposomes with 30 mol% HS-octa also 
inhibited RSV at 1 µM HS-octa and at 10 µM HS-octa inhibition of RSV increased to 1,250 ± 
250 PFU/ml RSV (p ≥ 0.01).  At 0.1 µM and lower concentrations of HS-octa, neither decoy 
liposome formulations inhibited RSV replication.   
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Figure 5.3 RSV replication in Vero cells is blocked by HS-octa decoy liposomes. 
 
 
 
Figure 5.3 RSV replication in Vero cells is blocked by HS-octa decoy liposomes.  
 
Control or HS-octa decoy liposomes were A, mixed with RSV 30 minutes before or B, added 15 
minutes after RSV onto confluent monolayers of Vero cells.  RSV was used at a multiplicity of 
infection of 1. After infection, cells were incubated in the presence of control or decoy liposomes 
for 24 h.  Viral growth was measured by a plaque forming unit assay and plotted as PFU/mL 
versus total HS-octa concentration present in the solution.  Control liposomes did not inhibit 
RSV growth (open squares); however, increasing concentrations of 30 mol% HS-octa (X-es) 
and 10 mol% HS-octa (circles) decoy liposomes inhibited RSV infectivity. The dotted line 
denotes the limit of detection of the assay. Data are biological repeats ± S.E. from one 
experiment. 
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 Additional inhibition was seen when RSV and liposomes were co-incubated for 30 
minutes before infection of Vero cells, decoy liposomes with 10 mol% and 30 mol% 
significantly reduced viral titers compared to titers from cells treated with co-incubated RSV and 
control liposomes (Figure 5.3B).  At 0.1 µM HS-octa, both sets of decoy liposomes inhibited 
approximately one log of viral titers; 1,525 ± 175 PFU/ml for 10 mol% HS-octa liposomes and 
2,175 ± 125 PFU/ml for 30 mol% HS-octa liposomes.  Increasing the concentration 10 fold did 
not significantly affect RSV inhibition by 10 mol% decoy liposomes, suggesting a plateau for 
these decoys.  However inhibition was increased with the 30 mol% decoy liposomes, RSV titers 
were down to 850 ± 50 PFU/ml at 1 µM HS-octa (p ≥ 0.01 compared to 0.1 µM HS-octa) and at 
the highest concentration tested, 10 µM HS-octa, RSV titers were below the limit of detection, 
45 PFU/ml.  The lack of virus at the highest dose most likely represents a 100% block of the 
initial infection and not a block of replication. 
 
Decoy liposomes with HS-octa liposomes inhibit Herpes Simplex Virus  
 Many diverse viruses have been described that bind to heparan.  Therefore, I investigated 
whether the inhibitory effect of HS-octa decoy liposomes on RSV also applies to HSV-1, a DNA 
alpha herpes virus.  HSV has been shown to bind heparan and heparan-related molecules 
(WuDunn and Spear 1989), in addition to host protein receptors.  I co-incubated the liposomes 
containing 10 mol%, 30 mol% HS-octa or control liposomes with HSV kos before infecting 
Vero cell monolayers.  Like RSV, control liposomes and low concentrations of 10 mol% and 30 
mol% HS-octa decoy liposomes did not block HSV infectivity (Figure 5.4).  Increasing 
concentrations of 10 mol% liposomes significantly inhibited HSV, blocking 57 ± 6.3% (p ≤ 
0.001) at 1 µM HS-octa.  Furthermore, 10 µM HS-octa of 10 mol% decoy liposomes blocked   
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Figure 5.4 HS-octa decoy liposomes inhibit HSV infectivity. 
 
 
Figure 5.4 HS-octa decoy liposomes inhibit HSV infectivity. 
 
HSV (25 PFU/mL) were incubated with control liposomes, LSTc-containing decoy liposomes, 
full-length heparin or HS-octa before the addition to Vero cells. Plaques per well of virus treated 
with control liposomes (0 mol% HS-octa) are defined as 100% infectivity (open square), and 
virus treated with different liposome formulations are expressed as the percent reduction from its 
respective control. Decoy liposomes with 30 mol% HS-octa (X-es) inhibited PR/8 to the greatest 
extent. Decoy liposomes with 10 mol% HS-octa (circles) also significantly inhibited infection; 
however, decoy liposomes with 3 mol% HS-octa (open diamonds) or 7.5 mol% HS-octa (open 
triangles) poorly inhibited infection.  HS-octa building block (grey squares) inhibited weakly, 
and the anticoagulant, full-length heparin (grey diamonds) inhibited both viruses, slightly less 
than 30 mol% HS-octa decoy liposomes.  The data represent the average ± S.E. of two 
experiments for RSV and HSV. 
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74.4 ± 3.6% HSV infectivity (p ≤ 0.001).  Like RSV, HSV was inhibited to the greatest extent by 
decoy liposomes containing 30 mol% HS-octa.  At only 0.01 µM HS-octa, decoy liposomes with 
30 mol% HS-octa inhibited 76.5 ± 3.9% of RSV infectivity (p ≤ 0.0001); achieving the same 
amount of HSV inhibition as 10 µM HS-octa of decoy liposomes with 10 mol% HS-octa.  
Almost 100% inhibition of HSV infectivity was achieved at 1 µM HS-octa, with 98.1 ± 1.9% (p 
≤ 0.0001) inhibition, and an increase to 10 µM totally inhibits HSV infectivity (Figure 5.4).   
 As was true for RSV and the HS building blocks, HSV was only weakly inhibited by HS-
octa in solution (Figure 5.4, grey diamonds).  When incorporated into decoy liposomes, the 
efficacy of HS-octa improved by roughly 5 logs for 10 mol% HS-octa liposomes and by about 7 
logs for 30 mol% HS-octa liposomes.  Full-length heparin in solution inhibited HSV infectivity 
better than free HS-octa, as with RSV, but it was not as inhibitory as the 30 mol% HS-octa 
liposomes.  These data demonstrate that the decoy liposome platform can be functionalized to 
target other classes of virus and that the inhibitory properties depend on the abundance of decoy 
on the liposomal surface. 
 
Decoy liposomes containing HS-octa block herpes simplex virus replication 
 To determine if the HS-octa decoy liposomes could inhibit HSV infectivity and 
replication, I co-incubated one of two doses of HSV with control or decoy liposomes, in 10-fold 
increments of HS-octa before infection of vero cell monolayers.  Virus and liposome treatment 
was removed after one hour and HSV replication was allowed to continue for 48 hours in the 
same concentration of control or decoy liposomes as during infection.  The presence or absence 
of HSV-induced cell cytotoxicity was used as the measurement of HSV replication or decoy 
liposome protection, respectively.  High concentrations HS-octa decoy liposomes blocked HSV-
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induced cell death, as seen by loss of crystal violet-stained cell monolayers, but not by control 
liposomes (Figure 5.5).  Vero cells infected with 10 MOI of HSV kos and treated with 1 or 10 
µM HS-octa decoy liposomes containing 30 mol% HS-octa were protected (Figure 5.5A).  An 
MOI of 10 ablated the vero cell monolayer when HSV was diluted alone in media (media 
control) or in the presence of control liposomes with equivalent lipid levels as the highest 
concentrated decoy liposome treatment.  At 1 MOI, decoy liposomes containing 30 mol% HS-
octa protected Vero cells from HSV-induced cytotoxicity at a dose of 0.1 µM HS-octa and above 
(Figure 5.5B), while control liposomes did not.  These data demonstrate that HS-octa decoy 
liposomes are capable of inhibiting larger amounts of HSV virus, and that they remain protective 
for multiple rounds infection.  
 
Decoy liposomes with HS-octa inhibit human parainfluenza virus 3 
hemagglutination  
 Human parainfluenza virus 3 (PIV3) is a member of the paramyxoviridae family and is 
the etiological agent that causes human parainfluenza disease that causes upwards of five million 
lower respiratory tract infections in children every year in the US alone (Henrickson, Kuhn et al. 
1994).  PIV3 binds to both α2-3 linked SA and HS for cell entry (Amonsen, Smith et al. 2007).  
In addition, PIV3 agglutinates RBCs.  HS-octa decoy liposomes will provide an alternative 
binding option and will inhibit hemagglutination when present in sufficient quantity.  I tested the 
HS-octa decoy liposomes against PIV3 in the standard HAI assay.  Decoy liposomes with 30 
mol% HS-octa inhibited PIV3 agglutination, while control liposomes at equal lipid 
concentrations did not (Table 5.1).  HS-octa decoy liposomes with 30 mol% HS-octa had HAI 
titers of 32 and an IC90 of 3.97 µM HS-octa.  The building block, HS-octa in solution did not  
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Figure 5.5 HS-octa decoy liposomes inhibit replication and HSV-induced cytotoxicity of Vero 
cells. 
 
Figure 5.5 HS-octa decoy liposomes inhibit replication and HSV-induced cytotoxicity of Vero 
cells. 
 
Control or HS-octa decoy liposomes were mixed with A, 10 MOI or B, 1 MOI of HSV kos 30 
minutes before addition onto confluent monolayers of Vero cells.  After infection, cells were 
incubated in the presence of control or decoy liposomes for 48 h.  Viral growth was measured by 
HSV-induced cytotoxicity, as seen by a loss of crystal-violet stained monolayers and displayed 
with total HS-octa concentration present in the solution.  Control liposomes did not inhibit HSV 
growth (0 µM HS-octa); however, 30 mol% HS-octa decoy liposomes inhibited HSV infectivity, 
at 1 µM and 0.1 µM HS-octa when challenged with 10 MOI or 1 MOI of HSV, respectively.  
Data shown are from one experiment. 
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Table 5.1 Assessment of HS-octa decoy liposomes by hemagglutination inhibition assay of 
human parainfluenza virus 3. 
 
Decoy HAI Titer  IC90 (µM HS) 
Control liposomes No inhibition N/A 
HS-octa decoy liposomes 32 3.97 (± 1.62) 
HS-octa in solution No inhibition > 120,000 
Full-length heparin in solution 64 83 (± 95.2) 
 
 
Table 5.1 Assessment of HS-octa decoy liposomes by hemagglutination inhibition assay of 
human parainfluenza virus 3. 
 
HS-octa decoy liposomes competitively bind to human PIV3. Decoy liposomes containing 30 
mol% HS-octa are effective at inhibiting hemagglutination of PIV3, while neither the building 
block HS-octa in solution nor control liposomes inhibit.  HS-octa decoy liposome inhibition is 
significantly greater than the full-length heparin (p ≤ 0.05).  IC90 values are shown as molarity of 
heparin / HS-octa ± the 95% confidence interval.  
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inhibit hemagglutination at the highest concentration tested, 120,000 µM HS.  Full-length 
heparin did inhibit, but significantly less than HS-octa decoy liposomes (p ≤ 0.05), having HAI 
titers of 64 and an IC90 of 83 µM HS.  These data demonstrate that HS-octa decoy liposomes 
competitively bind PIV3 and suggest that they will bind to many other viruses that have been 
described to bind to heparan sulfate. 
 131 
Heparin sulfate decoy liposomes inhibit respiratory syncytial virus and herpes 
simplex virus 
Discussion 
The data presented in this chapter describe the construction of heparin octasaccharide 
decoy liposomes that inhibit the HS-binding viruses, RSV, HSV and PIV3.  Using the proven 
decoy liposome platform, our collaborators have created decoy liposomes with a glycolipid 
receptor capable of binding to a large number of viruses and that inhibit more strongly when 
incorporated into liposomes than when in solution alone.  These new HS-octa decoy liposomes 
are a proof-of-principle that the liposome platform is effective against many other viruses that 
have well described host glycan receptors and in conjunction with glycan arrays, the platform 
could be used to target emerging virus strains 
A second human glycan molecule widely used by many viruses is heparin / heparan 
GAGs.  Heparan sulfate is a ubiquitous molecule secreted by many cells throughout the body and 
many viruses have evolved to bind HS, at least as an initial attachment.   One specific HS-GAG 
is heparin, a highly sulfonated HS that HS-binding viruses readily attach.  Heparin is 
commercially available and is used clinically as a potent anticoagulant (Zhang, McCallum et al. 
2008).  Our collaborators created a defined eight-sugar residue heparin oligosaccharide, or HS-
octa, that does not have anticoagulant activity and as described above, binds to viruses as a 
building block for incorporation into decoy liposomes.  I confirmed findings in the literature that 
full-length heparin blocks RSV and HSV infectivity, but does not affect IAV (Figure 5.1).  HS-
octa retains some of full-length heparin’s inhibitory properties; reducing infectivity by 
approximately one log for RSV, four logs for HSV, and it remains non-inhibitory for IAV.  The 
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reduced potency is to be expected: soluble HS inhibits viruses by binding to specific, positively 
charged domains on viral surface attachment and fusion proteins, and the number of binding 
motifs is reduced on HS-octa as compared to full-length heparin (Feldman, Hendry et al. 1999; 
Adamson, Thammawat et al. 2012). My hypothesis is that HS-octa will be more bio-available 
when incorporated into liposomes than it is in solution, and therefore more likely to form 
inhibitory multivalent interactions with HS-binding viruses. 
 Decoy liposomes functionalized with HS-octa blocked RSV and HSV infectivity, and the 
degree of inhibition depended on the mole percent of HS-octa.  Decoy liposomes with 3 mol% of 
HS-octa did not significantly inhibit RSV, but decoy liposomes with 7.5 mol% HS-octa 
significantly inhibited RSV infectivity at higher concentrations tested, reaching an IC50 at 1 µM 
HS-octa.  Increasing to 10 mol% HS-octa lowered the IC50 to approximately 0.2 µM HS-octa.  
Decoy liposomes with 30 mol% HS-octa, the highest mole percent tested, had the most profound 
effect, blocking 76% of RSV infectivity at 0.01 µM HS-octa, and achieving an approximate IC50 
at 0.004 µM HS-octa.  None of the other HS-octa decoy liposomes tested inhibited RSV at all 
when used at such low concentrations of HS-octa.  
 All of the inhibitory decoy liposomes containing HS-octa inhibited RSV to a greater 
extent than the building block, HS-octa in solution. Furthermore, decoy liposomes containing 10 
mol% HS-octa were as effective as full length heparin at inhibiting RSV, and decoy liposomes 
with 30 mol% HS-octa inhibited RSV one to two logs better than the full-length heparin.   These 
data suggest that the 10 mol% HS-octa liposomes can make the same quantity and quality of 
interactions with RSV as can the full-length molecule, despite the difference in chain length.  In 
addition, increasing the percentage of glycan percentage to 30 mol% HS-octa allows even more 
interactions with RSV, making it an even more potent inhibitor.    
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 HS-octa decoy liposomes are also strong inhibitors of HSV.  Like RSV, the degree of 
inhibition depends on the percentage of HS-octa incorporated into each liposome.  I focused on 
10 and 30 mol% HS-octa liposomes because they were the most effective RSV inhibitors.  
Decoy liposomes with 10 mol% and only 0.01 µM HS-octa significantly inhibited HSV 
infectivity, and inhibition increased to 75% 10 µM HS-octa.  With an IC50 of 1 µM HS-octa, 
these decoy liposomes inhibited better than HS-octa in solution, which never attained 50% 
inhibition, even at 40 µM HS-octa.  Decoy liposomes with 30 mol% HS-octa inhibited to the 
greatest extent, achieving an IC50 near 0.003 µM HS-octa.  Decoy liposomes with 30 mol% and 
0.01µM HS-octa inhibited three times the amount of HSV as decoy liposomes with 10 mol% 
HS-octa and twice the amount of HSV as full-length heparin at similar concentrations. As seen 
above with RSV, liposomes with higher mole percentages of HS-octa are more effective 
inhibitors of HSV, despite the fact that there are fewer liposomes per volume when used at 
equimolar concentrations.  These data demonstrate that decoy liposomes can be made to inhibit 
additional pathogens, as long as their target glycan is known. 
The data presented above demonstrate that HS-octa decoy liposomes inhibit the initial 
infection step.  To examine replication over subsequent rounds of infection, I tested decoy 
liposomes with HS-octa against RSV and HSV in an environment that allows for continued viral 
replication. In order to investigate whether the decoy liposomes inhibit viral replication, I 
infected Vero cells with RSV before adding liposomes (Figure 5.3A).  Post-infection treatment 
of decoy liposomes with either 10 mol% of 30 mol% resulted in a significant reduction of viral 
titers as compared to control liposomes, albeit to a lesser extent than co-incubation treatment. 
Decoy liposomes inhibited to a greater degree when they were co-incubated with RSV before 
infection (Figure 5.3B).  Decoy liposomes containing either 10 mol% or 30 mol% HS-octa 
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significantly reduced RSV titers, and the highest dose of 30 mol% HS-octa liposomes reduced 
RSV titers to the lower limit of detection (Figure 5.3B).  The difference of decoy liposome 
inhibition seen between post-infection and co-incubation most likely represents neutralization of 
the infecting inoculum and not inhibition of subsequent RSV replication.  It is possible that 
therapeutic treatment will have limits due to RSV’s syncytia method of spreading; an RSV 
infected cell can fuse with cellular membranes from surrounding uninfected cells, without 
requiring virus to enter the supernatant, making inhibiting viral spread more difficult.  
HS-octa decoy liposomes also impede HSV replication and spread.  When co-incubated 
with a high dose of HSV (10 MOI), decoy liposomes with 30 mol% and at least 10 µM HS-octa 
protected Vero cell monolayers from HSV-induced lysis.  A ten-fold lower dose of virus, 1 MOI, 
decoy liposomes with 30 mol% and as little as 1 µM HS-octa blocked HSV replication.  
Equivalent amounts of control liposomes did not block cell death at either HSV dose.  These data 
have the caveat of co-incubation before infection and therefore may represent, at least in part, 
neutralization of the initial inoculum.  For a true measure of inhibition to be obtained, this 
experiment needs to be performed with HSV infection before liposome treatment. 
The data described here demonstrate that HS-octa incorporated into decoy liposomes 
allows for optimal binding of HS-octa and HS-binding viruses, most likely by glycolipid 
migration through the liposome membrane.  Independent movement through the fluid bi-layer 
increases availability of virus binding motifs per liposome, unlike full-length HS-GAGs, which 
must move as a unit.  When one section of the full-length HS is bound, the rest of the chain has 
significant movement constrains, resulting in sub-optimal confirmations for additional HBS 
binding.  The reduction of HS chain length and incorporation into liposomes results in an 
increase in bio-availability of the binding motifs, despite the reduction of the total number of 
 135 
theoretical binding moieties on the full-length HS.  This increase of binding partners is what I 
hypothesize to be the driving force behind the additional inhibition seen with my decoy 
liposomes; their method of action is from binding and providing steric interference of virus 
attachment and fusion proteins so that they cannot infect cells.   
The data presented here demonstrate that the glycolipid can be exchanged so that the resulting 
decoy liposomes will bind and inhibit a new virus, or in the case of HS-octa decoy liposomes, a 
set of viruses. This offers a promising start to describing the inhibitory properties of HS-octa 
decoy liposomes to two important HS-binding viruses.  However there are many more, such as 
HIV, Ross River virus, and Venezuelan equine encephalitis virus to name only a few.  I fully 
expect HS-octa decoy liposomes to be inhibitory against these viruses as well.  Furthermore, 
exchanging the decoy glycolipid will allow decoy liposomes to target even more viruses in the 
future. 
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Chapter VI 
Conclusions and Future Directions 
 I have endeavored to extend the knowledge of the chemistry and applicability of decoy 
drugs with decoy liposomes.  My results in chapters 3 through 5 show that decoy liposomes can 
be used effectively to target important pathogens such as IAV, RSV and HSV.  In addition I 
demonstrate here that the liposome platform can be modified to create decoys that neutralize 
additional pathogens with additional decoy glycolipids.  It was previously shown that monomeric 
LSTc and LSTa tightly bind to IAV HA, and that an SA-containing polymer binds to HA more 
tightly than the monomeric building block.  These previous studies led us to incorporate LSTc 
into decoy liposomes, thus increasing the valency of SA, so that it inhibits IAV infectivity better 
than monomeric SA and SA-containing polymers.  Furthermore, work presented here shows that 
the liposome formulation can be modified in many ways to enhance or hinder inhibition.  In 
particular, increasing liposome size and including cholesterol increased the liposomes’ efficacy 
as a decoy platform.  In addition, our collaborators changed the decoy glycan to create decoy 
liposomes that target different pathogens.  Overall, the findings presented here demonstrate that 
the receptor-binding pocket is a valid and important therapeutic target, not only for IAV but also 
heparin binding viruses and suggest that decoy liposomes could be made with additional 
glycolipids to target more viruses and possibly any pathogen with a well-defined host receptor, 
including bacteria and protozoa. 
 In chapter 3, I examined the ability of LSTc-containing decoy liposomes to bind and 
inhibit IAV.  The field of antiviral therapeutics has been largely devoted to small molecule 
inhibitors that make high affinity, specific binding events to their target, for example the 
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neuraminidase inhibitors.  However, a second class of inhibitors, decoy receptor molecules, has 
slowly been gaining attention.  Decoy receptors rely on many, weak-affinity binding events to 
create an overall strong interaction.  Indeed, many biological processes utilize this multivalent 
interaction mechanism, especially when involving protein–carbohydrate interactions (Kiessling 
and Pohl 1996).  Many studies have shown that during IAV infection, a multivalent interaction 
between HA and SA is required for efficient viral binding (Kiessling and Pohl 1996).  In most of 
these studies multivalency was achieved by attaching SA to a polymer backbone.  Several groups 
have used SA-containing liposomes to achieve the multivalency (Kingerywood, Williams et al. 
1992; Spevak, Nagy et al. 1993; Sun, Kanie et al. 2000; Guo, Sun et al. 2002).  The liposome 
chemistry and SA linkages were different in each study and the results varied.  In all cases, the 
decoy liposomes were an improvement over the monomeric building block (if tested) and other 
monomeric SA in the literature.   
 While the decoy liposome studies showed that liposomes could be used to achieve 
polymer-like multivalency, they also demonstrated much room for improvement.  The previous 
studies all used an SA residue linked either directly to the lipid backbone, or to a steric linker.  
Here, SA linked to a long sialylated glycan increased binding to multiple subtypes of HA 
(Chandrasekaran, Srinivasan et al. 2008; Xu, Newhouse et al. 2009).  Indeed LSTc-containing 
decoy liposomes were able to bind and inhibit both H3N2 as well as H1N1 IAV, whereas Sun et 
al. (2000) could not inhibit H1N1 PR/8 IAV with their single SA residue glycolipid.  
Furthermore, all but two studies performed only HAI assays with their SA-containing decoy 
liposomes.  HAI is a fast and efficient method to test competitive binding, but hemagglutination 
inhibition does not always correlate to infectivity inhibition (Gamian, Chomik et al. 1991).  
Spevak et al. (1993) tested their liposomes against H3N2 IAV, but had conflicting results 
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between decoy liposomes that inhibited infectivity and those that blocked hemagglutination.  
This discrepancy may be due to the chemical make up and techniques used for construction.  
Their lipid backbone contained only one acyl chain, which would allow for tighter packing of the 
lipid tails, and they were irradiated to create ellipsoid liposomes, which have an area of high 
curvature around the plane of ellipse and a corresponding area of low curvature.   The higher 
degree of lipid packing and uneven curvature may have contributed to their inconsistent data.  
Taking all of these data together, I hypothesized that a decoy liposome formulation with low 
curvature and highly fluid lipids and containing lipid linked LSTc would bind many strains of 
IAV and block infection.   
 The LS-Tetrasaccharide family has been shown to bind tightly to multiple subtypes of 
HA (Eisen, Sabesan et al. 1997; Skehel and Wiley 2000; Ha, Stevens et al. 2001; Russell, 
Stevens et al. 2006), and its binding conformation has been detailed for both human- and avian-
adapted viruses (Xu, Newhouse et al. 2009).  Indeed Pritchet et al., (1987) used LSTc as a 
monomeric decoy inhibitor of IAV and saw relatively strong HAI inhibition, as compared to 
other monomeric SA decoys.   I examined whether inclusion of LSTc (or for α2-3 SA binding 
viruses, LSTa) into liposomes would increase the inhibition properties by creating a polymer-like 
decoy capable of multivalent interactions with IAV.  The LSTc-containing decoy liposomes had 
HAI IC90 in range for the H3N2 viruses tested, and better IC90 for PR/8 IAV than other decoy 
liposomes.  The inhibitory concentrations were better than all monomeric and most SA-
containing polymer decoys.  The binding data alone demonstrate that the LSTc decoy liposomes 
were able to create strong, multivalent interactions with IAV.  Furthermore, the decoy liposomes 
inhibited infectivity, attaining IC50 concentrations in a very tight range to the concentrations 
detected in the HAI assay, unlike previous work, that required more decoys to inhibit infectivity 
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than HAI (Spevak, Nagy et al. 1993).  The infectivity inhibition seen here showed that an 
increasing mole percentage of LSTc per liposome correlated to increased inhibition, where 
previous work saw a disconnect between HAI and infectivity (Spevak, Nagy et al. 1993).  Our 
data also saw a plateau of efficacy when increasing the mole percent of LSTc to at least 7.5 
mol% into decoy liposomes.  Decoy liposomes with 10 mol% LSTc or more per liposomes had 
no significant improvement over the inhibition seen with 7.5 mol% LSTc decoy liposomes as 
others have also seen (Spevak, Nagy et al. 1993).  
 Our LSTc decoy liposomes also formed stable, long-term interactions with virus.  As 
shown in vitro, when decoy liposomes were mixed with virus and left in the presence of 
replicating virus, they were able to prevent IAV spread.  As seen in vitro, when premixed with 
virus before inoculation decoy liposomes significantly extended survival in vivo.  Protection was 
restricted to premixing virus and liposomes.  When administered before or after infection, the 
doses we were able to deliver were was not sufficient to protect from an IC90 dose of virus. This 
difference in protection is most likely due to the immense surface area of the lung and the 
liposomes would be diluted significantly when given in a small volume to mice.  This could be 
remedied by using a higher dose of liposomes, but unfortunately our collaborators have not been 
able to produce sufficient decoys to perform these studies.  
 These data demonstrate the need to optimize the liposome formulation for better 
inhibition.  In chapter 4, I present a number of adaptations to the liposome formulation designed 
to improve viral infectivity inhibition.  Incorporation of cholesterol and increasing liposome size 
produced the most dramatic improvement in liposome efficacy.  Addition of the NAi oseltamivir 
increased virus replication inhibition by decoy liposomes, demonstrating synergy.  Of note, the 
SA linkage in monomeric LSTc is cleavable by IAV neuraminidase.  NA cleavage of decoy 
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receptors has hampered the IAV decoy field since its inception.  SA decoys with linkages 
resistant to NA inhibit IAV better than sensitive parent molecules (Guo, Sun et al. 2002). 
Improving my LSTc-decoy liposomes to make them NA resistant would be a very interesting 
avenue to pursue in future studies. 
 Mixing decoy liposomes with different IAV receptors improved efficacy over that of a 
single decoy liposome population alone.  Many IAV strains emerging from avian or swine 
circulation can infect humans, and bind to both α2-6 and α2-3 linked SA.  Therefore, I 
challenged IAV with a mix of decoy liposomes presenting both SA linkages.  Infectivity 
inhibition was synergistic when both types of SA were used, suggesting that the decoy liposome 
platform may be useful for targeting newly emergent strains, to which a vaccine has not yet been 
created.  Novel, antigenically different IAV isolates still bind to either the canonical α2-6 or α2-3 
linked SA (Glaser, Stevens et al. 2005; Pappas, Viswanathan et al. 2010; Lin, Xiong et al. 2012).  
A newly emerged, potentially pandemic IAV strain may spread rapidly when there is little pre-
existing immunity (Dawood, Iuliano et al. 2012).  The decoy liposomes described here, if 
stockpiled in advance, could theoretically be used against future novel antigenic strains.   
 The liposome platform may also be able to function as a second-generation glycan array.  
Glass coverslip fixed arrays do not allow for proper display of glycans, and incorporation of a 
wide range of SA-containing molecules could be used to quickly assay the binding preference of 
a new clinical IAV isolate.  Recent work has shown that a colorimetric assay can be used with 
LSTc and LSTa dendrimers (Hobbie, Viswanathan et al. 2013).  Using decoy liposomes as a 
monitoring platform would be an exciting new application, if effective. 
 The liposome backbone can be further adapted to target other pathogens by linking any 
defined receptor to the lipid backbone.  Here I present data that demonstrate neutralization of 
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additional pathogens with heparan sulfate octasaccharide functionalized decoy liposomes.  
Decoy liposomes containing HS-octa are able to inhibit the HS-binding viruses RSV, HSV and 
PIV3, in much the same manner as seen with IAV and LSTc decoy liposomes.  A mole percent 
incorporation series of HS-octa into liposomes showed a positive correlation between amount of 
HS-octa decoy molecule included per liposome with the amount of infectivity inhibition for RSV 
and HSV.  Unlike LSTc decoy liposomes, there was no inhibition plateau at middling levels of 
HS-octa - the highest mole percent attempted, 30 mol% HS-octa, inhibited both viruses to the 
largest extent.  This difference is possibly due to the size of each HS-octa chain.  HS-octa has a 
molecular weight of 2,500 and extends eight sugar residues away from the liposome surface, 
whereas LSTc has a molecular weight of 1,000 and extends only five residues from the liposome 
surface.  Additionally, HS-octa has a higher negative charge density than LSTc, and this may 
increase the order of HS-octa glycolipids on the surface before encountering virus.  The negative 
charge of HS-octa would be neutralized when bound to virus, due to the charged amino acids in 
the viral HBD, allowing for re-ordering and more fluidity of the remaining un-bound HS-octa on 
the liposome surface. 
When decoy liposomes were added to cell monolayers, infected with RSV, inhibition of 
spread was only modest.  This is possibly due to RSV’s method of spreading via syncytia fusion 
with cell-to-cell spread without virion release (Gower, Pastey et al. 2005).  HS-octa decoy 
liposomes were able to block a large inoculum of HSV virus from replicating and killing Vero 
cells, to date this experiment has only been done with premixing virus and liposomes.  HS-octa 
apparent binding constants can be approximated by inhibition of a hemagglutinating virus.  HAI 
of PIV3 demonstrated that decoy liposomes with 30 mol% HS-octa had an IC90 of 20 µM HS-
octa, representing a roughly 20 fold increase over full-length heparin.  The HS-octa building 
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block in solution did not inhibit agglutination at the highest concentration tested, which was also 
true for monomeric LSTc, so both types of decoy liposomes saw significant efficacy over their 
free building blocks.  These data demonstrate that decoy liposomes can be adapted to additional 
viruses.  The number of viruses and bacteria that have known glycan receptors is quite large, and 
HS-octa liposomes can theoretically target at least 25 viruses, including HIV (Zhu, Li et al. 
2011).  In the near future it would be interesting to characterize decoy liposome inhibition of 
additional HS-binding viruses and greatly expand the number of decoy molecules incorporated 
into liposomes, creating an adaptable platform capable of targeting many pathogens.   
The data presented here demonstrate that decoy liposomes can inhibit viruses in a 
species-specific manner and can be created to target different viruses.  However, these decoy 
liposomes are not an anti-viral silver bullet.  The liposome platform has a number of substantial 
hurtles that must be overcome before they can become more than a promising concept.  The 
majority of the inhibition data demonstrated here was obtained under optimized conditions, 
where virus and decoy liposomes were premixed before addition to target cells.  The decoy 
liposomes are inhibitory when premixed, but the inhibition is greatly reduced or completely 
eliminated (data not shown) when decoy liposomes are added after or at the exact same time as 
IAV.  Likewise in vivo, adding LSTc decoy liposomes either before, or after IAV infection did 
not protect mice as compared to mice that received control liposomes (Figure 3.11).  The lack of 
inhibition in these experiments may be a kinetic or dosing issue.  The decoy liposome were 
created in order to mimic the glycan topology of cellular SA, but cell-associated SA may form a 
better interaction with IAV when presented to virus at the same time, and therefore may 
outcompete the decoy liposomes. 
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 It is also possible that when adding decoy liposomes after or at the same time as 
infection, a higher dose may be required to see similar levels of inhibition as seen with 
premixing. One drawback that has hampered this body of work is that decoy liposomes are not 
small molecule inhibitors and they require a number of purification and chemical synthesis steps, 
and have been at times of limited supply.  And unfortunately, some avenues of investigation 
were not pursued due to a lack of decoy liposomes.  Another drawback of decoy liposomes is 
their ability to be used in an efficient manner in some infection routes. Respiratory infections are 
ideal targets for decoy liposomes because they can be easily administered into the lungs.  Other 
possible liposome delivery models include intravenous (Immordino, Dosio et al. 2006) and 
intracranial (Krauze, Noble et al. 2007) routes, but decoy liposomes have yet to be tried in these 
models.  Decoy liposomes may not be well suited for treating other infectious agents, for 
example, decoy liposomes may not be effective for dermal infections, such as HSV dermatitis.  
In addition, to be long-lasting in the circulation, liposomes should be PEGylated, and I have 
shown here that PEGylation reduces the currently formulated LSTc-DOPE decoy liposomes.   
 Overall, the data presented in this dissertation demonstrate the validity and utility of 
decoy liposomes to target and neutralize a highly conserved region on viruses, the receptor 
binding site.  Here I present data on inhibiting IAV, RSV and HSV infectivity.  With additional 
study, I believe decoy liposomes could be used against additional viruses, bacteria and other 
pathogens.  Maturation of liposome science, along with research into the best binding ligands for 
pathogens could bring the efficacy of decoy liposomes on par with small molecule inhibitors and 
may be a valid therapeutic for sick patients. 
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Appendix A 
RIP3-dependent programmed necrosis is required for a proper danger signal during 
influenza A virus infection 
 
The following data is from other IAV research I conducted while in the Finberg and 
Kurt-Jones laboratory.  While it is important research on the biology of IAV infection, it is not 
an integral component to the data presented in this dissertation and will not be submitted for 
publication in its current state.  However, it represents an initial foray into the field of 
programmed necrosis and IAV disease that may impact future research done in the lab. 
I would like to thank the following researchers who helped me in this project.  Dr. 
Francis Chan, PhD (University of Massachusetts Medical School, Worcester, MA) for kindly 
provided the RIP3 knockout mice, Anna Cerny for genotyping and animal husbandry, and Dr. 
Susan Swain (University of Massachusetts Medical School, Worcester, MA) for mouse-adapted 
PR/8 IAV. 
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Introduction 
Influenza normally presents as a self-limiting upper respiratory tract infection.  Scientists 
have elucidated many of the innate and adaptive immune pathways critical for response to IAV.  
The virus undergoes lytic replication in pulmonary epithelial cells, stimulates a robust 
proinflammatory cytokine response, and results in a large leucocyte influx into the lungs.  
Leukocytes and cytokines activate and mature DCs, which help activate IAV-specific B-cells 
which finally clear the infection (Seibert, Rahmat et al. 2013).  Programmed necrosis is a 
proinflammatory death process, unlike apoptosis, which is anti-inflammatory, and has been 
described to be important during viral infections, including vaccinia virus (Cho, Challa et al. 
2009), murine cytomegalovirus (Upton, Kaiser et al. 2010), mouse hepatitis virus and 
lymphocytic choriomeningitis virus (Mocarski, Upton et al. 2012).  Programmed necrosis is an 
actively mediated cell death pathway, dependent on receptor-interacting protein (RIP) 1 and 
RIP3.  IAV, like many important viruses, modulates the host apoptosis mechanism for its own 
advantage, and RIP3-dependent necrosis may be an especially important mechanism of cell 
death when apoptosis is blocked in infected cells (Mocarski, Upton et al. 2012).  RIP3-dependent 
necrosis can be activated by death receptors of the TNF Receptor (TNFR) superfamily, as well as 
by TNFR-independent pathways during viral infection (Mocarski, Upton et al. 2012).  RIP3 
knockout mice are unable to undergo programmed necrosis, while having normal immune 
activation.  The data presented here will delve into the requirement of RIP3-dependent necrosis 
for an immediate innate anti-IAV immune response. 
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Materials and Methods 
Mouse infection and lung collection – Sex matched C57BL/6 wild type mice were purchased 
from the Jackson Laboratory (Bar Harbor, ME).  RIP3-/- mice were bread in-house. Mice were 8 
to 10 weeks of age at the time of infection. Mice were infected with 490 HA units of PR/8 IAV 
either by the intranasal route (for histology studies) or by the intratracheal route (for all other 
studies).  Mice were given an overdose of anesthesia and lungs were removed.   
 
Histopathology – Lungs from infected and mock mice were removed as described above, except 
they were first inflated with 10% buffered formalin, removed and fixed for 24 h in 10% buffered 
formalin in tissue Tek histology cassettes.  Sectioning and H&E staining was performed by the 
University of Massachusetts Medicial scool DERC core facility.  
 
Collection and analysis of BAL cells – Mice were infected as described above, except as noted.  
Three days post-infection, mice were given an overdose of anesthesia, and BAL cells were 
harvested by lavaging the lung four consecutive times with one mL of PBS.  BAL cells from 
each individual mouse were kept separate as biological repeats, n = 3 per infected genotype and 
n =1 per naïve genotype.  BAL cells were stored on ice before use.  BAL cells were pelleted by 
centrifugation at 1400 rpm for 5 minutes and counted.  Cells were stained for the following 
groups of surface markers, either (1) FITC conjugated Ly-6G, PE conjugated CD11b, APC 
conjugated 7/4 and PacBlue conjugated F4/80 or (2) FITC conjugated Nk 1.1, PE conjugated 
CD11b, APC conjugated CD11c and PacBlue conjugated B220.  Cells were analyzed as 
described in Chapter 2. 
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Viral titers and cytokine lungs – Mice were infected and lungs were harvested as described 
above.  Excised lungs were frozen in 300 µL sterile PBS at −80°C prior to use.  Lung samples 
were thawed on ice, homogenized and clarified.  Viral titers were attained by serial dilution of 
the samples, and assayed as described in chapter 2.  Cytokine levels were assayed from the 
clarified lung homogenates by commercial ELISA kits according to the manufacture’s 
instructions.   
 
Myeloperoxidase levels – Lungs were harvested from infected mice as described above, except 
for the following.  Lungs were harvested days 1 and 3 post-infection.  Lungs were homogenized, 
clarified at 10,000 rpm for 15 minutes at 4°C.  Lung pellets were resuspended in hexadecyl-
trimethyl ammonium bromide, sonicated and snap frozen to crack the tissue homogenate.  MPO 
rates were determined with O-dianisidine dihydrochloride and absorbance was read at 450 over a 
period of thirty minutes to obtain a rate of MPO activity.   
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RIP3-dependent programmed necrosis is required for a proper danger signal during 
influenza A virus infection 
Results 
RIP3-/- mice have increased pulmonary pathology after IAV infection 
To investigate the quality of their immune response to IAV, I infected RIP3-/- or 
littermate controls with PR/8 IAV by intratracheal delivery and removed lungs three days post-
infection for histopathology analysis.  RIP3-/- mice had similar overall gross lung morphology, 
with the same lung area affected by infection (Figure 1).  However, RIP3-/- mice had exacerbated 
local pathology foci, and enhanced inflammatory cuffing, or cellular debris in the large airways 
(Figure 2A and B).  RIP3 knockout mice also had large areas of perivascular nuclear dust, a sign 
of inflammation and cell death, often from infiltrating neutrophils (Figure 2C) that were not 
present in the wild type lungs.  Finally, RIP3-/- lungs had signs of vasculitis and vessel wall 
breakdown, while the wild type did not (Figure 2D and E).  Taken together, these data 
demonstrate that RIP3-/- mice have worse pathology after infection and suggest that the lack of 
RIP3-dependent necrosis puts them at a significant disadvantage when challenged with IAV. 
 
RIP3-/- mice have higher viral titers from IAV infection 
To investigate the disparity of the lung pathology seen between RIP3-/- mice and 
littermate controls, I tested the extent of viral replication in the lungs of infected mice.  I 
harvested lungs from RIP3-/- and wild type infected mice one and three days post infection and 
titrated lung homogenates on MDCK cells (Figure 3).  RIP3-/- and wild type mice had similar 
pulmonary titers one day post-infection (Figure 3.A) but, 3 days post-infection, RIP3-/- mice  
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Figure 1. Wide field H&E staining of infected mouse airways. 
 
 
 
Figure 1. Wide field H&E staining of infected mouse airways. 
 
Groups of wild type mice (A) and RIP3-/- mice (B) were infected with PR/8 IAV, lungs were 
inflated, removed and fixed in buffered formalin.  Tissue sections were prepared as described in 
Materials and Methods and stained with eematoxylin and eosin (H&E).  Images were acquired 
with the same camera settings, at 20X magnification and adjusted for size and contrast using 
Adobe Photoshop, using the same settings for both. 
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Figure 2.  Detained H&E staining of infected mouse lungs. 
 
 
Figure 2.  Detained H&E staining of infected mouse lungs. 
 
Groups of wild type mice (A and D) and RIP3-/- mice (B, C and E) were infected with PR/8 
IAV, lungs were inflated, removed and fixed in buffered formalin.  RIP3-/- mice had enhanced 
inflammatory cuffing (B), large areas of perivascular nuclear dust (C), and vasculitis (E).  Tissue 
sections were prepared as described in Materials and Methods and stained with H&E.  Images 
were acquired at either 400X (A-C) or 200X (D, E).  Images were acquired with the same 
camera settings, at the magnification listed and adjusted for size and contrast using Adobe 
Photoshop, using the same settings for all images. 
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Figure 3. RIP3-/- mice have higher viral titers after IAV infection 
 
 
 
 
Figure 3. RIP3-/- mice have higher viral titers after IAV infection 
 
Groups of wild type mice (WT, black triangles) and RIP3-/- mice (red squares) were infected 
with PR/8 IAV, lungs were removed one (A) (WT n =5 and RIP3-/- n=3) or three (B) (WT n =6 
and RIP3-/- n=5) days post-infection and assayed for infectious virus by plaque assay.  The data 
represent the average of at least five biological replicates ± S.E. of one experiment. 
 
 
  
 152 
had significantly higher viral titers (RIP3-/-: 7.5×105 ± 1.4×105 PFU/ml vs. WT: 1.8×105 ± 
3.0×104 PFU/ml, p ≤ 0.01) (Figure 3.B).  This suggests that RIP3-/- mice cannot control viral 
replication to the same extent as wild type, and suggesting that the exacerbated pathology is due 
to a delayed immune response in knockout mice. 
 
RIP3-/- mice a dysregulation of pulmonary infiltrates after IAV infection 
 Next, I examined the immune infiltrate in RIP3-/- and wild type infected lungs in order to 
measure the degree of immune activation.  I infected mice with PR/8 and removed the lung 
airway associated cells by bronchoalveolar lavage (BAL) three days post-infection (Figure 4A). 
RIP3-/- mice had significantly fewer NK cells (RIP3-/-: 2.5×104 ± 3×103 vs. WT: 6.7×104 ± 1×104 
cells, p ≤ 0.05) and fewer CD11b+, CD11c+ dendritic cells (RIP3-/-: 1.9×104 ± 3×103 vs. WT: 
3×104 ± 3×103 cells, p ≤ 0.05) (Figure 4A left panel). RIP3-/- mice also had slightly fewer 
neutrophils (PMNs, 7/4 and Ly6G double positive), but the difference was not significant (p = 
0.07).  Furthermore, wild type and RIP3-/- mice had the same levels of activated PMNs (7/4, 
Ly6G and CD11b triple positive) (Figure 4A middle panel), pulmonary macrophages (F4/80 and 
CD11b double positive), and B-cells (B220 positive) (Figure 4A right panel).  The differences in 
BAL leukocytes are not overly dramatic, but NK cells are thought aid in the early lysis and 
control of IAV infected cells.  DCs are important for priming the adaptive immune response.  
The decrease of these two populations may explain the higher viral titers and histopathology in 
RIP3-/- mice.  In addition, at this time point post-infection, a sizable portion of leukocytes may be 
in the perivascular space, which a BAL would not collect, and RIP3-/- mice may have less 
perivascular leukocytes as well.  
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Figure 4 RIP3-/- mice have dysregulated leukocyte influx after IAV infection. 
 
 
Figure 4 RIP3-/- mice have dysregulated leukocyte influx after IAV infection. 
 
A, Wild type (black) and RIP3-/- mice (red) were infected with PR/8 IAV and BALs were 
harvested three days post infection, three mice per group.  BAL cells were kept as independent 
samples and stained for the leukocyte surface markers as described in Materials and Methods.  
Cells are expressed as number of cells based on the percent positive cells of the total counted 
cells. B, Wild type and RIP3-/- mice lungs were harvested one or three days post infection and 
tested for MPO activity.  Mock-infected mice received saline.   
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 FACs analysis of BAL cells will also overlook dead cells.  It is possible that RIP3-/- mice 
have increased amounts of non-programmed cell death, which could result from lytic IAV 
replication.  Therefore, to investigate the total number of PMNs, dead and alive, I assayed wild 
type and RIP3-/- lungs for myeloperoxidase (MPO) levels (Figure 4B).  MPO is a peroxidase 
enzyme highly expressed in PMNs.  MPO can be tested as an indirect readout of the number of 
PMNs in a tissue.  Without infection, RIP3-/- lungs had normal MPO levels, identical to wild-
type lungs.  After infection, MPO levels increased for both RIP3-/- and wild type, but one day 
post-infection, lungs from RIP3-/- mice had slightly less MPO (RIP3-/-: 0.48 ± 0.21 vs. WT: 1.03 
± 0.19 OD/min, p = 0.086).  Three days post-infection, RIP3-/- lungs had significantly higher 
MPO levels than wild type (RIP3-/-: 3.34 ± 0.38 vs. WT: 2.12 ± 0.20 OD/min, p ≤ 0.01).  These 
data suggest that RIP3-/- mice may have a delayed initial response and cellular influx to IAV, 
followed by excessive PMN influx.  Additionally, PMN cell death may be higher in the RIP3-/- 
mice as evidenced by the higher MPO levels but lower PMN BAL numbers.  Neutrophils are 
important during IAV infection, and a reduction of functioning pulmonary PMNs results in 
worse outcomes from IAV (Tumpey, Garcia-Sastre et al. 2005).  Furthermore, dead PMNs may 
release their granule components non-specifically, causing pathology, which may be the cause of 
enhanced RIP3-/- pathology seen above. 
 
IAV induces less early cytokine and chemokine production in mice lacking RIP3  
 Proinflammatory cytokines and chemokines are required to recruit leukocytes into the 
infected lung, and to establish an anti-viral state.  Ablation of proinflammatory cytokines during 
IAV infection leads to higher viral titers and lower survival (Schmitz, Kurrer et al. 2005).  
However, IAV isolates that stimulate excessive cytokine production, or a ‘cytokine storm’ as 
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seen with the 1918 pandemic IAV, cause elevated pathology and increased mortality (Tumpey, 
Garcia-Sastre et al. 2005; Seki, Kohno et al. 2010). Therefore I examined the pulmonary 
cytokine profile of wild type and RIP3-/- mice after IAV infection.  I found that mice lacking 
RIP3 had a general, delayed cytokine response to IAV (Figure 5).  Several key cytokines were 
lower than wild type levels one day post-infection, but regained wild type levels three days post-
infection. The inflammasome cytokine IL-1α was decreased over 2 fold in knockout animals.  
The granulocyte growth factor, G-CSF, was decreased two and a half fold. IP-10 (CXCL10) was 
reduced two fold and is a chemokine for monocytes, NK cells and DCs, the latter two of which 
are decreased in RIP3-/- mice.  IL-1Ra was also significantly reduced, down two and a half fold 
in RIP3-/- mice (Figure 5).  The inflammasome cytokine IL-1β also trended down slightly, as did 
the proinflammatory cytokines MCP1 and IL-6 (data not shown).  All of these cytokines had 
come back to wild type levels three days post infection.  The mouse PMN recruitment cytokine 
KC also trended lower one day post-infection, but unlike the other cytokines, it was significantly 
elevated three days post-infection (Figure 5).  Together with G-CSF, this may explain the 
reduced numbers of live PMN in the RIP3-/- mice; chemokines are recruiting PMNs, but the 
decreased survival signals in the lung to keep them from undergoing apoptosis.  These data may 
explain the elevated MPO levels and decreased PMN BAL numbers three days post-infection.  
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Figure 5 RIP3-/- mice have a delayed cytokine profile early after IAV infection. 
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Figure 5 RIP3-/- mice have a delayed cytokine profile early after IAV infection. 
 
Wild type (black) and RIP3-/- mice (red) were infected with PR/8 IAV, and lungs were 
harvested one or three days post infection and tested for cytokine and chemokine levels.  Mock-
infected mice received saline. RIP3-/- mice had significantly less IL-1α (A), G-CSF (B), IP-10 
(C), and IL-1Ra (D) one day post-infection.  RIP3-/- mice also had significantly elevated levels of 
KC (E) three-days post infection. Each time point represents groups of at least 5 mice. 
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RIP3-dependent programmed necrosis is required for a proper danger signal during 
influenza A virus infection 
Discussion 
 The data presented here begin to delve into the role of a specific danger signal during 
IAV infection.  The mechanism of pathogen associated molecular patterns (PAMPs) has been 
well described; conserved regions of pathogens are recognized by germ-line encoded innate 
receptors and initiate an immune response.  However, a second mechanism of immune activation 
has recently been elucidated, the release and recognition of danger-associated molecular patterns 
(DAMPs).  DAMPs are specific host molecules, often nuclear or cytosolic proteins, that when 
released from a necrotic cell, activate bystander cells to initiate and perpetuate an immune 
response.   Essentially they alert the immune response to danger, either from sterile injury or 
from a pathogen that has blocked innate immune recognition (Rubartelli and Lotze 2007).  
Furthermore, RIP3-dependent necrosis has been shown to release DAMPs (Seya, Shime et al. 
2012).  My data generated with mice lacking RIP3-dependent necrosis demonstrate that 
knockout mice have elevated lung pathology, higher viral loads and a delayed cytokine response 
immediately following infection. 
 The delayed cytokine phenotype is resolved quickly, by day three post-infection, but, the 
delay is enough to cause a significant reduction of NK and DC cells in the infected lung, and 
slightly fewer neutrophils.  NK cells, via the receptors NKp46 and NKp44 have been shown to 
bind to IAV HA, and this suggests that NK cells may be important for killing infected cells early 
in IAV infection (Arnon, Lev et al. 2001; Mandelboim, Lieberman et al. 2001), and DCs are the 
critical for priming the adaptive immune system.  PMNs have also been shown to be important 
during IAV infection.  The combined loss of cytokines and infiltrating leukocytes negatively 
affects the antiviral state, failing to control viral infection by three days post-infection. 
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 The observed delay in the RIP3-/- immune response was not sufficient to cause a 
reproducible mortality phenotype.  This is due, most likely, to the many innate PRRs present in 
the lungs.  Many PRRs are redundant, knocking out a single receptor alone does not result in an 
overt mortality phenotype with IAV, but ablation of both receptors significantly increases 
mortality (Seo, Kwon et al. 2010).  Likewise, the loss of DAMP release in RIP3-/- mice may not 
be enough to cause a reproducible mortality phenotype.  In addition, the loss of cytokine 
production only immediately after infection is indicative of redundant PRRs signaling in RIP3-/- 
mice compensating after viral replication increases the number of PAMPs in the lung.   
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